CN101044125A - Heterocyclic compounds and methods of use - Google Patents

Heterocyclic compounds and methods of use Download PDF

Info

Publication number
CN101044125A
CN101044125A CN 200580035918 CN200580035918A CN101044125A CN 101044125 A CN101044125 A CN 101044125A CN 200580035918 CN200580035918 CN 200580035918 CN 200580035918 A CN200580035918 A CN 200580035918A CN 101044125 A CN101044125 A CN 101044125A
Authority
CN
China
Prior art keywords
compound
replacement
phenyl
cancer
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN 200580035918
Other languages
Chinese (zh)
Inventor
W·拉赛德罗
E·第聂伯罗夫斯基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TargeGen Inc
Original Assignee
TargeGen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TargeGen Inc filed Critical TargeGen Inc
Publication of CN101044125A publication Critical patent/CN101044125A/en
Pending legal-status Critical Current

Links

Images

Abstract

Heterocyclic compounds derived from benzotriazine, triazines, triazoles and oxadiazoles are disclosed. The methods of synthesis and of use of such heterocyclic compounds are also provided.

Description

The heterogeneous ring compound and methods for using them
The cross reference of related application
[0001] the application requires under 35U.S.C. § 119 (e) in the U.S. Patent Application Serial 60/604 of submission on August 25th, 2004,298 and the U.S. Patent Application Serial 60/696 submitted on July 1st, 2005,168 benefit of priority is incorporated this paper into as a reference at this full content with above-mentioned application.
Technical field
[0002] relate generally to of the present invention uses the various illnesss of compounds for treating, disease and pathological state, relates more specifically to use various heterogeneous ring compounds to be used for the treatment of purpose.
Background technology
[0003] kinases is the cell protein extended familys that relate in the cascade signal transduction, and growth and death, existence, migration, differentiation, genetic expression, metabolism, protein synthesis and the regulation and control of cell cycle of cell in described cascade signal transduction process control.The general mechanism of transmitting these signals is the reversible phosphorylation, and it induces these enzyme occurred conformations to change and changed their 26S Proteasome Structure and Functions.Whole kinase gene groups of having found have so far contained range protein and the isoform thereof more than 500 kinds.The different branches of this genome tree have been characterized as being the group of phosphorylation serine/threonine residue specifically or phosphorylated tyrosine.Some kinases shows dual specificity, and the substrate phosphorylation that can either carry out tyrosine can carry out the substrate phosphorylation of serine/threonine again.Can be according to their positions in cell with its further differentiation.The transmembrane receptor protein kinases shows ectodomain, can binding partner.These part combining mechanisms cause the activation of kinase catalytic structural domain, thereby have started the cascade signal of function in the control born of the same parents.The example of receptor protein kinase is somatomedin such as EGF, FGF, PDGF and IGF.Non-receptor protein kinase then can be found to nuclear many cells in the cell internal membrane of cell.An example of non-receptor protein kinase is a mitogen-activated protein kinase (MAPK) of regulating path important in the cell signaling, described signal conduction is to pass through somatomedin, for example VEGF or hormone start on cell outer surface, and extend to nucleus by transcriptional factors.These nfs and then in the regulate process of cell cycle process and final cell proliferation and differentiation, controlling genetic expression again.
[0004] nearly all cancer cells functional character such as immortalization, somatomedin self propagation, the insensitivity to growth inhibitory signal, transfer, blood vessel attract MAPK cell signaling path because it has influence on, escape apoptosis and other functional character, thereby are important for drug targeting.The inappropriate activation that causes by this molecule that suddenlys change and all human cancers nearly 30% relevant.Generally speaking, the inhibition of imbalance kinases (disregulatedkinases) such as Ras, PI3K and Raf is a kind of important channel of the novel therapeutic means of exploitation cancer and other disease.A kind of approach is that exploitation can be bonded to kinase catalytic structural domain or adjusted and controlled territory so that regulate the small molecules of protein kinase function.In this regard, importantly develop the molecule that suppresses the specific signal conduction path and have practical treatment effectiveness with high selectivity.Although obtaining significant progress aspect the various compounds that are used for the treatment of cancer and diseases associated with inflammation of exploitation, but still have the demand to the specificity chemical structure that can regulate protein kinase, the functional disorder of described protein kinase has related to these diseases.
Summary of the invention
[0005] the invention provides the compound that influences the MAPK path.Compound of the present invention for example can be used for treating under the situation of multiple human diseases such as cancer in the adjusting that shows the MAPK path as pharmaceutical cpd, is useful.
[0006], provide compound, perhaps their N-oxide compound, N, N '-dioxide, N, N ', N with structure (A) according to one embodiment of the present invention "-trioxide or pharmacology on acceptable salt:
Figure A20058003591800491
Wherein Y can not exist or can be one of following part (moieties):
Figure A20058003591800492
[0007], provide compound, perhaps their N-oxide compound, N, N '-dioxide, N, N ', N with structure (B) according to another embodiment of the present invention "-trioxide or pharmacology on acceptable salt:
Wherein X can not exist or can be NH; And Y can not exist or can be one of following part (moieties):
[0008] in compound with structure (B), Z 1, Z 2And Z 3Each can be N, N=CH, CH, O, S or N-R independently 4, R wherein 4Be hydrogen or low-carbon alkyl, further condition is Z 1, Z 2And Z 3In at least one is not CH.
[0009] in compound with structure (A), substituent R 1Can be aryl, heterocycle, heteroaryl, the heterocycle of replacement and the heteroaryl of replacement of aryl, replacement.For example, R 1Can be one of following; C 6-C 12Aryl; C 3-C 12Heteroaryl, it has 1-3 heteroatoms such as N, S and O; The C that replaces 3-C 10Cycloalkyl, it has 0-3 heteroatoms such as N, S and O; The C that replaces 6-C 12Aryl; The C that replaces 3-C 12Heteroaryl, it has 1-3 heteroatoms such as N, S and O; C 7-C 24Aralkyl; C 7-C 24Alkylaryl; The C that replaces 7-C 24Aralkyl; With the C that replaces 7-C 24Alkaryl.
[0010] in compound with structure (B), substituent R 1Be independent of the substituent R that occurs in the structure (A) 1, can be the C that does not replace or replace 3-C 12Heteroaryl, it has 1-3 heteroatoms such as N, S or O.The substituent R that can in compound, occur with structure (B) 1The pyridyl that can comprise replacement.Substituting group in the pyridyl of described replacement can comprise amido part, aminoalkyl group (for example aminomethyl) or carboxylic group or carboxylate salt/ester group.The amido part that is connected in described pyridyl can be substituted by connecting substituting group on the nitrogen in described amido part again, and described substituting group is selected from alkyl (for example methyl), alkyl aminoalkyl (for example diethylin alkyl), pyridyl, alkyl pyrrolidine, alkyl morpholine and alkylpiperazine group.
[0011] the described substituent R that can in compound, occur with structure (A) or structure (B) 1Some examples can be selected from one of lower section (moieties):
Figure A20058003591800511
Figure A20058003591800521
Figure A20058003591800531
Wherein n is selected from 0,1,2 and 3 integer.
[0012] in having structure (A) or compound (B), R 2Can be any one in following independently: hydrogen, halogen, C 1-C 18Alkyl (for example methyl) ,-OH ,-NO 2,-CN, C 1-C 18Alkoxyl group (for example methoxyl group) ,-NHSO 2R 5,-SO 2NHR 5,-NHCOR 5,-NH 2,-NR 5R 6,-S (O) R 5,-S (O) 2R 5,-CO 2R 5,-CONR 5R 6, R wherein 5And R 6Be independently selected from hydrogen, C 1-C 12The C of alkyl and replacement 1-C 12Alkyl.
[0013] in compound with structure (A), substituent R 3Can be aryl, heterocycle, heteroaryl, the heterocycle of replacement and the heteroaryl of replacement of aryl, replacement.For example, R 3Can be one of following: C 6-C 12Aryl; C 3-C 12Heteroaryl, it has 1-3 heteroatoms such as N, S and O; The C that replaces 3-C 10Cycloalkyl, it has 0-3 heteroatoms such as N, S and O; The C that replaces 6-C 12Aryl; The C that replaces 3-C 12Heteroaryl, it has 1-3 heteroatoms such as N, S and O; C 7-C 24Aralkyl; C 7-C 24Alkylaryl; The C that replaces 7-C 24Aralkyl; With the C that replaces 7-C 24Alkaryl.
[0014] in compound with structure (B), substituent R 3Be independent of the substituent R that structure (A) occurs 3, can be hydrogen, C 1-C 18The C of alkyl, replacement 1-C 18Alkyl, C 1-C 12The C of cycloalkyl, replacement 1-C 12Cycloalkyl, has the C of the replacement of 0-3 heteroatoms such as N, S or O 3-C 10Cycloalkyl, aryl are such as C 6-C 12The aryl of aryl, replacement is such as the C that replaces 6-C 12The heterocycle of aryl, heterocycle, replacement, heteroaryl are such as the C with 1-3 heteroatoms such as N, S or O 3-C 12The heteroaryl of heteroaryl, replacement is such as the C of the replacement with 1-3 heteroatoms such as N, S or O 3-C 12Heteroaryl, C 7-C 24The C of aralkyl, replacement 7-C 24Aralkyl, C 7-C 24The C of alkylaryl and replacement 7-C 24Alkaryl.Operable substituent R 3Some specific exampless comprise tert-butyl-phenyl, Trifluoromethoxyphen-l, p-methoxy-phenyl, dimethylaminophenyl, aminophenyl, trifluoro ethoxy phenyl, trifluoromethoxy chloro-phenyl-, trifluoro-methoxyl bromobenzene base, trifluoro ethoxy chloro-phenyl-, chloro-phenyl-, dichlorophenyl, trifluoromethyl, trifluoromethyl chloro-phenyl-, chloromethane phenyl, phenyl acetanilide,Phenacetylaniline, N, N-alkyl-benzamide, isopropyl phenyl, alkoxyl phenyl, dialkoxy phenyl or acetyl phenyl.
[0015] briefly, the described substituent R that can in compound, occur with structure (A) or structure (B) 3Some examples can be selected from one of following part (moieties):
Figure A20058003591800551
Figure A20058003591800561
Figure A20058003591800571
[0016] according to another embodiment of the present invention, compound as phentriazine derivative is provided, described compound comprises the phentriazine part, second substituting group that it has first substituting group of at least one phenyl ring that is connected in phentriazine and is connected in the triazine ring of phentriazine, wherein said first substituting group comprises the pyridyl of replacement, and described second substituting group comprises the amide group of secondary amino group, replacement or the sulfonamido of replacement.
[0017] according to another embodiment of the invention; the compound that comprises the benzenesulfonamide derivative part (benzene-derived moiety) that bridges at heterocyclic moiety is provided; wherein said benzenesulfonamide derivative partly comprises the benzene molecular that replaces with alkylsulfonyl group or pyridyl group; the logical peroxide bridge of described pyridyl group is connected in described benzene molecular, and described heterocyclic moiety comprises triazole,  diazole,  azoles, pyrazoles, imidazoles, thiadiazoles and triazine.
[0018] according to another embodiment of the invention, goods are provided, described goods comprise wrapping material and the pharmaceutical composition that is included in these wrapping material, and wherein said wrapping material comprise label, and it has shown that this pharmaceutical composition can be used to treat the illness relevant with cancer.Described pharmaceutical composition can comprise structure (A) and (B) in illustrated at least a compound or their any combination.
[0019] according to another embodiment, sanatory method comprises compound from significant quantity to the object of needs treatments that use, and wherein said compound is in structure (A) and (B) or in their any combination illustrated.
[0020] on the one hand, described illness for example is cancer, illness in eye, inflammation, psoriatic or virus infection.More specifically, described cancer is esophagus/gastrointestinal cancer, colorectal carcinoma, liver cancer, skin carcinoma, mammary cancer, ovarian cancer, prostate cancer, lymphoma, leukemia, kidney, lung cancer, flesh cancer, osteocarcinoma, bladder cancer or the cancer of the brain.
[0021] according to another embodiment, a kind of pharmaceutical composition is provided, structure (A) and (B) or at least a compound of illustrating in their any combination on pharmacology in the acceptable carrier.
Description of drawings
[0022] Fig. 1 represents the result that the Raf1 of The compounds of this invention directly tests.
[0023] Fig. 2 represents the result of the XTT cell viability test of The compounds of this invention.
Detailed Description Of The Invention
[0024] the present invention relates to heterocyclic compound, such as the heterocyclic compound that is derived from phentriazine, triazine, triazole,  diazole, imidazoles and thiadiazoles, and described heterocyclic compound is used for the treatment of the purpose application.
[0025] following term and definition are employed, and as used among the application, they generally meet the terminology that international applications and pure chemical combined meeting (IUPAC) are recommended.
[0026] term " heterocycle " when being used for describing aromatic rings, means that described aromatic rings comprises at least one hetero atom. Abbreviation " Het " is used to indicate heterocycle structure sometimes.
[0027] term " hetero atom " is defined as comprising any atom except carbon atom, for example N, O or S.
[0028] term " aromatics " or " aryl " are defined as comprising the cyclic conjugated molecular entity with stability, because the delocalization effect, its stability is significantly greater than the localization structure of supposing, such as Kai Kule (Kekul é) structure.
[0029] term " heterocycle " when not being used to describe aromatic rings, is defined as comprising ring-type (namely the containing ring) group of non-aromatic group, and described cyclic group is to form to about 14 carbon atoms and at least one above-mentioned hetero atom by 3.
[0030] term " heterocycle of replacement " is defined as comprising the heterocyclic group of fragrance or non-aromatic structure, and it is further with one or more above-mentioned substituting groups.
[0031] term " alkyl " is defined as comprising unit price straight or branched alkyl, it has 1 to about 12 carbon atoms, for example methyl, ethyl, n-pro-pyl, isopropyl, normal-butyl, isobutyl group, the tert-butyl group, n-pentyl (being also referred to as n-amyl), n-hexyl and similar group. Abbreviation " Me " and " Et " be represent methylidene and ethyl respectively.
[0032] term " aralkyl " refers to that described aryl or heteroaryl are as defined herein by aryl or the heteroaryl of the connection of C1-C6 alkyl joint. The example of " aralkyl " includes, but not limited to benzyl, phenyl propyl, 2-pyridylmethyl, the different  azoles of 3-ylmethyl, 2-imidazole radicals ethyl.
[0033] term " methoxyl group " is defined as group-OCH3。
[0034] term " halogen " is defined as comprising the atom of fluorine, chlorine, bromine or iodine.
[0035] term " carboxyl " or " carboxylic group " are defined as having the acid moieties of structure-COOH.
[0036] term " amino " or " amino group " are defined as comprising-NRR ' part, wherein R and R ' are hydrogen (" primary amino radicals "), perhaps they one of be organic group (" secondary amino group "), perhaps they all are organic group (" uncle amino ").
[0037] term " aminoalkyl " or " aminoalkyl group " are defined as comprising-R-N (R ' R ") part, and wherein R is organic group, R ' and R " each naturally hydrogen or organic group. If R ' and R " in be organic group one of at least, then described part namely is defined as " alkyl aminoalkyl " or " alkyl aminoalkyl group ".
[0038] term " sulfonyl " or " sulfonyl group " are defined as comprising the part that comprises structure (S), and wherein R is organic group:
Figure A20058003591800591
[0039] term " sulfonamido " or " sulfonamido group " are defined as comprising the part that comprises structure (Sa), and wherein R is organic group:
Figure A20058003591800592
[0040] term " acid amides " or " acylamino-" or " amide group " or " acylamino-group " are defined as comprising and comprise the part that at least one is connected in the carboxyl groups＞C=O of nitrogen. Term " acid amides of replacement " is defined as comprising the part that comprises structure RNH-CO-, and wherein R is organic group.
[0041] term " phenyl " is defined as comprising the part with structure (Ph):
Figure A20058003591800601
[0042] term " tolyl (toluyl) " is defined as comprising the part with structure (Tl):
Figure A20058003591800602
[0043] term " heteroaryl " is defined as comprising aromatic ring, wherein said ring structure is to form to about 14 carbon atoms and at least one above-mentioned hetero atom by 3, and term " heteroaryl of replacement " refers to further with one or more above-mentioned substituent heteroaryl groups.
[0044] term " triazine " is defined as comprising the part that contains fragrant hexa-member heterocycle, and described hexa-member heterocycle contains 3 nitrogen-atoms in this ring. Shown in these type of assorted bad two following array structures of example (Tr):
Figure A20058003591800603
[0045] term " phentriazine " is defined as comprising the part that contains heterocycle structure, and wherein triazine ring and phenyl ring condense, shown in structure (BTr):
【0046】
Figure A20058003591800604
[0047] term " N-oxide ", " N, N '-dioxide " and " N, N ', N "-trioxide " be defined as comprising nitrogenous heterocyclic moiety, wherein at least one nitrogen-atoms and oxygen link to form structure N → O. Described heterocyclic moiety can be any nitrogen heterocyclic ring, such as phentriazine, triazine, pyridine, pyrimidine etc. For example, be in the situation of phentriazine at described heterocycle structure, some N-oxides or dioxide can be described to lower array structure:
Figure A20058003591800605
[0048] term " pteridine (pteridine) " is defined as comprising that the part that contains heterocycle structure, described heterocycle structure contain two condensed six-rings, and each ring contains two nitrogen-atoms, shown in structure (PTr):
Figure A20058003591800611
[0049] term " pyridazine " is defined as comprising and contains 6 yuan of heterocyclic parts of fragrance, and described fragrant 6 yuan of heterocycles contain two ortho position nitrogen-atoms in ring, shown in structure (PAz):
Figure A20058003591800612
[0050] term " pyrimidine " is defined as comprising and contains 6 yuan of heterocyclic parts of fragrance, and described fragrant 6 yuan of heterocycles contain position nitrogen-atoms between two in ring, shown in structure (PRm):
Figure A20058003591800613
[0051] term " thiadiazoles " is defined as comprising the 5 yuan of heterocyclic parts of fragrance that contain based on thiophene, and it contains two nitrogen-atoms and a sulphur atom, shown in structure (TDa):
Figure A20058003591800614
[0052] term " pyridyl " is defined as comprising the part that contains derived from the group of pyridine.A kind of structure of pyridyl is shown in structure (Py):
[0053] term " alkyl pyrrolidine " is defined as comprising the part that contains derived from the group of tetramethyleneimine (a kind of 5 yuan of saturated heterocyclics that contain a nitrogen-atoms), and wherein alkylidene group R is connected on the nitrogen-atoms of pyrrolidine ring.A kind of structure of alkyl pyrrolidine is shown in structure (APy):
Figure A20058003591800616
[0054] term " alkyl morpholine " is defined as comprising the part that contains derived from the group of morpholine (a kind of 6 yuan of saturated heterocyclics that contain a nitrogen-atoms and a Sauerstoffatom), and wherein alkylidene group R is connected on the nitrogen-atoms of morpholine ring.A kind of structure of alkyl morpholine is shown in structure (AMr):
Figure A20058003591800621
[0055] term " alkylpiperazine " is defined as comprising the part that contains derived from the group of piperazine (a kind of 6 yuan of saturated heterocyclics that contain two nitrogen-atoms), and wherein alkylidene group R is connected on the nitrogen-atoms of piperazine ring.A kind of structure of alkylpiperazine is shown in structure (APi):
[0056] term " different  azoles " is defined as comprising and contains 5 yuan of heterocyclic parts of fragrance, and described fragrant 5 yuan of heterocycles contain a nitrogen-atoms and a Sauerstoffatom, shown in structure (ISo):
Figure A20058003591800623
[0057] term " hydrophobic " be defined as not containing strong polar group such as-OH ,-COOH ,-NH 2The group of ,-NH-CO-, halogen or similar group or structure.
[0058] term " kinases " is defined as comprising that catalysis is added into phosphate group any enzyme of residue of protein; For example, Serine and threonine kinase enzyme catalysis are added into Serine and threonine residues with phosphate group.
[0059] term " significant quantity in the treatment " is defined as the amount of compound or pharmaceutical composition, it will cause tissue that researchist, animal doctor, doctor or other clinical positions person look for, system, animal or human's biology or medical response, for example recover or keep the damage or the infringement of blood vessel stable state or prevention blood vessel stable state; The ameliorate tumor burden; Reduce sickness rate and/or lethality rate.
[0060] term " acceptable on the pharmacology " is defined as a kind of carrier, no matter thinner or vehicle, all with the prescription in other composition compatible and harmless to its recipient.
[0061] term administering compound (administration of a compound) " or " administered compound (administrating a compound) " be defined as comprising the behavior that compound of the present invention or pharmaceutical composition is offered the object of needs treatment.
[0062] according to the embodiment of the present invention, provide two types heterogeneous ring compound to be used for the treatment of multiple disease, illness and symptom, comprised cancer.Heterogeneous ring compound of the present invention can suppress kinases such as any kinase whose activity in the MAPK signal path.
[0063] according to the embodiment of the present invention, provide the compound of the first kind to be used for the treatment of multiple disease, illness and symptom, comprised cancer.The compound of the described first kind can comprise the derivative of phentriazine.The derivative of operable phentriazine can comprise the compound that contains the phentriazine part, the substituting group that described phentriazine partly has at least one phenyl ring that is connected in phentriazine is connected in the substituting group of the triazine ring of phentriazine with at least one, and their N-oxide compound, N, N '-dioxide, N, N ', N "-trioxide or pharmacology on acceptable salt.
[0064] substituting group that is connected in the phenyl ring of phentriazine can comprise the pyridyl group of replacement.Substituting group in the pyridyl group that replaces can comprise amido part, aminoalkyl group (for example aminomethyl) or carboxylic group or carboxylate salt/ester group.The amido part that is connected in described pyridyl group can be substituted by connecting substituting group on the nitrogen in described amido part again, and described substituting group is selected from alkyl (for example methyl), alkyl aminoalkyl (for example diethylin alkyl), pyridyl, alkyl pyrrolidine, alkyl morpholine and alkylpiperazine group.
[0065] alternatively, the phenyl ring of described first kind compound can comprise and is positioned at this and encircles second substituting group on any available position, for example methyl, halogen or methoxyl group.Operable some specific exampless that contain the phenyl ring part comprise tert-butyl-phenyl, Trifluoromethoxyphen-l, p-methoxy-phenyl, dimethylamino, dimethylaminophenyl, aminophenyl, trifluoro ethoxy phenyl, trifluoromethoxy chloro-phenyl-, trifluoro-methoxyl bromobenzene base, trifluoro ethoxy chloro-phenyl-, chloro-phenyl-, dichlorophenyl, trifluoromethyl, trifluoromethyl chloro-phenyl-, chloromethane phenyl, phenyl acetanilide,Phenacetylaniline, N, N-alkyl-benzamide, isopropyl phenyl, alkoxyl phenyl, dialkoxy phenyl or acetyl phenyl.
[0066] substituting group that is connected in the triazine ring of phentriazine in the first kind compound can comprise the amide group of secondary amino group, replacement or the sulfonamido group of replacement; Each of these groups can further contain the part derived from benzene, thiophene or different  azoles.If being connected in the substituting group of the triazine ring of phentriazine in the first kind compound is secondary amino group, then described part derived from benzene, thiophene or different  azoles can be connected on the nitrogen of described secondary amino group.If the substituting group in the triazine ring is the amide group of replacement or the sulfonamido group of replacement, then described part derived from benzene, thiophene or different  azoles can be connected by acetyl group or sulfonyl group respectively.Part derived from benzene, thiophene or different  azoles may further include alkyl, for example tert-butyl-phenyl, chloro-phenyl-, dichlorophenyl, trifluoromethyl, trifluoromethyl chloro-phenyl-and chloromethane phenyl.
[0067] compound of the described first kind can be described to have the compound of formula (A), and their N-oxide compound, N, N '-dioxide, N, N ', N "-trioxide or pharmacology on acceptable salt.(A) is as follows for described formula:
Figure A20058003591800631
Wherein Y can not exist or can be one of following part (moieties):
Figure A20058003591800641
[0068] in structure (A), R 1Can be aryl, heterocycle, heteroaryl, the heterocycle of replacement and the heteroaryl of replacement of aryl, replacement, such as C 6-C 12Aryl; C 3-C 12Heteroaryl, it has 1-3 heteroatoms such as N, S and O; The C that replaces 3-C 10Cycloalkyl, it has 0-3 heteroatoms such as N, S and O; The C that replaces 6-C 12Aryl; The C that replaces 3-C 12Heteroaryl, it has 1-3 heteroatoms such as N, S and O; C 7-C 24Aralkyl; C 7-C 24Alkylaryl; The C that replaces 7-C 24Aralkyl; With the C that replaces 7-C 24Alkaryl.Particularly, R 1Can be any in the following part:
Figure A20058003591800651
Figure A20058003591800661
Figure A20058003591800671
Wherein n is selected from 0,1,2 and 3 integer.
[0069] in structure (A), substituent R 2One of can be following: hydrogen, halogen, C 1-C 18Alkyl (for example methyl) ,-OH ,-NO 2,-CN, C 1-C 18Alkoxyl group (for example methoxyl group) ,-NHSO 2R 5,-SO 2NHR 5,-NHCOR 5,-NH 2,-NR 5R 6,-S (O) R 5,-S (O) 2R 5,-CO 2R 5,-CONR 5R 6, R wherein 5And R 6Be independently selected from hydrogen, C 1-C 12The C of alkyl and replacement 1-C 12Alkyl.
[0070] in structure (A), radicals R 3Can be aryl, heterocycle, heteroaryl, the heterocycle of replacement and the heteroaryl of replacement of aryl, replacement.For example, R 3Can be one of following: C 6-C 12Aryl; C 3-C 12Heteroaryl, it has 1-3 heteroatoms such as N, S and O; The C that replaces 3-C 10Cycloalkyl, it has 0-3 heteroatoms such as N, S and O; The C that replaces 6-C 12Aryl; The C that replaces 3-C 12Heteroaryl, it has 1-3 heteroatoms such as N, S and O; C 7-C 24Aralkyl; C 7-C 24Alkylaryl; The C that replaces 7-C 24Aralkyl; With the C that replaces 7-C 24Alkaryl.Particularly, substituent R 3Can be one of following part:
Figure A20058003591800672
Figure A20058003591800681
Figure A20058003591800691
Figure A20058003591800701
Figure A20058003591800711
[0071] some general examples of the described compound of formula (A) comprise have formula (I) compound, have formula (II) compound, have the compound of formula (III) or have the compound of formula (IV):
Figure A20058003591800712
[0072] some limiting examples of the described particular compound of operable formula (A) comprise the compound of (1)-(33) that have formula:
Figure A20058003591800731
Figure A20058003591800741
[0073] phentriazine derivative above-described and that set forth with formula (A) can prepare shown in scheme I:
Figure A20058003591800742
Figure A20058003591800751
Scheme I
[0074] in order to prepare intermediate product A, wherein R 1Be 2-pyridine carboxamide for example, the synthetic route shown in can operational version II:
Figure A20058003591800752
Scheme II
[0075] as seen at scheme II, intermediate product A synthetic needs to use 4-chloro-2-pyridine carboxamide 4, and it can be synthetic in advance individually shown in scheme III:
Figure A20058003591800761
Scheme III
Formula (IV) phentriazine derivative described and that set forth with formula (A) can prepare shown in scheme IV:
Figure A20058003591800762
Scheme IV
[0076] according to the embodiment of the present invention, provide the compound of second type to be used for the treatment of multiple disease, illness and symptom, comprised cancer.The compound of described second type can comprise the benzenesulfonamide derivative part of bridging in heterocyclic moiety, or acceptable salt on their pharmacology.Bridge between described benzenesulfonamide derivative part and the heterocyclic moiety can comprise singly-bound or nitrogen-atoms.If described heterocyclic moiety contains at least one nitrogen-atoms, then this second type compound can be N-oxide compound or N, N '-dioxide or N, N ', N "-trioxide.
[0077] whether described compound can be N-oxide compound or N, N '-dioxide or N, N ', N "-trioxide, be decided by nitrogen-atoms number contained in the heterocyclic moiety.For example, if heterocyclic moiety only contains a nitrogen, then this second type compound can be the N-oxide compound.If heterocyclic moiety contains two nitrogen-atoms, then this second type compound can be N-oxide compound or N, N '-dioxide.If heterocyclic moiety contains three nitrogen-atoms, then this second type compound can be N-oxide compound, N, N '-dioxide, N, N ', N "-any in the trioxide.
[0078] described benzenesulfonamide derivative part can comprise that substituting group such as logical peroxide bridge is connected in the pyridyl group of benzene molecular, perhaps sulfonyl group.The pyridyl group that is connected in benzene molecular can further be replaced.Substituting group in the pyridyl group can comprise the same section (moieties) that is used for first kind compound of the present invention as mentioned above.The sulfonyl group that is connected in benzene molecular also can further be substituted.Substituting group in the sulfonyl group can comprise the above-mentioned pyridyl group that is used for the replacement of first kind compound of the present invention.
[0079] alternatively, the benzenesulfonamide derivative of described second type compound part can contain second substituting group, for example methyl, halogen or methoxyl group, and it can be positioned at any position of phenyl ring.Some exemplary benzenesulfonamide derivative parts that can be included in second type compound can comprise tert-butyl-phenyl, Trifluoromethoxyphen-l, p-methoxy-phenyl, dimethylamino, dimethylaminophenyl, aminophenyl, trifluoro ethoxy phenyl, trifluoromethoxy chloro-phenyl-, trifluoro-methoxyl bromobenzene base, trifluoro ethoxy chloro-phenyl-, chloro-phenyl-, dichlorophenyl, trifluoromethyl, trifluoromethyl chloro-phenyl-, chloromethane phenyl, phenyl acetanilide,Phenacetylaniline, N, N-alkyl-benzamide, isopropyl phenyl, alkoxyl phenyl, dialkoxy phenyl, acetyl phenyl.
[0080] compound of described second type comprises the have formula heterogeneous ring compound of (B), perhaps their N-oxide compound, N, N '-dioxide, N, N '; N " acceptable salt on-trioxide or the pharmacology, they can suppress kinases such as any kinase whose activity in the MAPK signal path.Described formula (B) can be expressed as followsin:
Figure A20058003591800771
[0081] in structure (B), Z 1, Z 2And Z 3In each can be N, CH, N=CH, O, S or N-R independently 4, R wherein 4Be hydrogen or low-carbon alkyl, condition is Z 1, Z 2And Z 3In be not CH one of at least; X can not exist or NH; Y can not exist or can be one of following part:
Figure A20058003591800772
[0082] further, in structure (B), substituent R 1, R 2And R 3Can be as follows:
[0083] R 1Can be the C that does not replace or replace 3-C 12Heteroaryl, it has 1-3 heteroatoms such as N, S or O;
[0084] R 2Can be any one in following: hydrogen, halogen, C 1-C 18Alkyl (for example methyl) ,-OH ,-NO 2,-CN, C 1-C 18Alkoxyl group (for example methoxyl group) ,-NHSO 2R 5,-SO 2NHR 5,-NHCOR 5,-NH 2,-NR 5R 6,-S (O) R 5,-S (O) 2R 5,-CO 2R 5,-CONR 5R 6, R wherein 5And R 6Be independently selected from hydrogen, C 1-C 18The C of alkyl and replacement 1-C 12Alkyl; And
[0085] R 3Can be hydrogen, C 1-C 18The C of alkyl, replacement 1-C 12Alkyl, C 1-C 12The C of cycloalkyl, replacement 1-C 12The C of cycloalkyl, replacement 3-C 10Cycloalkyl, it has 0-3 heteroatoms such as N, S or O, aryl such as C 6-C 12The aryl of aryl, replacement is such as the C that replaces 6-C 12The heterocycle of aryl, heterocycle, replacement, heteroaryl are such as C 3-C 12Heteroaryl, its heteroaryl with 1-3 heteroatoms such as N, S or O, replacement is such as the C that replaces 3-C 12Heteroaryl, it has 1-3 heteroatoms such as N, S or O, C 7-C 24The C of aralkyl, replacement 7-C 24Aralkyl, C 7-C 24The C of alkylaryl and replacement 7-C 24Alkaryl.
[0086] substituent R 1Can comprise the pyridyl of replacement or the pyrimidyl group of replacement.Substituting group in the pyrimidyl group of the pyridyl of described replacement or replacement can comprise amido part, aminoalkyl group (for example amino methyl) or carboxylic group or carboxylate salt/ester group.The amido part that is connected in described pyridyl/pyrimidyl group can be substituted by connecting substituting group on the nitrogen in described amido part again, and described substituting group is selected from alkyl (for example methyl), alkyl aminoalkyl (for example diethylin alkyl), pyridyl, alkyl pyrrolidine, alkyl morpholine and alkylpiperazine group.
[0087] particularly, can be used in R in the compound with structure (B) 1Limiting examples comprise any following part:
Figure A20058003591800781
Figure A20058003591800791
Figure A20058003591800801
Wherein n is selected from 0,1,2 and 3 integer.
[0088] can be used in R in the compound with structure (B) 3Some concrete limiting examples comprise tert-butyl-phenyl, Trifluoromethoxyphen-l, p-methoxy-phenyl, dimethylaminophenyl, aminophenyl, trifluoro ethoxy phenyl, trifluoromethoxy chloro-phenyl-, trifluoro-methoxyl bromobenzene base, trifluoro ethoxy chloro-phenyl-, chloro-phenyl-, dichlorophenyl, trifluoromethyl, trifluoromethyl chloro-phenyl-, chloromethane phenyl, phenyl acetanilide,Phenacetylaniline, N, N-alkyl-benzamide, isopropyl phenyl, alkoxyl phenyl, dialkoxy phenyl and acetyl phenyl.These parts and still can be used as substituent R 3Other parts (moieties) can be illustrated as follows:
Figure A20058003591800802
Figure A20058003591800821
Figure A20058003591800831
Wherein n is selected from 0,1,2 and 3 integer, and R ' is hydrogen, C 1-C 18The C of alkyl or replacement 1-C 18Alkyl.
[0089] some general examples of the described compound of formula (B) comprise the have formula compound of (V)-(XXVIII):
Figure A20058003591800841
Figure A20058003591800851
[0090] 1,2, under the situation of 4-triazole, there are three kinds of tautomeric structures, as follows:
Figure A20058003591800852
[0091] which kind of tautomeric structure is preponderated and is decided by substituting group and reaction conditions on the triazole part.As known to persons of ordinary skill in the art, usually, 1H-1,2, the 4-triazole is modal tautomeric form, if particularly amino substituting group is connected to this ring when going up.Although whole three kinds of tautomeric structures all can occur, for the sake of simplicity and for its direct analogue such as containing 1,3, the example of 4- diazole part compares, have 1,2, all categories structure of 4-triazole part and all examples in this article with a kind of tautomeric form 4H-1 for example, 2, the 4-triazole is represented.For the sake of simplicity, only use the 4H-tautomeric form to describe described structure and do not mean that example shown below (30)-(74) compound all is to exist with this concrete tautomeric form.
[0092] some examples of the described particular compound of formula (B) comprise the compound of (34)-(83) that have formula:
Figure A20058003591800861
Figure A20058003591800871
Figure A20058003591800881
Figure A20058003591800891
[0093] 1,2 of the suitable replacement of above-mentioned (V) class of using formula (B) elaboration, the 4-triazole can use one of some kinds of reaction scheme to be synthesized, for example shown in following plan V, VI and VII.According to the availability and the easy degree of synthetic of desired replacement, parent material, can select appropriate means.
Figure A20058003591800901
Plan V
Figure A20058003591800902
Plan V I
Figure A20058003591800911
Plan V II
[0094] 1,2 of above-mentioned (VI) class, the 4-triazole can be shown in plan V III or by being prepared as generalized optional route among the scheme IX.
Figure A20058003591800912
Plan V III
Figure A20058003591800921
Scheme IX
[0095] (VIII) the 2-amino-1,3 of the suitable replacement of class, 4- diazole can use one of some kinds of reaction scheme to be synthesized, for example, shown in scheme X, XI and XII.
Figure A20058003591800922
Scheme X
Scheme XI
Figure A20058003591800932
Scheme XII
[0096] (IX) the 2-amino-1,3 of the suitable replacement of class, 4- diazole can use one of some kinds of reaction scheme to be synthesized, for example, shown in scheme XIII and XIV.
Figure A20058003591800941
Scheme XIII
Figure A20058003591800942
Scheme XIV
[0097] (XI) the 2-amino-1,3 of the suitable replacement of class, the 4-thiadiazoles can be prepared by generalized method among the scheme XV.
Scheme XV
[0098] (XII) the 2-amino-1,3 of the suitable replacement of class, the 4-thiadiazoles can be prepared by generalized method among the scheme XVI.
Figure A20058003591800952
Figure A20058003591800961
Scheme XVI
[0099] (XXIII)-(XXV) the 3-amino-1,2 of the suitable replacement of class, the 4-triazine can be prepared by generalized method among the scheme XVII.
Figure A20058003591800962
Figure A20058003591800971
Scheme XVII
(XXVI)-(XXVIII) the 3-amino-1,2 of the suitable replacement of class, the 4-triazine can be prepared by generalized method among the scheme XVIII.
Figure A20058003591800972
Figure A20058003591800981
Scheme XVIII
[0100] Compounds and methods for of the present invention, no matter using separately or the time with other medicament (for example chemotherapeutic of the following stated or protein for treatment agent) combined administration, all be useful aspect the treatment various disease conditions, described illness comprises, but be not limited to, for example cancer, illness in eye, inflammation, psoriatic and virus infection.Treatable cancer kind includes, but not limited to esophagus/gastrointestinal cancer, colorectal carcinoma, liver cancer, skin carcinoma, mammary cancer, ovarian cancer, prostate cancer, lymphoma, leukemia, kidney, lung cancer, flesh cancer, osteocarcinoma, bladder cancer or the cancer of the brain.
[0101] embodiments of the present invention also provide goods, and it can comprise wrapping material and the pharmaceutical composition that is contained in these wrapping material.Wrapping material can comprise label, and it indicates this pharmaceutical composition can be used to top described one or more treatment of conditions.
[0102] described pharmaceutical composition can comprise compound of the present invention.Except that compound of the present invention, this medicine can also comprise other therapeutical agent, and can be according to the known technology of medicine formulation art, for example pass through to use traditional solid or liquid vehicle or thinner, and the medicated premix of the method for application type that is suitable for expecting (for example vehicle, tackiness agent, sanitas, stablizer, seasonings etc.) is prepared.
[0103] therefore, in one embodiment, the invention provides pharmaceutical composition, comprise therapeutical agent and compound of the present invention.This compound is to exist for the effective concentration of treatment cancer.
[0104] can be formulated into natural form or salt form be therapeutic composition to compound of the present invention.Acceptable non-toxic salt comprises base addition salt (forming with free carboxy or other anionic group) on the pharmacology, its can be derived from mineral alkali such as, for example sodium hydroxide, potassium hydroxide, ammonium hydroxide, calcium hydroxide or ironic hydroxide, and organic bases such as Isopropylamine, Trimethylamine 99,2-ethylamino-ethanol, Histidine, PROCAINE HCL, PHARMA GRADE and similar organic bases.This type of salt also can form acid salt with any free cations group, and generally can with mineral acid such as, for example hydrochloric acid, sulfuric acid or phosphoric acid, perhaps organic acid such as acetate, citric acid, tosic acid, methylsulfonic acid, oxalic acid, tartrate, amygdalic acid and similarly organic acid formation.
[0105] salt of the present invention can comprise the amine salt that the protonation by amino group and mineral acid forms, all example hydrochloric acids of described mineral acid, Hydrogen bromide, hydroiodic acid HI, sulfuric acid, phosphoric acid and similar mineral acid.Salt of the present invention also can comprise the amine salt that the protonation by amino group and appropriate organic forms, described organic acid such as tosic acid, acetate, methylsulfonic acid and similar organic acid.Other vehicle that is considered in the present invention's practice is the available vehicle of those of ordinary skills, for example at the United StatesPharmacopeia Vol.XXII and National Formulary Vol.XVII, U.S.PharmacopeiaConvention, Inc., Rockville, those vehicle that can find among the MD (1989), the associated viscera of the document is incorporated this paper into as a reference at this.In addition, the polymorphic form of The compounds of this invention is included among the present invention.
[0106] pharmaceutical composition of the present invention can be to contain the dosage unit preparations form of acceptable carrier on the atoxic pharmacology or thinner, be applied by any suitable mode, for example oral, such as form with tablet, capsule, particle or pulvis; Take in the hypogloeeis; Orally administer; Parenteral is taken, such as by in subcutaneous, intravenously, intramuscular, the sheath or intracisternal injection or infusion techniques (for example, as the injectable water of sterilization or non-aqueous solution or suspension); Intranasal is taken, such as passing through to suck spray; Topical application is such as with emulsion or ointment form; Perhaps rectal administration is such as the form with suppository.This compound can, for example be applied with the form that is suitable for discharging immediately or postpone to discharge.Comprise the suitable pharmaceutical compositions of The compounds of this invention by use, can realize discharging immediately or postpone and discharge, perhaps postponing to use device under the situation about discharging especially such as hypodermic implant or osmotic pump.The compounds of this invention also can be used by liposome.
[0107] except that primate such as the mankind, various other lactations also can be treated according to method of the present invention.For example, treatable Mammals includes, but not limited to ox, sheep, goat, horse, dog, cat, cavy, rat or other Bovidae, sheep section, equine, Canidae, cat family, rodents or murine.But present method also can be used in other species such as birds (for example chicken).
[0108] is used to use the pharmaceutical composition of the compound of this embodiment,, can be easily exists, and prepared by the known any method of pharmacy field with the form of dose unit no matter use separately or during with other therapeutical agent combined administration.All methods comprise that the carrier that makes activeconstituents and constitute one or more ancillary components is linked together.Generally speaking, pharmaceutical composition is by evenly closely activeconstituents being incorporated among liquid vehicle or pulverizing solid carrier or both, then if necessary, is required preparation and being prepared with product machine-shaping.In this pharmaceutical composition, the amount that active target compound is comprised is enough to the process of disease or symptom are produced required effect.The pharmaceutical composition that contains activeconstituents can be to be suitable for oral form, for example tablet, spray, lozenge, water quality or oleagenous suspension, dispersible pulvis or particle, emulsion, hard or soft capsule or syrup or elixir.
[0109] being intended to be used for oral composition can make the known any method in field according to pharmaceutical composition and prepared, and this based composition can comprise one or more reagent, it is selected from sweeting agent, seasonings, tinting material and sanitas, so that good to eat preparation outstanding in the pharmacy is provided.The activeconstituents that tablet comprises be present in atoxic pharmacy in the mixture of acceptable vehicle, described vehicle is suitable for tablet processing.These vehicle can be, for example inert diluent such as lime carbonate, yellow soda ash, lactose, calcium phosphate or sodium phosphate; Granulating agent and disintegrating agent, for example W-Gum or alginic acid; Tackiness agent, for example starch, gelatin or Sudan Gum-arabic, and lubricant, for example Magnesium Stearate, stearic acid or talcum.Described tablet can be do not wrap quilt or can be by known technology bag quilt, postponing its disintegration and absorption in gi tract, thereby in one long period, provide persistent effect.For example, can use time-delay material such as glyceryl monostearate or distearin.They also can be coated to be formed for the osmotic therapeutic tablets that controllability discharges.
[0110] being used for oral preparation also can exist with the form of hard gelatin capsule, wherein activeconstituents and inert solid diluent, for example lime carbonate, calcium phosphate or kaolin mix mutually, perhaps the form with soft capsule exists, wherein activeconstituents and water medium or oily medium, for example peanut oil, whiteruss or the mixing of olive oil phase.
[0111] aq suspension comprises and the vehicle that is suitable for processing aq suspension blended active substance mutually.This type of vehicle is a suspension agent, for example Xylo-Mucine, methylcellulose gum, Vltra tears, sodiun alginate, polyvinylpyrrolidone, tragacanth gum and Sudan Gum-arabic; Dispersion agent or wetting agent can be naturally occurring phosphatide, Yelkin TTS for example, the perhaps polycondensation product of oxyalkylene and lipid acid, the polycondensation product of polyoxyethylene stearic acid ester or oxyethane and long chain aliphatic alcohol for example, Shi seven ethylene oxy Ji Whale ceryl alcohols for example, perhaps oxyethane with come from the polycondensation product of the part ester class of lipid acid and hexitol, octadecanoic acid ester of polyethylene glycol for example, perhaps oxyethane with come from the polycondensation product of the part ester class of lipid acid and hexitan, polyethylene sorbitanic monoleate for example.As solubilizing agent same useful for example be polyoxyethylene glycol.Aq suspension also can comprise one or more sanitass, for example ethyl p-hydroxybenzoate or P-hydroxybenzoic acid n-propyl, one or more tinting materials, one or more seasoningss and one or more sweeting agents such as sucrose or asccharin.
[0112] oleagenous suspension can be by being suspended in vegetables oil with activeconstituents, and for example peanut oil, sweet oil, sesame oil or cocounut oil perhaps are suspended in mineral oil such as whiteruss and are carried out preparation.Oleagenous suspension can comprise thickening material, for example beeswax, paraffinum durum or cetyl alcohol.Can add such as top those illustrated sweeting agents and seasonings so that good to eat oral preparations to be provided.These compositions can be preserved by adding antioxidant such as xitix.
[0113] being adapted to pass through the dispersible powder that adds water and make water quality suspension and particle provides and dispersion agent or wetting agent, suspension agent and one or more sanitass blended activeconstituents mutually.Suitable dispersion agent or wetting agent and suspension agent are illustrated by above mentioned those materials.Other vehicle, for example sweeting agent, seasonings and tinting material also can exist.
[0114] syrup and elixir can with sweeting agent, for example glycerol, propylene glycol, sorbyl alcohol or sucrose are prepared together.This type of preparation also can contain negative catalyst, sanitas and seasonings and tinting material.
[0115] described pharmaceutical composition can be the injectable water quality suspension of sterilization or the form of oleagenous suspension.According to known technology, this suspension can use those the suitable dispersion agents mentioned or wetting agent and suspension agent to be prepared in the above.The injectable formulation of described sterilization also can be the injection solution or the suspension of sterilization, it is present in parenteral acceptable diluent or solvent or cosolvent or complex reagent or dispersion agent or vehicle or their combination, 1,3 butylene glycol for example, polyoxyethylene glycol, polypropylene glycol, ethanol or other alcohols, polyvidone (povidones), the TWEEN tensio-active agent of various brands, sodium lauryl sulphate, Sodium desoxycholate, N,N-DIMETHYLACETAMIDE, polysorbate, poloxamer (poloxamer), cyclodextrin, lipid, with vehicle such as inorganic salt (for example sodium-chlor), buffer reagent (Trisodium Citrate for example, sodium phosphate) and carbohydrate (for example sucrose and glucose).Acceptable carrier that can be used and solvent are water, glucose solution, Ringer's solution and isotonic sodium chlorrde solution.In addition, aseptic fixed oil is used as solvent or suspension medium routinely.For this purpose, any temperature that comprises synthetic glycerine monoesters or triglyceride is closed fixed oil and can be used.In addition, lipid acid can be used in the injectable formulation such as oleic acid.
[0116] according to the symptom of being treated, these pharmaceutical compositions can be by preparation and general or topical application.Preparation and application technique can be found in " Remington ' s Pharmaceutical Sciences " (MackPublishing Co, the Easton Pa.) of latest edition.Suitable way can, for example, comprise oral administration with or mucosal administration; And parenteral carries, and comprises in intramuscular, subcutaneous, the marrow, sheath is interior, indoor, intravenously, intraperitoneal or intranasal administration.For injection, pharmaceutical composition of the present invention can be at the aqueous solution, preferably prepares in such as Hank ' s solution, ringer's solution or physiological buffer salt solution at the physiological compatibility damping fluid.Use for tissue or cell, be suitable for and be used in the described preparation by the permeate agent of the concrete barrier that be permeated.This type of permeate agent generally is known in the art.Be used for the aqueous solution that pharmaceutical preparation that parenteral uses comprises the active compound of water-soluble form.In addition, the suspension of active compound can be made into suitable oily injectable suspensions.Suitable lipophilic solvent or carrier comprise fatty oil such as sesame oil or synthetic fatty acid ester such as ethyl oleate or triglyceride level or liposome.The water quality injectable suspensions can comprise the material that increases suspension viscosity, such as Xylo-Mucine, sorbyl alcohol or dextran.Randomly, described suspension also can comprise suitable stabilizers or increase described compound dissolution degree so that the reagent of preparation height concentrated solution.
[0117] for the rectal administration medicine, compound of the present invention also can be used with the form of suppository.These compositions can be made by medicine and suitable non-irritating excipient are mixed mutually, and described non-irritating excipient is solid under ordinary temp, but are liquid in rectal temperature, discharge described medicine thereby therefore will melt in rectum.This type of material is theobroma oil and polyoxyethylene glycol.
[0118] uses for the part, can use emulsion, ointment, gel, solution or the suspension etc. that contain The compounds of this invention.(for this purposes, topical application will comprise collutory and gargle).
[0119] in one embodiment, The compounds of this invention and anti-inflammatory agent, antihistaminic, chemotherapeutic, immunomodulator, therapeutic antibodies or kinases inhibitor, for example the tyrosine kinase inhibitor combined administration is in the object of this type of treatment of needs.Be not to want restriction, chemotherapeutic comprises metabolic antagonist, and such as methotrexate, the DNA linking agent is such as cis-platinum (cisplatin)/carboplatin (carboplatin); Alkylating agent is such as canbusil; The topoisomerase I inhibitor is such as gengshengmeisu; Microtubule inhibitor such as taxol (handkerchief nit west (paclitaxol)), and analogue.Other chemotherapeutic comprises, for example, vinca alkaloids, mitomycin type microbiotic, bleomycin type microbiotic, antifol, colchicine, Omaine, etoposide, Taxan, anthracycline antibiotics, Zorubicin, daunorubicin, carminomycin, pidorubicin, idarubicin, mitoxantrone (mithoxanthrone), 4-dimethoxy-daunorubicin, 11-deoxidation daunorubicin, 13-deoxidation daunorubicin, doxorubicin hydrochloride-14-benzoic ether, doxorubicin hydrochloride-14-octanoate, doxorubicin hydrochloride-14-naphthylacetic acid ester, amsacrine (amsacrine), carmustine (carmustine), endoxan, cytosine arabinoside (cytarabine), etoposide (etoposide), lovastatin (lovastatin), L-sarcolysin, topotecan (topetecan), oxalaplatin, Chlorambucil, methotrexate, lomustine (lomustine), Tioguanine, asparaginase, vincaleucoblastine, vindesine, tamoxifen (tamoxifen) or mustargen.Be not to want restriction, therapeutic antibodies comprises the proteic antibody at HER2, such as Herceptin (trastuzumab); At the antibody of somatomedin or growth factor receptors, such as rhuMAb-VEGF (bevacizumab), it is defined as target with vascular endothelial growth factor, and OSI-774, and it is defined as target with Urogastron; With the antibody of integrin receptor as target, such as Vitaxin (being also referred to as MEDI-522), and analogue.The carcinostatic agent kind that is applicable to the compositions and methods of the invention comprises, but be not limited to: 1) alkaloid, comprise microtubule inhibition (vincristin for example, vincaleucoblastine and vindesine etc.), microtubule stabilizer (for example handkerchief nit west [taxol], Docetaxel, taxotere (Taxotere) etc.), with chromatin function inhibition, comprise topoisomerase enzyme inhibitor, such as Etoposide (for example semi-synthetic derivative teniposide (Teniposide) [VM-26] of etoposide [VP-16] and podophyllotoxin etc.) with the topoisomerase I is the reagent (for example camptothecine and irinotecan (Isirinotecan) [CPT-11] etc.) of target; 2) covalency DNA binding reagents [alkylating agent], comprise mustargen (for example mustargen, Chlorambucil, endoxan, ifosfamide, busulfan (Busulfan) [busulfan (Myleran)] etc.), nitrosourea (for example carmustine, lomustine, semustine (Semustine) etc.) and other alkylating agent (for example Dacarbazine (Dacarbazine), methylol melamine, thiotepa (Thiotepa) and Mitocycin etc.); 3) non-covalent DNA binding reagents [antitumor antibiotics], comprise nucleic acid inhibitor (for example gengshengmeisu [dactinomycin] etc.), anthracycline drug (for example daunorubicin [Daunomycin and Cerubidine], Zorubicin (Doxorubicin) [doxorubicin hydrochloride (Adriamycin)], idarubicin (Idarubicin) [Yi Da mycin (Idamycin)] etc.), amerantrone (anthracycline drug analogue for example, such as [mitoxantrone] etc.), bleomycin (bleomycin sulfate) etc., and Plicamycin (Plicamycin (Mithramycin)) etc.; 4) metabolic antagonist, comprise antifol (methotrexate (Methotrexate) for example, methotrexate (Folex), methotrexate sodium (Mexate) etc.), purine metabolic antagonist (Ismipur [6-MP, Purinethol] for example, 6-Tioguanine [6-TG], azathioprine (Azathioprine), acycloguanosine (Acyclovir), ganciclovir (Ganciclovir), chlorine Desoxyadenosine (Chlorodeoxyadenosine), 2-chlorodeoxyadenosine (2-ChlorodeoxyAdenosine) [CdA], with 2 '-deoxycoformycin (2 '-Deoxycoformycin) [pentostatin (Pentostatin)] etc.), pyrimidine antagonistic (fluorine pyrimidine [5 FU 5 fluorouracil (Adrucil) for example for example, floxuridine (FdUrd) is (Floxuridine)] etc.) and cytarabin (for example cytosine arabinoside [ara-C] and fludarabine (Fludarabine) etc.); 5) enzyme comprises the altheine enzyme; 6) hormone, comprise glucocorticosteroid, such as estrogen antagonist (for example tamoxifen etc.), on-steroidal androgen antagonist (for example flutamide (Flutamide) etc.) and aromatase enzyme inhibition (for example anastrozole (anastrozole) [Arimidex (Arimidex)] etc.); 7) platinic compound (for example cis-platinum (cisplatin)/carboplatin (carboplatin) etc.); 8) with link coupled monoclonal antibodies such as cancer therapy drug, toxin and/or radionuclides; 9) biological respinse modifier (for example Interferon, rabbit [for example IFN-α etc.] and interleukin [for example IL-2 etc.] etc.); 10) adoptive immunotherapy; 11) hemopoieticgrowth factor; 12) reagent of inducing tumor cell differentiation (for example Vitamin-A Acid etc.); 13) gene therapy technology; 14) antisense therapy technology; 15) tumor vaccine; 16) at the treatment (for example Batimistat etc.) of metastases; With 17) angiogenesis inhibitor.
[0120] pharmaceutical composition of the present invention and method may further include other compound that therapeutic activity is arranged as mentioned in this article, and it is applied to the treatment of above-mentioned pathological symptom usually.The example of other therapeutical agent comprises as follows: ciclosporin (for example Ciclosporin A), CTLA4-Ig, antibody is such as ICAM-3, anti--the IL-2 acceptor (anti--Tac), anti--CD45RB, anti--CD2, anti--CD3 (OKT-3), anti--CD4, anti--CD80, anti--CD86, stop interactional reagent between CD40 and the gp39, such as CD40 and/or gp39 (being CD154) specific antibody, fusion rotein by CD40 and gp39 (CD40Ig and CD8gp39) structure, inhibitor, such as nuclear transposition inhibitor, NF-κ B depressant of functions such as Gusperimus (deoxyspergualin (DSG)), cholesteral biosynthesis inhibitor such as HMG CoA reductase inhibitor (lovastatin (lovastatin) and glycosides cut down department's fourth (simvastatin)), on-steroidal anti-inflammatory agent (NSAIDs) such as Ibuprofen BP/EP and cyclooxygenase inhibitors are such as rofecoxib, steroid such as prednisone (prednisone) or dexamethasone (dexamethasone), gold compound, antiproliferative is such as Rheumatrex, FK506 (Ta Keluomu (tacrolimus, Prograf)), mycophenolic acid morpholine ethyl ester (mycophenolate mofetil), cytotoxicity medicine such as azathioprine (Azathioprine) and endoxan, TNF-a inhibitor such as tenidap (tenidap), anti-TNF antibody or soluble TNF acceptor and rapamycin (rapamycin) (sirolimus (sirolimus) or Lei Paming (Rapamune)), perhaps their derivative.
[0121] can comprise protein for treatment agent such as cytokine, immunomodulator and antibody with other reagent of The compounds of this invention combined administration.As used herein, term " cytokine " " comprise chemokine, interleukin-, lymphokine, monokine, G CFS and receptor associated protein(RAP) and their functional fragment.As used herein, term " functional fragment " refers to have biological function or active polypeptide or peptide, described biological function or active in determining that functional experiment is identified.
[0122] described cytokine comprises endothelial mononuclear cell activating polypeptide II (EMAP-II), granulosa cell-scavenger cell-CSF (GM-CSF), granulosa cell-CSF (G-CSF), scavenger cell-CSF (M-CSF), IL-I, IL-2, IL-3, IL-4, IL-5, IL-6, IL-12 and IL-13, Interferon, rabbit and similar cytokine, and it changes relevant with concrete biology, morphology or the phenotype of cell or cell mechanism.
[0123] when other therapeutical agent and compound of the present invention are used in combination, they can be with for example mentioned amount or as be carried out use by the otherwise determined amount of those of ordinary skills in thePhysician Desk Reference (PDR).
[0124] relate in the process of symptom of cell proliferation in treatment or prevention, the proper dosage level generally can be every day per kilogram weight in patients about 0.01 to about 1000mg, it can be applied with single dose or multiple doses mode.For example, dosage level can be that every day about 0.01 is to about 250mg/kg; Narrower ground, every day about 0.5 is to about 100mg/kg.The proper dosage level can be every day about 0.01 to about 250mg/kg, every day about 0.05 is to about 100mg/kg, perhaps every day about 0.1 is to about 50mg/kg, perhaps every day about 1.0mg/kg.For example, in this scope, this dosage can be every day about 0.05 to about 0.5mg/kg, perhaps every day about 0.5, perhaps every day about 5 was to about 50mg/kg to about 5mg/kg.For oral, described composition can provide with tablet form, described tablet contains about 1.0 to about 1, the 000mg activeconstituents, for example about 1.0, about 5.0, about 10.0, about 15.0, about 20.0, about 25.0, about 50.0, about 75.0, about 100.0, about 150.0, about 200.0, about 250.0, about 300.0, about 400.0, about 500.0, about 600.0, about 750.0, about 800.0, about 900.0 and about 1,000.0mg activeconstituents, be used to the patient that will be treated that dose titration scheme according to symptom is provided.Described compound can be according to every day 1 to 4 time, such as once a day or twice instructions about how to take medicine use.Before carrying out next course of treatment, can withdrawal for some time.
[0125] still, be to be understood that, for any particular patient, concrete dosage level and administration frequency all can change, and be decided by various factors, comprise the activity of used particular compound, the metabolic stability of this compound and length, age, body weight, general health, sex, diet, medicining mode and time, row's medicine speed, drug regimen, the severity of concrete symptom and the treatment that the patient is accepting of effect.
[0126] compound of the present invention can use separately, and perhaps be used for the treatment of tumor treatment antibody or the chemistry with significant quantity is connected in tumor tissues targeting antibodies (perhaps its therapeutic fragment), chemotherapeutic or immunotoxicity agent and is used in combination.The illustrative examples that can be used for the chemotherapeutic of this purpose comprises Zorubicin, Docetaxel or taxol.Should further understand, the present invention includes the combination treatment that comprises The compounds of this invention, it includes but not limited to blood vessel stable state agent (vasculostatic agents), such as tyrosine kinase inhibitor, Serine or threonine kinase enzyme inhibitors, Src-family's group inhibitor for example, and any chemotherapeutic or therapeutic antibodies.
[0127] the present invention also provides the filler test that carries out with suitable cell method, any kinases in the described cell expressing MAPK path.This type of cell comprises from Mammals, yeast, fruit bat or colibacillary cell.For example, Raf polypeptide or any kinases such as the MEK in Raf downstream or the cell of ERK1/2 will be expressed, perhaps the cell that Raf polypeptide or MAPK path polypeptide are made response contacts with test-compound, to observe in conjunction with situation or to the stimulation situation or the inhibition situation of functional response.In order to determine the activity of Raf polypeptide or MAPK path polypeptide, the cell that will contact with candidate compound compares with the same cell that does not contact.
[0128] the present invention expection by using MAPK path polypeptide amount of suppression compounds for treating and/or improve this type of disease.Under the situation of any concrete principle of the function of not wishing to be subject to MAPK path polypeptide, believe that the useful inhibitor of MAPK path polypeptide function is those compounds that suppress the kinase activity of MAPK path polypeptide.Other inhibition position is certainly possibly owing to its position in the signal transduction cascade.Interactional inhibitor between Raf polypeptide or MAPK path polypeptide and other factor for example between the protein-protein may cause developing the medicament of regulating Raf polypeptide or MAPK path polypeptide active.
[0129] be an approach that developing drugs very likely is interfered with proteic allosteric site as target.Further, the traditional method that suppresses various protein kinases comprises the ATP combining site as target.The present invention is intended to be limited by any concrete restraining effect mechanism.Testing method of the present invention can detect candidate compound in conjunction with situation, be the mark that interrelates with candidate compound by directly or indirectly wherein, perhaps detect in the experiment of competition effect of thing comprising competing with mark to the adhesion situation of the cell that has Raf polypeptide or MAPK path polypeptide.Further, these analyze the detection system that experiment can utilize the cell that is suitable for having Raf polypeptide or MAPK path polypeptide, test out whether candidate compound can produce because the signal that activation generated of MAPK path polypeptide.The inhibitor of activation generally is to test existing under the condition of known agonist, and to because the existence of candidate compound and the influence that activation produced of this agonist is observed.The standard method of carrying out this type of filler test is known in the art, and in following examples illustrated (for example direct method and raf1-MEK1 method of testing or MAPK path cell tests method).
[0130] the following example is provided in order to further illustrating advantages and features of the invention, but is not to be intended to limit scope of the present invention.
Embodiment 1 general method
[0131] embodiment 1 has described the general synthesis program that is used to prepare compound described in the subsequent embodiment.All solvents are used without being further purified.Unless otherwise mentioned, reaction can be carried out under the condition of inert-free gas environment usually.The yield of being reported is based on not optimized conditions and single test calculating.Yield can be by changing reaction conditions, such as solvent, use alkali or acid, temperature, use catalyzer and reaction times to be optimized.At Emrys TMUse initiation module (Biotage/Personalchemistry) in the Process pipe (2-5mL) and carry out microwave reaction.All 1H NMR moves on 500MHz Bruker NMR or BrukerAvance 400MHz NMR.Chemical shift is that unit is reported with delta (δ), i.e. per 1,000,000 umber (ppm) under the downfield of tetramethylsilane.Coupling constant is that unit is reported with hertz (Hz).Waters LC/MS system is used to identity and purity check.This system comprises 2795 separation modules, 996 photodiode array detectors and ZQ2000 mass spectrograph.Zorbax SB post (150 * 4.6mm, 3.5 μ, Agilent Technologies) is used to LC.Column temperature is 40 ℃.Use gradient elution to separate with acetonitrile (0.05%TFA (B)) as moving phase compound water (0.05%TFA (A)).Flow velocity is 1mL/min.The gradient program of using in sepn process is 0-15 minute: 5-60%B; 15-15.5 minute: 60-100%B; 15.5-17 minute: 100%B.
Synthesizing of embodiment 2 3-amino-benzos [1,2,4] triazine-7-alcohol-1-oxide compound
Figure A20058003591801051
[0132] 7.7g (0.05 mole) 4-amino-3-nitro phenol is dissolved in the 20mL glacial acetic acid, and in being furnished with the 500mL round-bottomed flask of long condenser, the shiny red solution that is produced is heated to about 100 ℃.The 20mL concentrated hydrochloric acid solution that in this solution, adds the cyanamide that contains 16.81g (8.0 equivalents, 0.4 mole).Approximately 5-10 minute, reaction mixture began violent boiling, therefore removed heating unit and under no heating condition its stirring was calmed down until boiling.Again application of heat device and with reaction mixture refluxed 48 hours then.Add 150mL30%NaOH subsequently and the dark red solution that is produced was refluxed 3 hours again.Then it is cooled to room temperature and forms dark red mill base.Red precipitate is filtered, heavily be dissolved in the 200mL water, and add 1N HCl while stirring in batches and reach 5-4 until pH.This solution colour becomes pale yellowly by dark red, and forms light yellow meticulous precipitation.With this sedimentation and filtration, with 50mL water washing twice,, finally use 50mL ether washed twice with 50mL acetonitrile washed twice, and vacuum-drying, obtain 4.6g glassy yellow solid.Yield: 51.7%.
【0133】 1H NMR(DMSO-d 6)：δ6.96(s，2H)，7.35-7.38(m，2H)，7.45-7.47(m，1H)，10.36(s，1H)。
Synthesizing of embodiment 3 3-amino-benzos [1,2,4] triazine-7-alcohol
[0134] with 4.6g (25.82 mmole) 3-amino-benzo [1,2,4] triazine-7-alcohol-1-oxide dissolution in 1: 1 mixture of 200mL dimethyl formamide and methyl alcohol.0.5g 10%Pd/C is added in this solution, and hydrogen was charged in the solution 3 hours.9: 1 mixtures of use methylene chloride are as eluent and use ultraviolet lamp, by TLC monitoring reaction process.Starting material are highly fluorescigenic under ultraviolet ray, and product then is not.After reaction is finished, the dark solution that is produced is filtered by short silicagel pad, and vacuum is removed solvent, generation burgundy solid.40mL ethyl acetate and 40mL methyl alcohol are added in this solid, and the suspension that is produced is heated to about 10 minutes of backflow.Make this suspension be cooled to room temperature then.Solid filtering is collected, with 40mL ethyl acetate, the washing of 40mL ether, and vacuum-drying, the product of generation 3.2g green solid form.Yield: 76%.
【0135】 1H NMR(DMSO-d 6)：δ7.18(s，1H)，7.36(d，J＝2.6Hz，1H)，7.40-7.42(dd，J 1＝9.1Hz，J 2＝2.6Hz，1H)，7.45-7.46(d，J＝9.1Hz，1H)。
Synthesizing of embodiment 4 4-chloro-pyridine-2-carboxylic acids methyl ester hydrochlorides
Figure A20058003591801061
[0136] with the anhydrous N of 2.4mL (0.031 mole, 0.16 equivalent), dinethylformamide is added dropwise in 40-50 ℃ temperature range in the thionyl chloride of 72mL (1.23 moles, 5.0 equivalents) under argon gas covers.Under this temperature,, slowly add 24.0g (0.195 mole, 1.0 equivalents) pyridine carboxylic acid then with solution stirring 10 minutes in batches.Reaction mixture was heated 30 hours at 70-75 ℃ under argon gas with reflux exchanger.Observe SO 2The release of gas.The color of reaction mixture becomes the tangerine look by green, becomes purple then in 2 hours later on, produces the tangerine look solution that has yellow mercury oxide subsequently.It is cooled to room temperature and adds the 150mL dry toluene.This suspension is concentrated into altogether approximately 50mL on Rotary Evaporators.This process is repeated 3 times.
[0137] the tangerine look suspension that produces is cooled to-20 ℃ and add 200mL methyl alcohol.Reaction mixture placed under the room temperature stirred 18 hours.Then this clear yellow solution is changed in the round-bottomed flask, and solvent removed in vacuo.The yellow solid that produces is dissolved in the 50mL methyl alcohol by being heated to 50 ℃, in case cooling just adds the 300mL ether.This solution was left standstill 18 hours at 0 ℃.The white precipitate that forms is filtered collection,, produce 29.05g white fine hair shape solid product with ether thorough washing and vacuum-drying.Yield: 71.5%.
【0138】 1H NMR(DMSO-d 6)：δ3.88(s，3H)，7.81-7.83(dd，J 1＝1.9Hz，J 2＝5.4Hz，1H)，8.06-8.07(d，J＝1.9Hz，1H)，8.68-8.69(d，J＝5.4Hz，1H)。
Synthesizing of embodiment 5 4-chloro-pyridine-2-carboxylic acids methyl nitrosoureas
Figure A20058003591801062
[0139] methanol suspension with 15mL 17.8g (0.103 mole, 1 equivalent) hydrochloric acid 4-chloro-pyridine-2-carboxylic acids methyl esters is cooled to 0 ℃, and with the tetrahydrofuran solution of 2.0M methylamine so that the speed that internal temperature remains on below 5 ℃ slowly handle.Reaction mixture was stirred 2 hours at 0 ℃, make it rise to room temperature then lentamente and stirred 18 hours.Solvent removed in vacuo adds about 200mL ethyl acetate and filters the suspension that is produced.With the washing precipitation of 100mL ethyl acetate.With the ethyl acetate solution that merges 100mL salt water washing 3 times, and dry on sodium sulfate.Solvent removed in vacuo produces 14.16g tangerine look oily product.Yield: 80.5%.
【0140】 1H NMR(DMSO-d 6)：δ2.81-2.82(d，J＝4.8Hz，3H)，7.73-7.75(dd，J 1＝2.1Hz，J 2＝5.4Hz，1H)，8.00-8.01(d，J＝2.1Hz，1H)，8.60-8.61(d，J＝5.4Hz，1H)，8.84(q，J＝4.8Hz，1H)。
Synthesizing of embodiment 6 4-(3-amino-benzo [1,2,4] triazine-7-base oxygen base)-pyridine-2-carboxylic acids methyl nitrosourea
Figure A20058003591801071
[0141] 3-amino-benzo [1,2, the 4] triazine-7-alcohol with 3.2g (19.73 mmole) is dissolved in the 80mL anhydrous dimethyl formamide under argon gas.The solid potassium tert-butoxide of 2.44g (21.71 mmoles, 1.1 equivalents) is added in this solution.With the scarlet mixture heating up that produces to about 100 ℃ and under this temperature, stirred 15 minutes.The anhydrous dimethyl formamide solution that adds 10mL3.7g (21.71 mmoles, 1.1 equivalents) 4-chloro-pyridine-2-carboxylic acids methane amide adds the anhydrous K of 3.28g (23.68 mmoles, 1.2 equivalents) subsequently 2CO 3This reaction mixture was heated 30 hours at 140 ℃.By LC/MS monitoring reaction process.Make it be cooled to room temperature then.The dark brown mill base that produces is poured in 500mL water and the 100mL ethyl acetate.The sedimentation and filtration that forms is collected,, produced 3.22g dark yellow solid product with 50mL water, 50mL methyl alcohol, the washing of 50mL ether and vacuum-drying.Filtrate is used 100mL ethyl acetate extraction 4 times.With extract 100mL water washing 3 times that merge, use salt water washing 3 times then and drying on anhydrous sodium sulphate.Solvent removed in vacuo produces the product of extra 1.2g yellow solid form.Yield: be 75% after the merging.
【0142】 1H NMR(DMSO-d 6)：δ2.78-2.79(d，J＝4.8Hz，3H)，7.25-7.27(dd，J 1＝2.6Hz，J 2＝5.6Hz，1H)，7.50-7.51(d，J＝2.6Hz，1H)，7.66-7.68(d，J＝9.2Hz，1H)，7.71-7.73(dd，J 1＝2.7Hz，J 2＝9.2Hz，1H)，7.71(s，2H)，8.03-8.05(d，J＝2.7Hz，1H)，8.54-8.55(d，J＝5.6Hz，1H)，8.78-8.80(q，J＝4.8Hz，1H)。
Embodiment 7 4-[3-(4-chloro-3-trifluoromethyl-phenyl amino)-benzo [1,2,4] triazine-7-base oxygen base]-pyridine-2-carboxylic
Synthesizing of acid methyl acid amides trifluoroacetate
Figure A20058003591801072
[0143] under argon atmospher, in the bottle that the 2mL anhydrous dimethyl formamide is housed, adds 15.4mg (0.0168 mmole by this particular order, 0.05 three (dibenzyllideneatone), two palladiums (0) equivalent), 21.0mg (0.033 mmole, 0.1 BINAP equivalent), 220.0mg (0.675 mmole, 2.0 Carbon Dioxide caesium equivalent), 175.1mg (0.675 mmole, 2.0 5-bromo-2-chlorobenzotrifluoride equivalent) and 100mg (0.337 mmole, 1.0 (3-amino-the benzo [1 of 4-equivalent), 2,4] triazine-7-base oxygen base)-the pyridine-3-carboxylic acid methyl nitrosourea.Fed argon gas 5 minutes to mixture.Cover bottle cap then, and under argon atmospher, reaction mixture is heated to 120 ℃ and stirred 18 hours.This moment, LC/MS showed that about 40% changes product into.Pointed as in the previous examples, the long reaction times has caused the formation and the part degraded of by product.Therefore, reaction mixture is cooled to room temperature, filters, and carry out purifying with the acetonitrile/water mixture that contains 0.1%TFA by anti-phase preparation HPLC by 0.3 μ m syringe filter.
【0144】ESI-MS：[M+H] +，475，477. 1H NMR(DMSO-d6)：δ2.79-2.90(d，J＝4.8Hz，3H)，7.31-7.33(dd，J 1＝2.4Hz，J 2＝5.4Hz，1H)，7.55-7.55(d，J＝2.4Hz，1H)，7.73-7.75(d，J＝8.9Hz，1H)，7.89-7.91(dd，J 1＝2.5Hz，J 2＝9.2Hz，1H)，7.94-7.95(d，J＝9.2Hz，1H)，8.24(d，J＝2.5Hz，2H)，8.25-8.27(dd，J 1＝2.6Hz，J 2＝8.9Hz，1H)，8.55(d，J＝2.6Hz，1H)，8.60(d，J＝5.4Hz，1H)，8.81-8.82(q，J＝4.8Hz，1H)，11.36(s，1H)。
Embodiment 8 4-[3-(4-chloro-phenyl amino)-benzo [1,2,4] triazine-7-base oxygen base]-the pyridine-2-carboxylic acids methyl nitrosourea
Synthesizing of trifluoroacetate
Figure A20058003591801081
[0145] under argon gas, in the bottle that the 2mL anhydrous dimethyl formamide is housed, adds 15.4mg (0.0168 mmole by this particular order, 0.05 three (dibenzyllideneatone), two palladiums (0) equivalent), 21.0mg (0.033 mmole, 0.1 BINAP equivalent), 220.0mg (0.675 mmole, 2.0 Carbon Dioxide caesium equivalent), 161.0mg (0.675 mmole, 2.0 1-chloro-4-iodobenzene equivalent) and 100mg (0.337 mmole, 1.0 (3-amino-the benzo [1 of 4-equivalent), 2,4] triazine-7-base oxygen base)-the pyridine-3-carboxylic acid methyl nitrosourea.Fed argon gas 5 minutes to mixture.Cover bottle cap then, and under argon gas, reaction mixture is heated to 120 ℃ and stirred 18 hours.This moment, LC/MS showed that about 30% changes product into.Viewed as in the previous examples, the long reaction times has caused the formation and the part degraded of by product.Therefore, reaction mixture is cooled to room temperature, filters, and carry out purifying with the acetonitrile/water mixture that contains 0.1%TFA by anti-phase preparation HPLC by 0.22 μ m syringe filter.
【0146】ESI-MS：[M+H] +，407，409. 1H NMR(DMSO-d 6)：δ2.79-2.80(d，J＝4.88Hz，3H)，7.30-7.32(dd，J 1＝2.6Hz，J 2＝5.6Hz，1H)，7.44-7.46(d，J＝6.8Hz，2H)，7.54-7.55(d，J＝2.6Hz，1H)，7.84-7.87(dd，J 1＝2.6Hz，J 2＝9.05Hz，1H)，7.92-7.94(d，J＝9.05Hz，1H)，8.00-8.01(d，J＝6.8Hz，2H)，8.19-8.20(d，J＝2.6Hz，1H)，8.58-8.59(d，J＝5.6Hz，1H)，8.81-8.82(q，J＝4.88Hz，1H)，11.08(s，1H)。
Embodiment 9 4-[3-(3-trifluoromethyl-phenylsulfonamido)-benzo [1,2,4] triazine-7-base oxygen base]-pyridine-2-carboxylic acids
Synthesizing of methyl nitrosourea trifluoroacetate
Figure A20058003591801091
[0147] 4-(3-amino-benzo [1,2,4] triazine-7-base oxygen the base)-pyridine-3-carboxylic acid methyl nitrosourea with 100mg (0.337 mmole, 1.0 equivalents) is dissolved in the 2mL anhydrous dimethyl formamide, and is heated to about 100 ℃.The solid potassium tert-butoxide of 45.4mg (0.405 mmole, 1.2 equivalents) is added in this solution.The dark red solution that produces was stirred 30 minutes at 100 ℃, make it be cooled to room temperature then.By syringe 3-trifluoromethyl-benzene sulfonyl chloride of 100mg (0.405 mmole, 1.2 equivalents) is added this mixture.It was at room temperature stirred 2 hours.Reaction mixture is filtered by 0.22 μ m syringe filter, and carry out purifying with the acetonitrile/water mixture that contains 0.1%TFA by anti-phase preparation HPLC.
【0148】ESI-MS：[M+H] +，505，506，507. 1H NMR(DMSO-d 6)：δ2.78-2.79(d，J＝4.8Hz，3H)，7.29-7.31(dd，J 1＝2.6Hz，J 2＝5.7Hz，1H)，7.56(d，J＝2.6Hz，1H)，7.87-7.90(t，J＝7.8Hz，1H)，7.93-7.94(d，J＝9.2Hz，1H)，7.97-7.99(dd，J 1＝2.6Hz，J 2＝9.2Hz，1H)，8.06-8.08(d，J＝7.8Hz，1H)，8.21(d，J＝2.5Hz，1H)，8.43-8.46(m，2H)，8.57-8.58(d，J＝5.7Hz，1H)，8.80-8.81(q，J＝4.8Hz，1H)。
Embodiment 10 4-[3-(3-trifluoromethyl-benzamido)-benzo [1,2,4] triazine-7-base oxygen base]-pyridine-2-carboxylic acids
Synthesizing of methyl nitrosourea trifluoroacetate
Figure A20058003591801092
[0149] 4-(3-amino-benzo [1,2,4] triazine-7-base oxygen the base)-pyridine-3-carboxylic acid methyl nitrosourea with 100mg (0.337 mmole, 1.0 equivalents) is dissolved in the 2mL anhydrous dimethyl formamide, and is heated to about 100 ℃.The solid potassium tert-butoxide (t-BuOK) of 45.4mg (0.405 mmole, 1.2 equivalents) is added in this solution.The dark red solution that produces was stirred 30 minutes at 100 ℃, make it be cooled to room temperature then.By syringe 3-trifluoromethyl-Benzoyl chloride of 84.5mg (0.405 mmole, 1.2 equivalents) is added this mixture.It was at room temperature stirred 2 hours.Reaction mixture is filtered by 0.22 μ m syringe filter, and carry out purifying with the acetonitrile/water mixture that contains 0.1%TFA by anti-phase preparation HPLC.
【0150】ESI-MS：[M+H] +，469，470. 1H NMR(DMSO-d 6)：δ2.80-2.81(d，J＝4.88Hz，3H)，7.37-7.39(dd，J 1＝2.6Hz，J 2＝5.7Hz，1H)，7.64(d，J＝2.6Hz，1H)，7.81-7.84(t，J＝7.8Hz，1H)，8.03-8.06(m，2H)，8.15-8.17(d，J＝9.2Hz，1H)，8.33-8.34(d，J＝2.6Hz，1H)，8.36-8.38(d，J＝8.0Hz，1H)，8.45(s，1H)，8.62-8.63(d，J＝5.7Hz，1H)，8.84-8.85(q，J＝4.88Hz，1H)，12.29(s，1H)。
Embodiment 11 4-[4-(trifluoromethoxy-benzamido)-benzo [1,2,4] triazine-7-base oxygen base]-pyridine-2-carboxylic acids
Synthesizing of methyl nitrosourea trifluoroacetate
Figure A20058003591801101
[0151] 4-(3-amino-benzo [1,2,4] triazine-7-base oxygen the base)-pyridine-3-carboxylic acid methyl nitrosourea with 100mg (0.337 mmole, 1.0 equivalents) is dissolved in the 2mL dry DMF, and is heated to about 100 ℃.The solid t-BuOK of 45.4mg (0.405 mmole, 1.2 equivalents) is added in this solution.The dark red solution that produces was stirred 30 minutes at 100 ℃, make it be cooled to room temperature then.By syringe 4-trifluoromethoxy-Benzoyl chloride of 64 μ L (91.0mg, 0.405 mmole, 1.2 equivalents) is added this mixture.It was at room temperature stirred 2 hours.Reaction mixture is filtered by 0.22 μ syringe filter, and carry out purifying with the acetonitrile/water mixture that contains 0.1%TFA as solvent systems by anti-phase preparation HPLC.
【0152】ESI-MS：[M+H] +，485，486. 1H NMR(DMSO-d 6)：δ2.80-2.81(d，J＝4.8Hz，3H)，7.37-7.38(dd，J 1＝2.6Hz，J 2＝5.6Hz，1H)，7.55-7.57(d，J＝8.8Hz，2H)，7.63-7.64(d，J＝2.6Hz，1H)，8.03-8.05(dd，J 1＝2.7Hz，J 2＝9.1Hz，1H)，8.14-8.15(d，J＝9.1Hz，1H)，8.20-8.22(d，J＝8.8Hz，2H)，8.32-8.33(d，J＝2.7Hz，1H)，8.83-8.84(q，J＝4.8Hz，1H)，12.12(s，1H)。
Embodiment 12 4-[3-(trifluoromethoxy-benzamido)-benzo [1,2,4] triazine-7-base oxygen base]-pyridine-2-carboxylic acids
Synthesizing of methyl nitrosourea trifluoroacetate
[0153] 4-(3-amino-benzo [1,2,4] triazine-7-base oxygen the base)-pyridine-3-carboxylic acid methyl nitrosourea with 100mg (0.337 mmole, 1.0 equivalents) is dissolved in the 2mL dry DMF, and is heated to about 100 ℃.The solid t-BuOK of 45.4mg (0.405 mmole, 1.2 equivalents) is added in this solution.The dark red solution that produces was stirred 30 minutes at 100 ℃, make it be cooled to room temperature then.By syringe 3-trifluoromethoxy-Benzoyl chloride of 64 μ L (91.0mg, 0.405 mmole, 1.2 equivalents) is added this mixture.It was at room temperature stirred 2 hours.Reaction mixture is filtered by 0.22 μ syringe filter, and carry out purifying with the acetonitrile/water mixture that contains 0.1%TFA as solvent systems by anti-phase preparation HPLC.
【0154】ESI-MS：[M+H] +，485，486. 1H NMR(DMSO-d 6)：δ2.80-2.81(d，J＝4.8Hz，3H)，7.37-7.39(dd，J 1＝2.5Hz，J 2＝5.6Hz，1H)，7.63-7.64(d，J＝2.6Hz，1H)，7.67-7.74(m，2H)，8.03-8.05(dd，J 1＝2.8Hz，J 2＝9.36Hz，1H)，8.05(m，1H)，8.12-8.14(m，1H)，8.14-8.16(d，J＝9.36Hz，1H)，8.33(d，J＝2.8Hz，1H)，8.62-8.63(d，J＝5.7Hz，1H)，8.83-8.84(q，J＝4.8Hz，1H)，12.21(s，1H)。
Embodiment 13 4-[3-(chloro-phenylsulfonamido)-benzo [1,2,4] triazine-7-base oxygen base]-the pyridine-2-carboxylic acids methyl nitrosourea
Synthesizing of trifluoroacetate
Figure A20058003591801111
[0155] 4-(3-amino-benzo [1,2,4] triazine-7-base oxygen the base)-pyridine-3-carboxylic acid methyl nitrosourea with 100mg (0.337 mmole, 1.0 equivalents) is dissolved in the 2mL dry DMF, and is heated to about 100 ℃.The solid potassium tert-butoxide of 45.4mg (0.405 mmole, 1.2 equivalents) is added in this solution.The dark red solution that produces was stirred 30 minutes at 100 ℃, make it be cooled to room temperature then.By syringe the 3-chlorobenzene sulfonyl chloride of 85.8mg (0.405 mmole, 1.2 equivalents) is added this mixture.It was at room temperature stirred 2 hours.Reaction mixture is filtered by 0.22 μ m syringe filter, and carry out purifying with the acetonitrile/water mixture that contains 0.1%TFA by anti-phase preparation HPLC.
【0156】ESI-MS：[M+H] +，471，473，474. 1H NMR(DMSO-d 6)：δ2.78-2.79(d，J＝4.9Hz，3H)，7.30-7.32(dd，J 1＝2.6Hz，J 2＝5.6Hz，1H)，7.57(d，J＝2.6Hz，1H)，7.65-7.68(t，J＝9.0Hz，1H)，7.75-7.77(m，1H)，7.98-7.99(m，2H)，8.10-8.12(d，J＝7.8Hz，1H)，8.15(t，J＝1.8Hz，1H)，8.22(d，J＝2.5Hz，1H)，8.57-8.58(d，J＝5.4Hz，1H)，8.80-8.83(q，J＝4.9Hz，1H)。
Embodiment 14 4-[2-(trifluoromethyl-phenylsulfonamido)-benzo [1,2,4] triazine-7-base oxygen base]-the pyridine-2-carboxylic acids first
Synthesizing of base acid amides trifluoroacetate
Figure A20058003591801112
[0157] 4-(3-amino-benzo [1,2,4] triazine-7-base oxygen the base)-pyridine-3-carboxylic acid methyl nitrosourea with 100mg (0.337 mmole, 1.0 equivalents) is dissolved in the 2mL dry DMF, and is heated to about 100 ℃.The solid potassium tert-butoxide of 45.4mg (0.405 mmole, 1.2 equivalents) is added in this solution.The dark red solution that produces was stirred 30 minutes at 100 ℃, make it be cooled to room temperature then.By syringe the 2-trifluoromethyl benzene sulfonyl chloride of 100mg (0.405 mmole, 1.2 equivalents) is added this mixture.It was at room temperature stirred 2 hours.Reaction mixture is filtered by 0.22 μ syringe filter, and the anti-phase preparation HPLC that contains the acetonitrile/water mixture of 0.1%TFA by use carries out purifying.
【0158】ESI-MS：[M+H] +，505，506，507. 1H NMR(DMSO-d 6)：δ2.78-2.79(d，J＝4.8Hz，3H)，7.29-7.31(dd，J 1＝2.6Hz，J 2＝5.7Hz，1H)，7.56(d，J＝2.6Hz，1H)，7.87-7.99(m，5H)，8.21(d，J＝2.6Hz，1H)，8.56-8.58(d，1H)，8.59-8.60(d，J＝8.0Hz，1H)，8.80-8.81(q，J＝4.8Hz，1H)。
Embodiment 15 4-[2-chloro-5-(trifluoromethyl-phenylsulfonamido)-benzo [1,2,4] triazines-7-base oxygen base]-pyridine-2-carboxylic
Synthesizing of acid methyl acid amides trifluoroacetate
Figure A20058003591801121
[0159] used experimental technique is with identical described in the embodiment 9.
【0160】ESI-MS：[M+H] +，539，541，542. 1H NMR(DMSO-d 6)：δ(ppm)2.78-2.79(d，J＝4.9Hz，3H)，7.27-7.29(dd，J 1＝2.6Hz，J 2＝5.7Hz，1H)，7.55(d，J＝2.6Hz，1H)，7.63-7.65(d，J＝9.1Hz，1H)，7.86-7.88(d，J＝8.4Hz，1H)，7.91-7.94(dd，J 1＝2.6Hz，J 2＝9.1Hz，1H)，8.04-8.06(dd，J 1＝2.0Hz，J 2＝8.4Hz，1H)，8.17-8.18(d，J＝2.6Hz，1H)，8.56-8.57(d，J＝5.7Hz，1H)，8.60-8.61(d，J＝2.0Hz，1H)，8.80-8.81(q，J＝4.9Hz，1H)。
Embodiment 16 4-[3-chloro-6-methoxyl group-phenylsulfonamido)-benzo [1,2,4] triazine-7-base oxygen base]-pyridine-2-carboxylic acids
Synthesizing of methyl nitrosourea trifluoroacetate
[0161] used experimental technique is with identical described in the embodiment 9.
【0162】ESI-MS：[M+H] +，501，503，504. 1H NMR(DMSO-d 6)：δ(ppm)2.78-2.79(d，J＝4.9Hz，3H)，3.85(s，3H)，7.20-7.22(d，J＝8.9Hz，1H)，7.29-7.31(dd，J 1＝2.6Hz，J 2＝5.7Hz，1H)，7.55(d，J＝2.6Hz，1H)，7.67-7.70(dd，J 1＝2.8Hz，J 2＝8.9Hz，1H)，7.80-7.81(d，J＝9.2Hz，1H)，7.92-7.95(dd，J 1＝2.8Hz，J 2＝9.2Hz，1H)，8.05-8.06(d，J＝2.8Hz，1H)，8.19-8.20(d，J＝2.6Hz，1H)，8.57-8.58(d，J＝5.6Hz，1H)，8.80-8.81(q，J＝4，9Hz，1H)，13.00(br.s.1H)。
Embodiment 17 4-[3-(5-chloro-thiophene-2-sulfonamido)-benzo [1,2,4] triazine-7-base oxygen base]-the pyridine-2-carboxylic acids first
Synthesizing of base acid amides trifluoroacetate
Figure A20058003591801123
[0163] used experimental technique is with identical described in the embodiment 9.
【0164】ESI-MS：[M+H] +，477，479. 1H NMR(DMSO-d 6)：δ(ppm)2.79-2.80(d，J＝4.8Hz，3H)，7.26-7.27(d，J＝4.1Hz，1H)，7.32-7.34(dd，J 1＝2.6Hz，J 2＝5.6Hz，1H)，7.59(d，J＝2.6Hz，1H)，7.88-7.89(d，J＝4.1Hz，1H)，7.99-8.02(dd，J 1＝2.7Hz，J 2＝9.1Hz，1H)，8.12-8.14(d，J＝9.1Hz，1H)，8.26(d，J＝2.7Hz，1H)，8.59(d，J＝5.6Hz，1H)，8.82-8.83(q，J＝4.8Hz，1H)，13.00(br.s.1H)。
Embodiment 18 4-[2-chloro-3-trifluoromethyl-benzamidos)-benzo [1,2,4] triazine-7-base oxygen base]-pyridine-2-carboxylic
Synthesizing of acid methyl acid amides trifluoroacetate
Figure A20058003591801131
[0165] used experimental technique is with identical described in the embodiment 10.
【0166】ESI-MS：[M+H] +，503，505，506. 1H NMR(DMSO-d 6)：δ(ppm)2.80-2.81(d，J＝4.8Hz，3H)，7.36-7.37(dd，J 1＝2.6Hz，J 2＝5.6Hz，1H)，7.61(d，J＝2.6Hz，1H)，7.82-7.83(d，J＝8.4Hz，1H)，7.90-7.92(dd，J 1＝2.1Hz，J 2＝8.4Hz，1H)，8.00-8.03(m，2H)，8.09(m，1H)，8.29(m，1H)，8.61-8.62(d，J＝5.6Hz，1H)，8.83-8.84(q，J＝4.8Hz，1H)，12.41(s，1H)。
Embodiment 19 4-[2-chloro-3-trifluoromethyl-benzamidos)-benzo [1,2,4] triazine-7-base oxygen base]-pyridine-2-carboxylic
Synthesizing of acid methyl acid amides trifluoroacetate
Figure A20058003591801132
[0167] used experimental technique is with identical described in the embodiment 10.
【0168】ESI-MS：[M+H] +，435，437. 1H NMR(DMSO-d 6)：δ(ppm)2.80-2.81(d，J＝4.8Hz，3H)，7.37-7.39(dd，J 1＝2.6Hz，J 2＝5.6Hz，1H)，7.59-7.62(t，J＝7.8Hz，1H)，7.63-7.64(d，J＝2.6Hz，1H)，7.72-7.74(m，1H)，8.03-8.05(m，2H)，8.13(m，1H)，8.15(d，J＝9.1Hz，1H)，8.33(d，J＝2.6Hz，1H)，8.62-8.63(d，J＝5.6Hz，1H)，8.83-8.84(q，J＝4.8Hz，1H)，12.12(s，1H)。
Embodiment 20 4-[2,4-two chloro-benzamidos)-benzo [1,2,4] triazine-7-base oxygen base]-the pyridine-2-carboxylic acids methyl
Synthesizing of acid amides trifluoroacetate
Figure A20058003591801133
[0169] used experimental technique is with identical described in the embodiment 10.
【0170】ESI-MS：[M+H] +，469，471，472. 1H NMR(DMSO-d 6)：δ(ppm)2.80-2.81(d，J＝4.8Hz，3H)，7.35-7.37(dd，J 1＝2.6Hz，J 2＝5.6Hz，1H)，7.55-7.57(dd，J 1＝1.9Hz，J 2＝8.3Hz，1H)，7.61(d，J＝2.6Hz，1H)，7.68-7.69(d，J＝8.3Hz，1H)，7.76-7.77(d，J＝1.9Hz，1H)，8.01(m，2H)，8.28-8.29(m，1H)，8.61(d，J＝5.6Hz，1H)，8.83-8.84(q，J＝4.8Hz，1H)，12.28(s，1H)。
Embodiment 21 4-[2-fluoro-3-chloro-5-trifluoromethyl-benzamidos)-benzo [1,2,4] triazine-7-base oxygen base]-pyridine
Synthesizing of-2-carboxylic acid methyl acid amides trifluoroacetate
[0171] used experimental technique is with identical described in the embodiment 10.
【0172】ESI-MS：[M+H] +，521，523，524. 1H NMR(DMSO-d 6)：δ(ppm)2.80-2.81(d，J＝4.8Hz，3H)，7.36-7.38(dd，J 1＝2.6Hz，J 2＝5.6Hz，1H)，7.62(d，J＝2.6Hz，1H)，8.02-8.05(dd，J 1＝2.6Hz，J 2＝9.2Hz，1H)，8.07-8.09(d，J＝9.2Hz，1H)，8.14-8.15(dd，1H)，8.31-8.32(d，J＝2.6Hz，1H)，8.33-8.34(dd，J 1＝2.1Hz，J 2＝6.4Hz，1H)，8.62(d，J＝5.6Hz，1H)，8.83-8.84(q，J＝4.8Hz，1H)，12.45(s，1H)。
Embodiment 22 4-[3-(4-chloro-3-trifluoromethyl-benzamido)-benzo [1,2,4] triazine-7-base oxygen base]-pyridine-2-
Synthesizing of carboxylic acid methyl acid amides trifluoroacetate
Figure A20058003591801142
[0173] used experimental technique is with identical described in the embodiment 10.
【0174】ESI-MS：[M+H] +，503，505，506. 1H NMR(DMSO-d 6)：δ(ppm)2.80-2.81(d，J＝4.8Hz，3H)，7.37-7.39(dd，J 1＝2.6Hz，J 2＝5.6Hz，1H)，7.63-7.64(d，J＝2.6Hz，1H)，7.95-7.97(d，J＝8.4Hz，1H)，8.04-8.06(dd，J 1＝2.7Hz，J 2＝9.3Hz，1H)，8.15-8.17(d，J＝9.3Hz，1H)，8.33-8.34(d，J＝2.7Hz，1H)，8.34-8.36(dd，J 1＝2.1Hz，J 2＝8.4Hz，1H)，8.54-8.56(d，J＝2.1Hz，1H)，8.62-8.63(d，J＝5.6Hz，1H)，8.83-8.84(q，J＝4.8Hz，1H)，12.35(s，1H)。
Embodiment 23 4-[3-(2-chloro-3-trifluoromethyl-benzamido)-benzo [1,2,4] triazine-7-base oxygen base]-pyridine-2-
Synthesizing of carboxylic acid methyl acid amides trifluoroacetate
[0175] used experimental technique is with identical described in the embodiment 10.
【0176】ESI-MS：[M+H] +，503，505，506. 1H NMR(DMSO-d 6)：δ(ppm)2.80-2.81(d，J＝4.8Hz，3H)，7.35-7.36(dd，J 1＝2.6Hz，J 2＝5.5Hz，1H)，7.60-7.61(d，J＝2.6Hz，1H)，7.66-7.69(t，J＝7.8Hz，1H)，7.92-7.94(m，2H)，7.99-8.02(m，2H)，8.29(d，J＝2.8Hz，1H)，8.61-8.62(d，J＝5.6Hz，1H)，8.83-8.84(q，J＝4.8Hz，1H)，12.43(s，1H)。
Embodiment 24 4-[3-(3-trifluoromethoxy-benzamido)-benzo [1,2,4] triazine-7-base oxygen base]-pyridine-2-carboxylic
Synthesizing of acid methyl acid amides trifluoroacetate
Figure A20058003591801151
[0177] used experimental technique is with identical described in the embodiment 10.
【0178】ESI-MS：[M+H] +，485，486，487. 1H NMR(DMSO-d 6)：δ(ppm)2.80-2.81(d，J＝4.8Hz，3H)，7.35-7.37(dd，J 1＝2.6Hz，J 2＝5.6Hz，1H)，7.48-7.50(d，J＝8.3Hz，1H)，7.53-7.56(dt，J 1＝0.9Hz，J 2＝7.6Hz，1H)，7.62(d，J＝2.6Hz，1H)，7.66-7.68(dt，J 1＝1.7Hz，J 2＝8.0Hz，1H)，7.78-7.79(dt，J 1＝1.7Hz，J 2＝7.6Hz，1H)，7.99-8.02(m，2H)，8.29(d，J＝2.6Hz，1H)，8.61(d，J＝5.6Hz，1H)，8.83-8.84(q，J＝4.8Hz，1H)，12.22(s，1H)。
Embodiment 25 4-{3-[(5-methyl-different  azoles-3-carbonyl)-amino]-benzo [1,2,4] triazine-7-base oxygen base]-pyridine-2-
Synthesizing of carboxylic acid methyl acid amides trifluoroacetate
[0179] used experimental technique is with identical described in the embodiment 10. 1H NMR(DMSO-d 6)：δ(ppm)2.53(s，3H)，2.80-2.81(d，J＝4.8Hz，3H)，6.79(s，1H)，7.37-7.38(dd，J 1＝2.5Hz，J 2＝5.5Hz，1H)，7.63-7.64(d，J＝2.4Hz，1H)，8.04-8.06(dd，J 1＝2.5Hz，J 2＝9.2Hz，1H)，8.15-8.17(d，J＝9.2Hz，1H)，8.32-8.33(d，J＝2.5Hz，1H)，8.61-8.62(d，J＝5.5Hz，1H)，8.83-8.84(q，J＝4.8Hz，1H)，12.04(s，1H)。
The kinase whose inhibiting external test of 26 couples of Raf of embodiment
[0180] ability of the kinase activity of formula of the present invention (A) compound inhibition Raf1 is assessed with two kinds of methods: direct assay method and Raf1-MEK1 assay method.In direct assay method, in the 96-orifice plate, pass through recombinant human raf1 (29.4U/ hole, Upstate, Lake Placid, NY), ATP (3 μ M), myelin basic protein substrate (MBP, 1mg/ml, Upstate, Lake Placid, NY) and test agent (concentration range be about 1nM/l to about 10 μ M) combined, under the situation that has the kinase reaction damping fluid, carry out kinase reaction.The Raf1-MEK1 assay method use the raf1 in 2.9U/ hole and the inactivation MEK1 in 0.25ug/ hole (MEK1, inactivation, Upstate, LakePlacid, NY) and 3uM ATP., use based on the assay method (KinaseGlo, Promega Corp.) of luciferase residue ATP is measured, after 60 minutes 30 ℃ of reactions as the tolerance of kinase activity.To average and be used for determining the IC of test compounds from the data in four holes then 50Value (Prism software package, GraphPad Software, San Diego CA).
[0181] test result is as follows: a kind of known Raf inhibitor, compd A, the IC that shows 50Be 16nM; A kind of known Raf inhibitor, compd B, the IC that shows 50Be 43nM; The compounds of this invention C, the IC that shows 50Be 76nM.The The compounds of this invention of other of Fig. 1 illustrated, the IC that they show 50Below 100 μ M.
In embodiment 27 test cell lines to the inhibiting mensuration of MAPK path
[0182] western blot analysis: the former generation Human umbilical vein endothelial cells (HUVECs) that will go down to posterity in early days is kept at and contains SingleQuots (Cambrex, East Rutherford, NJ), among the EGM-2 of 10%FBS, 10mM HEPES and 50 μ g/ml gentamicins.Before handling this cell with inhibitor, by replace the complete culture solution that contains serum with the nutrient solution of serum-free and no SingleQuot so that HUVECs hunger 18 hours.With the cell after this hunger with inhibitor (0-20 μ M) pre-treatment 60 minutes under multiple concentration.Then (Peprotech, Rocky Hill NJ) handled 6 minutes, and immediately with ice-cold PBS cleaning cell with 50ng/mlVEGF or FGF with this HUVECs.With cell with ice-cold RIPA damping fluid cracking, this damping fluid contains 100mM Tris pH7.5,150mMNaCl, 1mM EDTA, 1% Septochol, 1%Triton X-100,0.1%SDS, 2mM PMSF, a Complete-Mini proteinase inhibitor (Complete-Mini protease inhibitor) tablet (Roche, Indianapolis, IN; Every 7ml lysis buffer a slice) and inhibitors of phosphatases NaF (500mM) and ortho-vanadate (1mM).Cell is scraped, shift lysate and, centrifugal 10 minutes of 000g 15.Supernatant is changed in the new pipe also with BCA protein reagent (Pierce, Rockford, IL) mensuration protein concentration.The cell lysate that will contain 20 μ g total proteins separates with 10%SDS-PAGE, it is transferred on the nitrocellulose, and seals in containing the TBST liquid of 5% milk.As an anti-anti-phosphorylation ERK Thr202/Tyr204 (Cell Signaling, Beverly, MA), anti-phosphorylation MEK Ser217/221 (Cell Signaling) and c-Raf (BD BioscencesPharmingen, San Diego, CA) with the goat anti-mouse of horseradish peroxidase or goat antirabbit two anti-detections, and (as seen Rochester NY) makes band to use SuperSignal West Pico chemical illuminating reagent system (Pierce) and Kodak's X-ray film.
[0183] when testing in this experiment, Bay 43-9006 (Raf/FGF inhibitor) shows the expression that has reduced p-MEK and p-ERK, IC 50Be 200 to 300nM.U0126 (mek inhibitor) shows and has reduced p-Erk level, IC 50Be 200 to 300nM, and the p-MEK level is unaffected.The result is illustrated in the table 1.As can be seen, compound of the present invention shows the reduction of p-MEK and p-ERK level, has the IC of 400nM to 20 μ M 50
Embodiment 28 cell viability analyses
[0184] XTT analyzes: HUVECs is inoculated in the tissue culture treated 96-orifice plate of handling through type i collagen albumen with 10,000 cells/well, and in aforesaid complete EGM-2 nutrient solution grow overnight.Morning next day is with DMSO serial dilution inhibitor and with in 1% the DMSO final concentration adding cell.(Sigma, St.Louis MO) measure cell viability with the XTT assay method after 24-48 hour.Also take a picture with the morphology difference of more viewed XTT trend for cell.(Prism Software package, GraphPadSoftware, San Diego CA) determines IC with quantitation software 50Value.Some kinds of inhibitor have stoped cell proliferation, and apoptosis-induced when being lower than the concentration of 1 μ M, and the triplicate experiment is to confirm observations.Compound of the present invention shows the IC of 100nM to 40 μ M in this experiment 50(table 1).
Table 1. embodiment 26,27 and 28 test result
Figure A20058003591801171
Figure A20058003591801181
Figure A20058003591801201
Synthesizing of embodiment 29 S-methyl N-[4-chloro-3-(trifluoromethyl)-phenyl] isothiourea hydriodide
Figure A20058003591801221
[0185] 4-chloro-3-trifluoromethyl-phenylthiourea (5.0g, 19.63 mmoles) is dissolved among the anhydrous MeOH of about 80mL, and adds methyl-iodide (2.93g, 20.61 mmoles) by syringe.With reaction mixture refluxed 12 hours.Then it is cooled to room temperature and solvent removed in vacuo, obtains water white oil (7.85g), it is used to next step without being further purified.
[0186] according to the method for this embodiment, prepares S-methyl N-[4-Trifluoromethoxyphen-l] isothiourea hydriodide, S-methyl N-[4-hydroxyl-phenyl] isothiourea hydriodide, S-methyl N-[3-hydroxyl-phenyl] isothiourea hydriodide and S-methyl N-[3-(trifluoromethyl) phenyl] isothiourea hydriodide.
[0187] 1,2, under the situation of 4-triazole, three kinds of tautomeric structures can appear, as follows:
Figure A20058003591801222
[0188] even may there be whole three kinds of tautomeric structures, for the sake of simplicity and for analogue direct with it such as containing 1,3, the example of 4- diazole part compares, and has 1,2, the all categories structure of 4-triazole part and all examples by with a kind of tautomeric form, such as using 4H-1,2, the 4-triazole is represented.Dominant tautomeric structure is decided by substituting group and the reaction conditions on the triazole part.As shown in document, 1H-1,2, the normally modal tautomeric form of 4-triazole is if particularly amino substituting group is connected to this ring when going up.For the sake of simplicity, only use the 4H-tautomeric form to describe this structure and do not mean that following examples compound must exist with this concrete tautomeric form.Use this method, the IUPAC title of following examples only is provided with the 4-H tautomeric form, but should be appreciated that substituent numbering may be different with the numbering that is provided when explaining accurately tautomeric structure.
Embodiment 30 4-[5-(4-chloro-3-trifluoromethyl-phenyl amino)-4H[1,2,4] triazole-3-yl]-phenol synthetic
Figure A20058003591801223
[0189] 4-hydroxybenzoyl hydrazine (3.0g, 19.66 mmoles) and S-methyl N-[4-chloro-3-(trifluoromethyl) phenyl] isothiourea hydriodide (7.8g, 19.66 mmoles) are suspended in the 100mL anhydrous pyridine.Under Ar gas with reaction mixture refluxed 18 hours.Then it is cooled to room temperature and vacuum and removes pyridine.The yellow oil that produces is dissolved in the amount of ethyl acetate again, is loaded on the short silicagel pad and with 5: 1 hexane/ethyl acetate wash-outs, then with 100% eluent ethyl acetate with the collection product.Use ISCO system (80g prepacked column, the hexane with containing 20% to 50%EtOAc gradient move 25 minutes), with this product by silica gel column chromatography second time purifying once more.Solvent removed in vacuo obtains this title product, is white solid (2.83g).Yield 40.4%.
【0190】ESI-MS：[M+H] +355.1，356.8. 1H NMR(DMSO-d 6)：δ6.89-6.91(d，J＝8.7Hz，2H)，7.53-7.55(d，J＝8.8Hz，1H)，7.70-7.72(dd，J 1＝8.8Hz，J 2＝2.6Hz，1H)，7.77-7.79(d，J＝8.7Hz，2H)，8.24-8.25(d，J＝2.6Hz，1H)，9.81(s，1H)，9.98(s，1H)，13.62(s，1H)。
Embodiment 31 4-{4-[5-(4-chloro-3-trifluoromethyl-phenyl amino)-4H-[1,2,4] triazole-3-yl]-phenoxy group }-pyrrole
Synthesizing of pyridine-2-carboxylic acid methyl acid amides trifluoroacetate
【0191】ESI-MS：[M+H] +，490，491. 1H NMR(DMSO-d 6)：δ2.78-2.79(d，J＝4.8Hz，3H)，7.24-7.25(m，1H)，7.40-7.42(d，J＝8.7Hz，2H)，7.48(s，1H)，7.56-7.58(d，J＝8.8Hz，1H)，7.79-7.82(dd，J 1＝2.6Hz，J 2＝8.8Hz，1H)，8.07-8.09(d，J＝8.7Hz，2H)，8.24-8.25(d，J＝2.6Hz，1H)，8.55-8.56(m，1H)，8.80-8.81(m，1H)，9.95(s，1H)。
Embodiment 32 (4-chloro-3-trifluoromethyl-phenyl)-5-[4-(pyridin-3-yl oxygen base)-phenyl]-4H-[1,2,4] triazole-3-
Base }-amine trifluoroacetate synthetic
Figure A20058003591801232
[0192] with 4-[5-(4-chloro-3-trifluoromethyl-phenyl amino)-4H[1,2,4] triazole-3-yl]-phenol (127.8mg, 0.36 mmole) is dissolved in the 3mL dry DMF in 5mL microwave tube (Personal Chemistry).Add two (trimethyl silyl) acid amides potassium (144.0mg, 0.72 mmole) of solid, reaction mixture is heated to 80 ℃ and stirred 15 minutes, add 3-bromopyridine (68.3mg, 0.432 mmole) then, add anhydrous K subsequently 2CO 3(50.0mg, 0.36 mmole).Cover bottle cap then and 250 ℃ of microwave heatings 30 minutes.Then reaction mixture is diluted with about 1mL MeOH, filter, and carry out purifying with the acetonitrile/water system that contains 0.01%TFA by anti-phase preparation HPLC by 0.22 μ m syringe filter.This product is with tfa salt form separated (15.1mg).
【0193】ESI-MS：[M+H] +，432，433. 1H NMR(DMSO-d 6)：δ7.19-7.21(d，J＝8.8Hz，2H)，7.49-7.51(dd，J 1＝4.5Hz，J 2＝8.6Hz，1H)，7.53-7.55(d，J＝8.8Hz，1H)，7.58-7.60(m，1H)，7.74-7.76(m，1H)，7.95-7.98(d，J＝8.8Hz，2H)，8.21-8.21(d，J＝2.6Hz，1H)，8.44(m，1H)，8.48(m，1H)，9.88(s，1H)。
Synthesizing of embodiment 33 4-(pyridin-3-yl oxygen base) methyl benzoate
Figure A20058003591801241
[0194] under argon gas, 3-pyridone (6.17g, 64.87 mmoles) is dissolved in the 100mL dry DMF.Add solid K 2CO 3(8.96g, 64.87 mmoles) add pure 4-fluorophenyl carbamate (10.0g, 64.87 mmoles) subsequently.Reaction mixture was heated 10 hours at 135 ℃.Confirm not exist starting material by LC/MS.Reaction mixture is cooled to room temperature and pours in about 500mL water.The solution that produces (in extraction process, is added a spot of MeOH, Et 3 times with about 150mL EtOAc extraction 2O and salt solution help this sepn process).With the saturated NaHCO of EtOAc layer that merges 3Washed twice is with the salt solution washed twice and in anhydrous Na 2SO 4Last dry.Solvent removed in vacuo obtains scarlet oil, and the EtOAc/ hexanes mixtures of using 1: 1 is purified by silica gel chromatography as eluent, obtains this title product (4.8g, 32.3% yield) of yellow solid form.
【0195】ESI-MS：[M+H] +，230，231. 1H NMR(DMSO-d 6)：δ3.83(s，3H)，7.09-7.12(d，J＝8.8Hz，2H)，7.48-7.51(dd，J 1＝8.4Hz，J 2＝4.9Hz，1H)，7.58-7.61(dq，J 1＝8.4Hz，J 2＝1.4Hz，1H)，7.96-7.99(d，J＝8.8Hz，2H)，8.46-8.47(m，2H)。
Synthesizing of embodiment 34 4-(pyridin-3-yl oxygen base) benzoyl hydrazine
Figure A20058003591801242
[0196] 4-(pyridin-3-yl oxygen base) methyl benzoate (4.8g, 20.94 mmoles) is dissolved among about 150mLEtOH, and by syringe add anhydrous hydrazine (4.08g, 4.0mL).The yellow solution that produces was refluxed 24 hours.Solvent removed in vacuo obtains this title product (4.8g, 100% yield) then, is yellow viscous oil, and it slowly solidifies.
【0197】ESI-MS：[M+H] +，230，231. 1H NMR(DMSO-d 6)：δ4.13(br s.，2H)，7.06-7.09(d，J＝8.7Hz，2H)，7.45-7.47(dd，J 1＝8.4Hz，J 2＝4.9Hz，1H)，7.51-7.54(dq，J 1＝8.4Hz，J 2＝1.4Hz，1H)，7.85-7.88(d，J＝8.8Hz，2H)，8.42-8.43(m，2H)，9.74(s，1H)。
Embodiment 35 (4-chloro-3-trifluoromethyl-phenyl)-5-[4-(pyridin-3-yl oxygen base)-phenyl]-4H-[1,2,4] triazole-3-
Base }-amine synthetic
Figure A20058003591801243
[0198] 4-(pyridin-3-yl oxygen base) benzoyl hydrazine (2.33g, 10.2 mmoles) is dissolved in about 70mL anhydrous pyridine, and adds S-methyl N-[4-chloro-3-(trifluoromethyl) phenyl] isothiourea hydriodide (4.04g, 10.2 mmoles).Reaction mixture was refluxed 18 hours under argon gas.Vacuum is removed pyridine, and uses EtOAc as eluent, and the residue that produces is carried out purifying by silica gel chromatography, obtains this title product (0.56g), is white solid.
【0199】ESI-MS：[M+H] +，432，433. 1H NMR(DMSO-d 6)：δ7.20-7.23(d，J＝8.8Hz，2H)，7.46-7.49(dd，J 1＝8.4Hz，J 2＝4.5Hz，1H)，7.54-7.57(m，2H)，7.75-7.77(dd，J 1＝8.8Hz，J 2＝2.6Hz，1H)，7.97-7.99(d，J＝8.8Hz，2H)，8.23-8.24(d，J＝2.6Hz，1H)，8.43(m，1H)，8.46(d，J＝2.6Hz，1H)，9.88(s，1H)，13.91(s，1H)。
Embodiment 36 6-{4-[5-(4-chloro-3-trifluoromethyl-phenyl amino)-4H-[1,2,4] triazole-3-yl]-phenoxy group }-phonetic
Pyridine-2,4-diamines synthetic
Figure A20058003591801251
[0200] with 4-[5-(4-chloro-3-trifluoromethyl-phenyl amino)-4H[1,2,4] triazole-3-yl] phenol (1.3g, 3.66 mmoles) is dissolved in the anhydrous two  alkane of 18mL in 10-20mL microwave tube (Personal Chemistry).Add solid Cs 2CO 3(1.19g, 3.66 mmoles, 1.0 equivalents) and with reaction mixture 80 ℃ of heated and stirred 10 minutes, add 4-chloro-2 then, 4-di-amino-pyrimidine (0.530g, 3.66 mmoles).Cover bottle cap and 200 ℃ of microwave heatings 25 minutes.Then reaction mixture is diluted with about 10mL MeOH, change in the round-bottomed flask and the extremely about 20mL of vacuum concentration.The red solution that produces is loaded on the short silicagel pad, and wash-out is to remove unreacted starting material for the first time with 100% ethyl acetate, usefulness contains the EtOAc eluted product of 20%MeOH then.Product is further purified by ISCO system (80g prepacked column, 40 minutes methods are with the ethyl acetate that contains 0% to 10%MeOH gradient).Solvent removed in vacuo obtains this title product, is pale solid (0.785g).Yield 46.3%.
【0201】ESI-MS：[M+H] +，463，464，465. 1H NMR(DMSO-d 6)：δ5.15(s，1H)，6.03(s，2H)，6.31(s，2H)，7.25-7.27(d，J＝8.6Hz，2H)，7.55-7.57(d，J＝8.8Hz，1H)，7.77-7.78(m，1H)，7.96-7.97(d，J＝8.8Hz，2H)，8.25-8.26(d，J＝2.6Hz，1H)，9.91(s，1H)，13.91(s，1H)。Analyze. calculated value (C 19H 14ClF 3N 8O * 0.4EtOAc): C, 49.68; H, 3.48; N, 22.50, observed value: C, 49.61; H, 3.55; N, 22.90.
Embodiment 37 6-{4-[5-(4-chloro-3-trifluoromethyl-phenyl amino)-4H-[1,2,4] triazole-3-yl]-phenoxy group }-phonetic
Pyridine-2,4-diamines mesylate synthetic
Figure A20058003591801252
[0202] with 6-{4-[5-(4-chloro-3-trifluoromethyl-phenyl amino)-4H-[1,2,4] triazole-3-yl]-phenoxy group }-pyrimidine-2,4-diamines * 0.4EtOAc mixture (470.0mg, 0.943 mmole) be dissolved in about 50mL anhydrous methanol, and adding methylsulfonic acid (0.0612mL, 0.943 mmole, 1 equivalent).With the solution stirring that produces 30 minutes.Solvent removed in vacuo, and the light yellow foam that will produce 70 ℃ under the high vacuum condition dry 3 hours, obtain this title compound, be pale solid (527.3mg).Yield 100%.
【0203】ESI-MS：[M+H] +，463，464. 1H NMR(DMSO-d 6)：δ2.36(s，3H)，5.40(s，1H)，7.39-7.40(d，J＝8.6Hz，2H)，7.57-7.58(d，J＝8.8Hz，1H)，7.78(m，1H)，7.80(br.s.，4H)，8.02-8.03(d，J＝8.8Hz，2H)，8.25-8.26(d，J＝2.6Hz，1H)，9.94(s，1H)，13.98(br..s.1H)。Analyze. calculated value (C 19H 14ClF 3N 8O * 1CH 3SO 3H): C, 42.98; H, 3.25; N, 20.05, observed value: C, 42.93; H, 3.62; N, 20.12.
Embodiment 38 4-[(2,6-di-amino-pyrimidine-4-yl) oxygen base] methyl benzoate synthetic
Figure A20058003591801261
[0204] 4-methyl hydroxybenzoate (1.52g, 10.0 mmoles) is dissolved in the anhydrous two  alkane of 18mL in 10-20mL microwave tube (Personal Chemistry), and with solid Cs 2CO 3Add this solution.This suspension was at room temperature stirred 10 minutes, add 4-chloro-2 then, 6-di-amino-pyrimidine (1.45g, 10.0 mmoles).Cover bottle cap and 200 ℃ of microwave heatings 40 minutes.Add MeOH then, dissolve formed suspension, produce limpid amber solution.Solution is changed over to round-bottomed flask and is concentrated into about 20mL.As eluent, this solution is carried out purifying by silica gel chromatography with 100% ethyl acetate.Again from 4: 1 EtOAc/MeOH mixture of about 50mL with the product recrystallization.Product is filtered, with 40mL EtOAc washing, with the anhydrous Et of 40mL 2O washing and vacuum-drying obtain this title product, are white solid (0.812g).Yield 31.2%.
【0205】ESI-MS：[M+H] +，261.01. 1H NMR(DMSO-d 6)：δ3.84(s，3H)，5.19(s，1H)，6.06(br.s，2H)，6.37(br.s，2H)，7.19-7.21(d，J＝8.7Hz，2H)，7.95-7.97(d，J＝8.7Hz，2H)。 13C NMR(DMSO-d 6)52.1，78.3，121.0，125.3，130.9，157.8，163.2，165.7，166.6，169.2。
Embodiment 39 4-[(2,6-di-amino-pyrimidine-4-yl) oxygen base] benzoyl hydrazine synthetic
Figure A20058003591801262
[0206] oxygen base with 4-[(2,6-di-amino-pyrimidine-4-yl)] methyl benzoate (2.74g, 10.52 mmoles) is suspended in about 180mL anhydrous methanol, and anhydrous hydrazine (1.021g, 1.0mL, 31.85 mmoles, 3.03 equivalents) added this suspension.With reaction mixture refluxed 3 hours, distill MeOH then very lentamente and reach about 30mL until cumulative volume.This solution was at room temperature placed 48 hours.Slowly crystallization goes out white precipitate.With its collection, with 40mL EtOAc washing, with the anhydrous Et of 40mL 2O washing and vacuum-drying obtain this title product, are meticulous white powder (2.02g).Yield 73.7%.
【0207】ESI-MS：[M+H] +，261.12. 1H NMR(DMSO-d 6)：δ4.54(br.s.，2H)，5.13(s，1H)，6.01(br.s，2H)，6.30(br.s，2H)，7.13-7.14(d，J＝8.7Hz，2H)，7.83-7.84(d，J＝8.7Hz，2H)，9.75(s，1H)。 13C NMR(DMSO-d 6)77.9，120.9，128.5，129.3，155.8，163.3，165.4，166.6，169.7。
Embodiment 40 6-{4-[5-(4-chloro-3-trifluoromethyl-phenyl amino)-4H-[1,2,4] triazole-3-yl]-phenoxy group }-phonetic
Pyridine-2,4-diamines synthetic
Figure A20058003591801271
[0208] oxygen base with 4-[(2,6-di-amino-pyrimidine-4-yl)] benzoyl hydrazine (1.48g, 5.68 mmoles) and S-methyl N-[4-chloro-3-(trifluoromethyl) phenyl] isothiourea hydriodide (2.33g, 5.89 mmoles) be suspended in the 30mL anhydrous pyridine.Under Ar atmosphere with reaction mixture refluxed 18 hours.The yellow solution that forms is cooled to room temperature and vacuum removal pyridine.The yellow spumescence solid that produces is dissolved among 5: 1 the EtOAc/MeOH of 50mL again; Add about 15g silica gel and solvent removed in vacuo.The silica gel that will the be soaked into ISCO post of packing into, and with the ISCO system (the 80g prepacked column is with the solvent orange 2 A that contains 0% to 10% solvent B gradient [solvent orange 2 A-contain 4mL MeOH, 4mL Et 3The 4L CH of N 2Cl 2Solvent B-contains 4mL Et 3The 4L MeOH of N], move 50 minutes) purified product.Solvent removed in vacuo obtains this title product, is white solid (1.33g).Yield 50.5%.
【0209】ESI-MS：[M+H] +，463，464. 1H NMR(DMSO-d 6)：δ5.15(s，1H)，6.03(s，2H)，6.31(s，2H)，7.25-7.27(d，J＝8.6Hz，2H)，7.55-7.57(d，J＝8.8Hz，1H)，7.77-7.78(m，1H)，7.96-7.97(d，J＝8.8Hz，2H)，8.25-8.26(d，J＝2.6Hz，1H)，9.91(s，1H)，13.91(s，1H)。Analyze. calculated value (C 19H 14ClF 3N 8O * 0.4 EtOAc): C, 49.68; H, 3.48; N, 22.50, observed value: C, 49.61; H, 3.55; N, 22.90.
Embodiment 41 6-{4-[5-(4-chloro-3-trifluoromethyl-phenyl amino)-4H-[1,2,4] triazole-3-yl]-phenoxy group }-rattle away
Synthesizing of piperazine-3-base amine trifluoroacetate
Figure A20058003591801272
[0210] with 4-[5-(4-chloro-3-trifluoromethyl-phenyl amino)-4H[1,2,4] triazole-3-yl]-phenol (120.0mg, 0.338 mmole) is dissolved in the 3mL dry DMF in 5mL microwave tube (Personal Chemistry).Add two (trimethyl silyl) acid amides potassium (81.0mg, 0.406 mmole) of solid, reaction mixture 80 ℃ of heated and stirred 15 minutes, is added 3-amino-6-chloro-pyridazine (48.2mg, 0.372 mmole) then, add anhydrous K subsequently 2CO 3(46.7mg, 0.338 mmole).Cover bottle cap then and 200 ℃ of microwave heatings 30 minutes.After reaction is finished, reaction mixture is diluted with about 1mL MeOH, filter, and carry out purifying with the acetonitrile/water system that contains 0.01%TFA by anti-phase preparation HPLC by 0.22 μ m syringe filter.This product is with tfa salt form separated (18.2mg).
【0211】ESI-MS：[M+H] +，448，449. 1H NMR(DMSO-d 6)：δ7.42-7.43(d，J＝8.7Hz，2H)，7.54-7.56(d，J＝9.7Hz，1H)，7.56-7.58(d，J＝8.8Hz，1H)，7.76-7.79(m，1H)，7.78-7.80(d，J＝9.7Hz，1H)，8.01-8.04(d，J＝8.8Hz，2H)，8.25-8.26(d，J＝2.6Hz，1H)，8.49(br.s.，2H)，9.94(s，1H)。
Embodiment 42 4-[5-(4-trifluoromethoxy-phenyl amino)-4H-[1,2,4] triazole-3-yl]-phenol synthetic
Figure A20058003591801281
[0212] 4-hydroxybenzoyl hydrazine (0.643g, 4.23 mmoles) and S-methyl N-[4-(trifluoromethoxy) phenyl] isothiourea hydriodide (1.6g, 4.23 mmoles) are suspended in the 10mL anhydrous pyridine.With reaction mixture refluxed 24 hours, its color was become orange red by yellow during this period.Then it is cooled to room temperature and is stirring and pouring in the 150mL frozen water.The white solid that forms is collected, and water thoroughly cleans and at air drying.Use the Isco post, use the hexane that contains 10% to 100% gradient ethyl acetate by silica gel chromatography the residue purifying that produces.Solvent removed in vacuo obtains this title product, is pink solid (575.2mg).Yield 40.4%.
【0213】ESI-MS：[M+H] + 337，338. 1H NMR(DMSO-d 6)：δ6.85-6.87(d，J＝8.0Hz，2H)，7.19-7.20(d，J＝8.0Hz，2H)，7.61-7.63(d，J＝8.7Hz，2H)，7.75-7.77(d，J＝8.7Hz，2H)，9.39(s，1H)，9.92(s，1H)，13.42(s，1H)。
Embodiment 43 4-{4-[5-(4-trifluoromethoxy-phenyl amino)-4H-[1,2,4] triazole-3-yl]-phenoxy group }-pyridine
Synthesizing of-2-carboxylic acid methyl acid amides trifluoroacetate
Figure A20058003591801282
[0214] with 4-[5-(4-trifluoromethoxy-phenyl amino)-4H[1,2,4] triazole-3-yl]-phenol (66.4mg, 0.197 mmole) is dissolved in the 2mL dry DMF in 5mL microwave tube (Personal Chemistry).Add two (trimethyl silyl) acid amides potassium (39.4mg, 0.197 mmole) of solid, reaction mixture 80 ℃ of heated and stirred 15 minutes, is added 4-chloro-2-pyridine carboxamide (33.7mg, 0.197 mmole) then, add anhydrous K subsequently 2CO 3(27.3mg, 0.197 mmole).Cover bottle cap then and 200 ℃ of microwave heatings 15 minutes.Then reaction mixture is diluted with about 1mL MeOH, filter, and carry out purifying with the acetonitrile/water system that contains 0.01%TFA by anti-phase preparation HPLC by 0.22 μ m syringe filter.This product is with tfa salt form separated (46.6mg).
【0215】ESI-MS：[MH-H] + 471，472. 1H NMR(DMSO-d 6)：δ2.78-2.79(d，J＝4.8Hz，3H)，7.23-7.25(dd，J 1＝5.6Hz，J 2＝2.6Hz，1H)，7.25-7.27(d，J＝8.6Hz，2H)，7.38-7.40(d，J＝8.6Hz，2H)，7.47-7.47(d，J＝2.6Hz，1H)，7.66-7.70(d，J＝8.7Hz，2H)，8.08-8.11(d，J＝8.7Hz，2H)，8.55-8.56(d，J＝5.6Hz，1H)，8.79-8.82(t，J＝4.8Hz，1H)，9.58(s，1H)。
Embodiment 44 5-[4-(pyridin-4-yl oxygen base)-phenyl]-4H-[1,2,4] triazole-3-yl }-(4-trifluoromethoxy-benzene
Base)-amine trifluoroacetate synthetic
Figure A20058003591801291
[0216] with 4-[5-(4-trifluoromethoxy-phenyl amino)-4H[1,2,4] triazole-3-yl]-phenol (106.0mg, 0.315 mmole) is dissolved in the 2mL dry DMF in 5mL microwave tube (Personal Chemistry).Add two (trimethyl silyl) acid amides potassium (157.2mg, 0.788 mmole) of solid, reaction mixture 80 ℃ of heated and stirred 15 minutes, is added 4-chloropyridine hydrochloric acid (56.7mg, 0.378 mmole) then, add anhydrous K subsequently 2CO 3(44.0mg, 0.315 mmole).Cover bottle cap then and 250 ℃ of microwave heatings 20 minutes.Then reaction mixture is diluted with about 1mL MeOH, filter, and carry out purifying with the acetonitrile/water system that contains 0.01%TFA by anti-phase preparation HPLC by 0.22 μ m syringe filter.This product is with tfa salt form separated (66.5mg pale solid).
【0217】ESI-MS：[M+H] +，415，416. 1H NMR(DMSO-d 6)：δ7.26-7.27(d，J＝8.7Hz，2H)，7.46-7.48(m，2H)，7.46-7.48(d，J＝7.1Hz，2H)，7.67-7.70(d，J＝8.7Hz，2H)，8.13-8.16(d，J＝8.7Hz，2H)，8.77-8.78(d，J＝7.1Hz，2H)，9.64(s，1H)。
Embodiment 45 6-{4-[5-(4-trifluoromethoxy-phenyl amino)-4H-[1,2,4] triazole-3-yl]-phenoxy group }-pyridazine
Synthesizing of-3-base amine trifluoroacetate
Figure A20058003591801292
[0218] with 4-[5-(4-trifluoromethoxy-phenyl amino)-4H[1,2,4] triazole-3-yl]-phenol (112.0mg, 0.33 mmole) is dissolved in the 2mL dry DMF in 5mL microwave tube (Personal Chemistry).Add two (trimethyl silyl) acid amides potassium (132.8mg, 0.66 mmole) of solid, reaction mixture 80 ℃ of heated and stirred 15 minutes, is added 3-amino-6-chlorine pyridazine (47.4mg, 0.366 mmole) then, add anhydrous K subsequently 2CO 3(46.0mg, 0.33 mmole).Cover bottle cap then and 250 ℃ of microwave heatings 15 minutes.Then reaction mixture is diluted with about 1mL MeOH, filter, and carry out purifying with the acetonitrile/water system that contains 0.01%TFA by anti-phase preparation HPLC by 0.22 μ m syringe filter.This product is with tfa salt form separated (the brown crystalline solid of 52.1mg).
【0219】ESI-MS：[M+H] +，431. 1H NMR(DMSO-d 6)：δ7.25-7.26(d，J＝8.7Hz，2H)，7.39-7.41(d，J＝8.7Hz，2H)，7.52-7.54(d，J＝9.7Hz，1H)，7.67-7.68(d，J＝8.7Hz，2H)，7.76-7.78(d，J＝9.7Hz，1H)，8.03-8.06(d，J＝8.7Hz，2H)，9.58(s，1H)。
Embodiment 46 6-{4-[5-(4-trifluoromethoxy-phenyl amino)-4H-[1,2,4] triazole-3-yl]-phenoxy group }-pyrimidine
-2,4-diamines trifluoroacetate synthetic
Figure A20058003591801301
[0220] with 4-[5-(4-trifluoromethoxy-phenyl amino)-4H[1,2,4] triazole-3-yl]-phenol (112.0mg, 0.33 mmole) is dissolved in the 2mL dry DMF in 5mL microwave tube (Personal Chemistry).Add two (trimethyl silyl) acid amides potassium (132.8mg, 0.66 mmole) of solid, reaction mixture 80 ℃ of heated and stirred 15 minutes, is added 4-chloro-2 then, 6-diamino-pyrimidine (53.0mg, 0.366 mmole) adds anhydrous K subsequently 2CO 3(46.0mg, 0.33 mmole).Cover bottle cap then and 250 ℃ of microwave heatings 15 minutes.Then reaction mixture is diluted with about 1mL MeOH, filter, and carry out purifying with the acetonitrile/water system that contains 0.01%TFA by anti-phase preparation HPLC by 0.22 μ m syringe filter.This product is with tfa salt form separated (51.1mg light brown solid).
【0221】ESI-MS：[M+H] +，445，446. 1H NMR(DMSO-d 6)：δ5.36(s，1H)，7.25-7.27(br.d，J＝8.0Hz，2H)，7.35-7.36(br.d，J＝8.0Hz，2H)，7.67-7.68(d，J＝8.7Hz，2H)，7.67(br.s.，4H)，8.02-8.04(d，J＝8.7Hz，2H)，9.57(br.s，1H)。
Embodiment 47 4-(5-{[3-(trifluoromethyl) phenyl] amino }-4H-1,2,4-triazole-3-yl)-phenol synthetic
[0222] under argon gas, S-methyl N-[3-(trifluoromethyl) phenyl] isothiourea hydriodide (9.09g, 25.11 mmoles) and 4-hydroxybenzoyl hydrazine (3.82g, 25.11 mmoles) are suspended in about 50mL anhydrous pyridine.This mixture was refluxed 12 hours under argon gas.Then this deep yellow solution is cooled to room temperature, and vacuum is removed pyridine.The reddish yellow solid that produces is dissolved in 4: 1 the EtOAc/MeOH mixture of about 50mL again, adds about 20g silica gel, and solvent removed in vacuo.The silica gel that will be soaked into is packed in the 25g ISCO sample hose, and with ISCO system (solid process, the 80g post was with the hexane that contains 0% to 50%EtOAc gradient, 45 minutes) purified product.Solvent removed in vacuo obtains this title product, is white solid (3.83g).Yield 47.6%.
【0223】ESI-MS：[M+H] +，321.09. 1H NMR(DMSO-d 6)：δ6.89-6.90(d，J＝8.6Hz，2H)，7.09-7.11(d，J＝7.3Hz，1H)，7.42-7.46(t，J＝7.9Hz，1H)，7.73-7.74(d，J＝7.0Hz，1H)，7.77-7.79(d，J＝8.6Hz，2H)，8.09(s，1H)，9.65(s，1H)，9.97(br.s.，1H)。
Embodiment 48 6-[4-(5-{[3-(trifluoromethyl) phenyl] amino }-4H-[1,2,4] triazole-3-yl]-phenoxy group }-pyrimidine
-2,4-diamines synthetic
[0224] with 4-(5-{[3-(trifluoromethyl) phenyl] amino }-4H-1,2,4-triazole-3-yl) phenol (160mg, 0.5 mmole) is dissolved in the anhydrous two  alkane of 3mL in 2-5mL microwave tube (Personal Chemistry).Add solid Cs 2CO 3(163.0mg, 0.5 mmole) adds 4-chloro-2 subsequently, 6-di-amino-pyrimidine (79.5mg, 0.55 mmole).Cover bottle cap then and 200 ℃ of microwave heatings 20 minutes.Add about 3mL MeOH then to dissolve formed suspension, this solution is changed in the round-bottomed flask, and solvent removed in vacuo.Residue is dissolved among the 3mL DMF again, filters, and carry out purifying with the acetonitrile/water system that contains 0.01%TFA by anti-phase preparation HPLC by 0.22 μ m syringe filter.
[0225] part that will contain product is collected, and at EtOAc and saturated NaHCO 3Distribute between the aqueous solution.With ethyl acetate layer salt water washing, dry and filtration on anhydrous sodium sulphate.Solvent removed in vacuo obtains this title compound, is pale solid (92.2mg).
【0226】ESI-MS：[M+H] +，429.08. 1H NMR(DMSO-d 6)：δ5.15(s，1H)，6.02(s，2H)，6.30(s，2H)，7.12(m，1H)，7.25-7.27(d，J＝7.4Hz，2H)，7.45-7.47(m，1H)，7.75-7.76(m，1H)，7.95-7.97(d，J＝8.6Hz，2H)，8.10(s，1H)，9.73(s，1H)，13.84(s，1H)。
Embodiment 49 5-[4-(pyrimidine-5-base oxygen base) phenyl]-N-[3-(trifluoromethyl) phenyl]-4H-1,2,4-triazole-3-amine
Synthetic
Figure A20058003591801312
[0227] with 4-(5-{[3-(trifluoromethyl) phenyl] amino }-4H-1,2,4-triazole-3-yl)-phenol (100mg, 0.31 mmole) is dissolved in the anhydrous two  alkane of 3mL in 2-5mL microwave tube (Personal Chemistry).Add solid Cs 2CO 3(203.4mg, 0.62 mmole) adds 5-bromo pyrimi piperidine (100mg, 0.62 mmole) subsequently.Add the 1mL dry DMF then, cover bottle cap and 250 ℃ of microwave heatings 30 minutes.Add about 3mL MeOH then to dissolve formed suspension, this solution is changed in the round-bottomed flask, and solvent removed in vacuo.Residue is dissolved among the 3mL DMF again, filters, and carry out purifying with the acetonitrile/water system that contains 0.01%TFA by anti-phase preparation HPLC by 0.22 μ m syringe filter.The part that will contain product is collected, and at EtOAc and saturated NaHCO 3Distribute between the aqueous solution.With ethyl acetate layer salt water washing, dry and filtration on anhydrous sodium sulphate.Solvent removed in vacuo obtains this title compound, is light brown spumescence solid (34.7mg).
【0228】ESI-MS：[M+H] +，399.06. 1H NMR(DMSO-d 6)：δ7.12(m，1H)，7.30-7.32(d，J＝7.4Hz，2H)，7.46(m，1H)，7.76(m，1H)，8.00-8.02(d，J＝8.6Hz，2H)，8.09(s，1H)，8.73(s，2H)，9.06(s，1H)，9.73(s，1H)，13.95(s，1H)。
Embodiment 50 5-[4-(pyridin-3-yl oxygen base) phenyl]-N-[3-(trifluoromethyl) phenyl]-4H-[1,2,4]-triazole-3-amine
Synthetic
Figure A20058003591801321
[0229] with 4-(5-{[3-(trifluoromethyl) phenyl] amino }-4H-1,2,4-triazole-3-yl)-phenol (100mg, 0.31 mmole) is dissolved in the 2mL dry DMF in 2-5mL microwave tube (Personal Chemistry).Add solid Cs 2CO 3(203.4mg, 0.62 mmole) adds 3-bromopyridine (74.0mg, 0.468 mmole) subsequently.Cover bottle cap and 250 ℃ of microwave heatings 30 minutes.Add about 1mL MeOH then to dissolve formed suspension.The red tan solution that produces is filtered by 0.22 μ m syringe filter, and carry out purifying with the acetonitrile/water system that contains 0.01%TFA by anti-phase preparation HPLC.The part that will contain product is collected, and at EtOAc and saturated NaHCO 3Distribute between the aqueous solution.With ethyl acetate layer salt water washing, dry and filtration on anhydrous sodium sulphate.Solvent removed in vacuo obtains this title compound, is yellow solid (22.4mg).
【0230】ESI-MS：[M+H] +，398.11. 1HNMR(DMSO-d 6)：δ7.09(d，J＝7.6Hz，1H)，7.20-7.22(d，J＝8.6Hz，2H)，7.46-7.48(m，2H)，7.52-7.54(m，1H)，7.75-7.76(d，J＝8.2Hz，1H)，7.99-8.02(d，J＝8.6Hz，2H)，8.09(s，1H)，8.42-8.43(d，J＝4.5Hz，1H)，8.45-8.46(d，J＝2.6Hz，1H)，9.73(s，1H)，13.85(s，1H)。
Embodiment 51 4-methoxyl group-6-[4-(5-{[3-(trifluoromethyl) phenyl] amino }-4H-1,2,4-triazole-3-yl) phenoxy group]
Synthesizing of pyrimidine-2-amine
Figure A20058003591801322
[0231] with 4-(5-{[3-(trifluoromethyl) phenyl] amino }-4H-1,2,4-triazole-3-yl)-phenol (100mg, 0.31 mmole) is dissolved in the anhydrous two  alkane of 3mL in 2-5mL microwave tube (Personal Chemistry).Add solid Cs 2CO 3(101.7mg, 0.31 mmole) adds 2-amino-4-chloro-6-methoxy pyrimidine (55.0mg, 0.34 mmole) subsequently.Cover bottle cap and 200 ℃ of microwave heatings 15 minutes.Add about 3mL MeOH then to dissolve formed suspension.The red tan solution that produces is changed in the round-bottomed flask, and solvent removed in vacuo.Residue is dissolved among the 3mL DMF again, filters, and carry out purifying with the acetonitrile/water system that contains 0.01%TFA by anti-phase preparation HPLC by 0.22 μ m syringe filter.The part that will contain product is collected, and at EtOAc and saturated NaHCO 3Distribute between the aqueous solution.With ethyl acetate layer salt water washing, dry and filtration on anhydrous sodium sulphate.Solvent removed in vacuo obtains this title compound, is pale solid (55.6mg).
【0232】ESI-MS：[M+H] +，443.87. 1H NMR(DMSO-d 6)：δ3.80(s，3H)，5.53(s，1H)，6.70(s，2H)，7.11-7.12(d，J＝7.4Hz，1H)，7.30-7.32(d，J＝8.4Hz，2H)，7.44-7.47(t，J＝7.6Hz，1H)，7.74-7.76(d，J＝8.4Hz，1H)，7.97-7.98(d，J＝8.4Hz，2H)，8.10(s，1H)，9.73(s，1H)，13.88(s，1H)。
Embodiment 52 6-[4-(5-{[3-(trifluoromethyl) phenyl] amino }-4H-[1,2,4]-triazole-3-yl) phenoxy group]-pyrimidine
Synthesizing of-4-amine
Figure A20058003591801331
[0233] with 4-(5-{[3-(trifluoromethyl) phenyl] amino }-4H-1,2,4-triazole-3-yl)-phenol (100mg, 0.31 mmole) is dissolved in the anhydrous two  alkane of 3mL in 2-5mL microwave tube (Personal Chemistry).Add solid Cs 2CO 3(101.7mg, 0.31 mmole) adds 4-amino-6-chloro-pyrimidine (48.5mg, 0.37 mmole) subsequently.Cover bottle cap and 200 ℃ of microwave heatings 5 minutes.Add about 3mL MeOH then to dissolve formed suspension.The red tan solution that produces is changed in the round-bottomed flask, and solvent removed in vacuo.Residue is dissolved among the 3mL DMF again, filters, and carry out purifying with the acetonitrile/water system that contains 0.01%TFA by anti-phase preparation HPLC by 0.22 μ m syringe filter.The part that will contain product is collected, and at EtOAc and saturated NaHCO 3Distribute between the aqueous solution.With ethyl acetate layer salt water washing, dry and filtration on anhydrous sodium sulphate.Solvent removed in vacuo obtains this title compound, is white solid (76.6mg).
【0234】ESI-MS：[M+H] +，461.0. 1H NMR(DMSO-d 6)：δ2.31(s，3H)，5.49(s，1H)，6.93(s，2H)，7.14(m，1H)，7.33-7.35(d，J＝7.5Hz，2H)，7.45-7.48(t，J＝7.6Hz，1H)，7.75(m，1H)，8.00-8.02(d，J＝8.6Hz，2H)，8.10(s，1H)，9.75(s，1H)，13.88(s，1H)。
Embodiment 53 2-(methylthio group)-6-[4-(5-{[3-(trifluoromethyl) phenyl] amino }-4H-1,2,4-triazole-3-yl)-benzene oxygen
Base]-pyrimidine-4-amine synthetic
Figure A20058003591801332
[0235] with 4-(5-{[3-(trifluoromethyl) phenyl] amino }-4H-1,2,4-triazole-3-yl)-phenol (100mg, 0.31 mmole) is dissolved in the anhydrous two  alkane of 3mL in 2-5mL microwave tube (Personal Chemistry).Add solid Cs 2CO 3(101.7mg, 0.31 mmole) adds 4-amino-6-chloro-2-(methylthio group)-pyrimidine (60.3mg, 0.34 mmole) subsequently.Cover bottle cap and 200 ℃ of microwave heatings 10 minutes.Add about 3mL MeOH then to dissolve formed suspension.The red tan solution that produces is changed in the round-bottomed flask, and solvent removed in vacuo.Residue is dissolved among the 3mL DMF again, filters, and carry out purifying with the acetonitrile/water system that contains 0.01%TFA by anti-phase preparation HPLC by 0.22 μ m syringe filter.The part that will contain product is collected, and at EtOAc and saturated NaHCO 3Distribute between the aqueous solution.With ethyl acetate layer salt water washing, dry and filtration on anhydrous sodium sulphate.Solvent removed in vacuo obtains this title compound, is white solid (39.5mg).
【0236】ESI-MS：[M+H] +，461.0. 1H NMR(DMSO-d 6)：δ3.80(s，3H)，5.53(s，1H)，6.70(s，2H)，6.30(s，2H)，(d，J＝8.6Hz，2H)。
Embodiment 54 4-[5-(4-trifluoromethoxy-phenyl)-4H-[1,2,4]-triazole-3-base is amino]-phenol synthetic
Figure A20058003591801341
[0237] 4-trifluoromethoxy benzoyl hydrazine (1.1g, 5.0 mmoles) and S-methyl N-[4-hydroxyl-phenyl] isothiourea hydriodide (1.55g, 5.0 mmoles) are suspended in the 10mL anhydrous pyridine.With reaction mixture refluxed 24 hours, its color was become orange red by yellow during this period.Then it is cooled to room temperature and is stirring and pouring in the 150mL frozen water.Water layer is decanted, and the residue that produces is carried out purifying by silica gel chromatography with 1: 1 ethyl acetate/hexane mixture.Solvent removed in vacuo obtains this title product, is powder gray solid (684.0mg).40.6% yield.
【0238】ESI-MS：[M+H] +，337，338. 1H NMR(DMSO-d 6)：δ7.68-6.71(d，J＝8.8Hz，2H)，7.32-7.35(d，J＝8.8Hz，2H)，7.47-7.49(d，J＝8.8Hz，2H)，8.04-8.07(d，J＝8.8Hz，2H)，9.05(br.s，1H)。
Embodiment 55 4-{4-[5-(4-trifluoromethoxy-phenyl)-4H-[1,2,4] triazole-3-base amino]-phenoxy group }-pyridine
Synthesizing of-2-carboxylic acid methyl acid amides trifluoroacetate
[0239] with 4-[5-(4-trifluoromethoxy-phenyl)-4H[1,2,4] triazole-3-base is amino]-phenol (134.5mg, 0.4 mmole) is dissolved in the 2mL dry DMF in 5mL microwave tube (Personal Chemistry).Add two (trimethyl silyl) acid amides potassium (120.0mg, 0.6 mmole) of solid, reaction mixture 80 ℃ of heated and stirred 15 minutes, is added 4-chloro-2-pyridine-2-carboxamide (68.2mg, 0.4 mmole) then, add anhydrous K subsequently 2CO 3(62.0mg, 0.44 mmole).Cover bottle cap then and 150 ℃ of microwave heatings 30 minutes.Then reaction mixture is diluted with about 1mL MeOH, filter, and carry out purifying with the acetonitrile/water system that contains 0.01%TFA by anti-phase preparation HPLC by 0.22 μ m syringe filter.This product is with tfa salt form separated (31.7mg white solid).
【0240】ESI-MS：[M+H] + 471，472. 1H NMR(DSO-d 6)：δ2.77-2.78(d，J＝4.8Hz，3H)，7.13-7.15(d，J＝8.3Hz，2H)，7.13(m，1H)，7.40(br.s，1H)，7.51-7.53(d，J＝8.3Hz，2H)，7.70-7.73(d，J＝8.8Hz，2H)，8.09-8.11(d，J＝8.8Hz，2H)，8.48-8.49(d，J＝5.3Hz，1H)，8.77-8.78(q，J＝4.8Hz，1H)，9.56(s，1H)。
Embodiment 56 3-[5-(4-chloro-3-trifluoromethyl-phenyl amino)-4H[1,2,4]-triazole-3-yl]-phenol synthetic
Figure A20058003591801351
[0241] 3-hydroxybenzoyl hydrazine (2.98g, 19.58 mmoles) and S-methyl N-[4-chloro-3-(trifluoromethyl) phenyl] isothiourea hydriodide (7.78g, 19.63 mmoles) are suspended in the 40mL anhydrous pyridine.With reaction mixture refluxed 18 hours, its color became scarlet by yellow during this period.Then it is cooled to room temperature and is stirring and pouring in the 250mL frozen water.Water layer is decanted, and oily residue is carried out purifying by silica gel chromatography on the Isco post with the hexane that contains 0=＞50% gradient ethyl acetate.Solvent removed in vacuo obtains this title product, is white solid (2.176g).31.3% yield.
【0242】ESI-MS：[M+H] + 355.1，356.8，. 1H NMR(DMSO-d 6)：δ6.88-6.90(dq，J 1＝7.9Hz，J 2＝0.9Hz，1H)，7.31-7.34(t，J＝7.9Hz，1H)，7.35-7.39(m，2H)，7.54-7.56(d，J＝8.8Hz，1H)，7.74-7.76(dd，J 1＝8.8Hz，J 2＝2.7Hz，1H)，8.23-8.24(d，J＝2.7Hz，1H)，9.79(s，1H)，9.87(s，1H)，13.86(s，1H)。
Embodiment 57 4-{3-[5-(4-chloro-3-trifluoromethyl-phenyl amino)-4H-[1,2,4] triazole-3-yl]-phenoxy group }-pyrrole
Synthesizing of pyridine-2-carboxylic acid methyl acid amides trifluoroacetate
Figure A20058003591801352
[0243] with 3-[5-(4-chloro-3-trifluoromethyl-phenyl amino)-4H[1,2,4] triazole-3-yl]-phenol (100mg, 0.282 mmole) is dissolved in the 2mL dry DMF in 5mL microwave tube (Personal Chemistry).Add two (trimethyl silyl) acid amides potassium (140.6mg, 0.705 mmole) of solid, reaction mixture 80 ℃ of heated and stirred 15 minutes, is added 4-chloro-2-pyridine-2-carboxamide (52.9mg, 0.31 mmole) then, add anhydrous K subsequently 2CO 3(19.5mg, 0.141 mmole).Cover bottle cap then and 250 ℃ of microwave heatings 20 minutes.Then reaction mixture is diluted with about 1mL MeOH, filter, and carry out purifying with the acetonitrile/water system that contains 0.01%TFA by anti-phase preparation HPLC by 0.22 μ m syringe filter.This product is with tfa salt form separated (25.0mg white solid).
【0244】ESI-MS：[M+H] +489，490，491. 1H NMR(DMSO-d 6)：δ2.78-2.79(d，J＝4.8Hz，3H)，7.25-7.26(dd，J 1＝2.5Hz，J 2＝5.5Hz，1H)，7.38(m，1H)，7.48-7.49(d，J＝2.5Hz，1H)，7.55-7.57(d，J＝8.8Hz，1H)，7.67-7.70(t，J＝7.8Hz，1H)，7.73(br.s.，1H)，7.78(br.s.，1H)，7.91-7.93(d，J＝7.8Hz，1H)，8.20-8.21(d，J＝2.6Hz，1H)，8.56-8.57(d，J＝5.5Hz，1H)，8.80-8.81(q，J＝4.8Hz，1H)，9.93(s，1H)。
Embodiment 58 6-{3-[5-(4-chloro-3-trifluoromethyl-phenyl amino)-4H-[1,2,4] triazole-3-yl]-phenoxy group }-phonetic
Pyridine-2,4-diamines trifluoroacetate synthetic
Figure A20058003591801361
[0245] with 3-[5-(4-chloro-3-trifluoromethyl-phenyl amino)-4H[1,2,4] triazole-3-yl]-phenol (100mg, 0.282 mmole) is dissolved in the 2mL dry DMF in 5mL microwave tube (Personal Chemistry).Add two (trimethyl silyl) acid amides potassium (140.6mg, 0.705 mmole) of solid, reaction mixture 80 ℃ of heated and stirred 15 minutes, is added 4-chloro-2 then, 6-diamino-pyrimidine (44.8mg, 0.31 mmole) adds anhydrous K subsequently 2CO 3(19.5mg, 0.141 mmole).Cover bottle cap then and 250 ℃ of microwave heatings 20 minutes.Then reaction mixture is diluted with about 1mL MeOH, filter, and carry out purifying with the acetonitrile/water system that contains 0.01%TFA by anti-phase preparation HPLC by 0.22 μ m syringe filter.This product is with tfa salt form separated (37.8mg light brown solid).
【0246】ESI-MS：[M+H] + 464，465. 1H NMR(DMSO-d 6)：δ5.40(s，1H)，7.33-7.35(d，J＝7.6Hz，1H)，7.57-7.59(d，J＝8.8Hz，1H)，7.62-7.65(t，J＝7.8Hz，1H)，7.73(br.s.，1H)，7.80(br.m.，1H)，7.88-7.89(d，J＝7.8Hz，1H)，8.21-8.22(d，J＝2.6Hz，1H)，9.96(s，1H)。
Embodiment 59 (4-chloro-3-trifluoromethyl-phenyl)-5-[3-(pyridin-4-yl oxygen base)-phenyl]-4H-[1,2,4] triazole-3-
Base }-amine trifluoroacetate synthetic
Figure A20058003591801362
[0247] with 3-[5-(4-chloro-3-trifluoromethyl-phenyl amino)-4H[1,2,4] triazole-3-yl]-phenol (100mg, 0.282 mmole) is dissolved in the 2mL dry DMF in the 5mL microwave tube.Add two (trimethyl silyl) acid amides potassium (140.6mg, 0.705 mmole) of solid, reaction mixture 80 ℃ of heated and stirred 15 minutes, is added 4-chloro-pyridine hydrochloric acid (46.5mg, 0.31 mmole) then, add anhydrous K subsequently 2CO 3(19.5mg, 0.141 mmole).Cover bottle cap then and 250 ℃ of microwave heatings 20 minutes.Then reaction mixture is diluted with about 1mL MeOH, filter, and carry out purifying with the acetonitrile/water system that contains 0.01%TFA by anti-phase preparation HPLC by 0.22 μ m syringe filter.This product is with tfa salt form separated (34.6mg light brown solid).
【0248】ESI-MS：[M+H] +432，433. 1H NMR(DMSO-d 6)：δ7.43-7.45(br.s.1H)，7.46-7.47(d，J＝7.0Hz，2H)，7.56-7.58(d，J＝8.8Hz，1H)，7.72-7.75(t，J＝7.8Hz，1H)，7.80(br.s.，1H)，7.81(br.s，1H)，7.98-8.00(d，J＝7.8Hz，1H)，8.21-8.22(d，J＝2.6Hz，1H)，8.76-8.78(d，J＝7.0Hz，1H)，9.98(s，1H)。
Embodiment 60 6-{3-[5-(4-chloro-3-trifluoromethyl-phenyl amino)-4H-[1,2,4] triazole-3-yl]-phenoxy group }-rattle away
Synthesizing of piperazine-3-base amine trifluoroacetate
[0249] with 3-[5-(4-chloro-3-trifluoromethyl-phenyl amino)-4H[1,2,4] triazole-3-yl]-phenol (100mg, 0.282 mmole) is dissolved in the 2mL dry DMF in the 5mL microwave tube.Add two (trimethyl silyl) acid amides potassium (140.6mg, 0.705 mmole) of solid, reaction mixture 80 ℃ of heated and stirred 15 minutes, is added 3-amino-6-chloro-pyridazine (40.2mg, 0.31 mmole) then, add anhydrous K subsequently 2CO 3(19.5mg, 0.141 mmole).Cover bottle cap then and 250 ℃ of microwave heatings 20 minutes.Then reaction mixture is diluted with about 1mL MeOH, filter, and carry out purifying with the acetonitrile/water system that contains 0.01%TFA by anti-phase preparation HPLC by 0.22 μ m syringe filter.This product is with tfa salt form separated (35.5mg light brown solid).
【0250】ESI-MS：[M+H] +448，449. 1H NMR(DMSO-d 6)：δ7.38-7.39(br.s.1H)，7.55-7.57(d，J＝9.6Hz，1H)，7.57-7.58(d，J＝8.6Hz，1H)，7.62-7.65(t，J＝7.8Hz，1H)，7.78(br.s.，1H)，7.80(br.s，1H)，7.82-7.84(d，J＝9.6Hz，1H)，7.86-7.88(d，J＝7.8Hz，1H)，8.22-8.23(d，J＝2.6Hz，1H)，8.52(br.s，2H)，9.94(s，1H)。
Embodiment 61 4-(5-{[4-chloro-3-(trifluoromethyl)-phenyl] amino }-1,3,4- diazole-2-yl) phenol synthetic
[0251] with titanium dioxide mercury (II) (yellow) (4.55g, 21.0 mmoles) at the argon gas low suspension in the anhydrous MeOH of 60mL.Form bright orange suspension.In this suspension, add 4-hydroxybenzoyl hydrazine (3.20g, 21.0 mmoles) and 4-chloro-3-trifluoromethyl-phenyl lsothiocyanates (5.0g, 21.0 mmoles).With reaction mixture refluxed 2 hours.Solvent removed in vacuo.Black residue is dissolved among the 100mL EtOAc again, and the black suspension that produces is filtered by short silicagel pad.Filtrate is mixed with the dried silica gel of 10g and solvent removed in vacuo.The silica gel that will be soaked into is contained on the silicagel column, and with starting from 50: 50 ratios and ending at the hexane of 0: 100 ratio: the ethyl acetate mixture gradient is separated product.The part that all contains product is merged; Solvent removed in vacuo obtains gray solid.This solid is heated in 4: 1 EtOAc/MeOH mixture of 50mL.Formed suspension is cooled to room temperature and filtration, obtains this title product, be white crystalline solid (4.54g, 60.7% yield).
【0252】ESI-MS：[M+H] +356.0. 1H NMR(DMSO-d 6)：δ6.92-6.95(d，J＝8.8Hz，2H)，7.69-7.70(d，J＝8.8Hz，1H)，7.71-7.73(d，J＝8.8Hz，2H)，7.82-7.84(dd，J 1＝8.8Hz，J 2＝2.6Hz，1H)，8.16-8.17(d，J＝2.6Hz，1H)，10.21(br s.，1H)，11.11(br s.，1H)。
Embodiment 62 6-[4-(5-{[4-chloro-3-trifluoromethyl-phenyl] amino }-1,3,4- diazole-2-yl)-phenoxy group]-phonetic
Pyridine-2,4-diamines synthetic
Figure A20058003591801381
[0253] with 4-(5-{[4-chloro-3-(trifluoromethyl)-phenyl] amino-1,3,4- diazole-2-yl)-phenol (1.067g, 3.0 mmoles) is dissolved under argon gas in about 70mL dry DMF.Add two (trimethyl silyl) acid amides potassium (0.718g, 3.6 mmoles) of solid, and the yellow solution that produces was heated 1.5 hours at 70 ℃.Add solid K then 2CO 3(0.414g, 3.0 mmoles) add 2 subsequently, 6-diamino-4-chloro-pyrimidine (0.520g, 3.6 mmoles).Reaction mixture was refluxed 30 hours under argon gas.Then it is cooled to room temperature and pours in about 500mL water.With 100mL EtOAc this aqueous mixture is extracted 5 times.With the EtOAc extraction liquid that merges 100mL salt water washing 3 times, and in anhydrous Na 2SO 4Last dry.Solvent removed in vacuo obtains the reddish yellow residue, is purified by silica gel chromatography as eluent with EtOAc.The part that will contain product is collected, and solvent removed in vacuo obtains product, is the reddish yellow solid.From 10mL EtOAc,, collect,, obtain this title compound (0.527g, 38% yield), be the light brown solid with ether thorough washing and vacuum-drying with this solid recrystallization.
【0254】ESI-MS：[M+H] +464，465. 1H NMR(DMSO-d 6)：δ5.20(s，1H)，6.05(br s.，2H)，6.34(br.s.，2H)，7.27-7.30(d，J＝8.7Hz，2H)，7.71-7.72(d，J＝8.8Hz，1H)，7.84-7.88(dd，J 1＝8.8Hz，J 2＝2.6Hz，1H)，7.89-7.91(d，J＝8.7Hz，2H)，8.18-8.19(d，J＝2.6Hz，1H)，11.26(s，1H)。Analyze. calculated value C 19H 13ClF 3N 7O 2: C, 49.20; H, 2.83; N, 21.14, observed value: C, 49.08; H, 3.21; N, 20.95.
Embodiment 63 6-[4-(5-{[4-chloro-3-trifluoromethyl-phenyl] amino }-1,3,4- diazole-2-yl)-phenoxy group]-phonetic
Pyridine-2,4-diamines trifluoroacetate synthetic
Figure A20058003591801382
[0255] with 4-(5-{[4-chloro-3-(trifluoromethyl)-phenyl] amino-1,3,4- diazole-2-yl)-phenol (100mg, 0.281 mmole) is dissolved in the 2.5mL dry DMF in the 5mL microwave tube.Add two (trimethyl silyl) acid amides potassium (140.6mg, 0.703 mmole) of solid, reaction mixture 80 ℃ of heated and stirred 15 minutes, is added 6-chloro-2 then, 4-diamino-pyrimidine (81.3mg, 0.562 mmole) adds anhydrous K subsequently 2CO 3(19.5mg, 0.141 mmole).Cover bottle cap then and 200 ℃ of microwave heatings 15 minutes.Then reaction mixture is diluted with about 1mL MeOH, filter, and carry out purifying with the acetonitrile/water system that contains 0.01%TFA by anti-phase preparation HPLC by 0.22 μ m syringe filter.This product is with tfa salt form separated (75.8mg light brown solid).
【0256】ESI-MS：[M+H] +464，465. 1H NMR(DMSO-d 6)：δ5.41(s，1H)，7.39-7.42(d，J＝8.7Hz，2H)，7.63(br s.，4H)，7.72-7.74(d，J＝8.8Hz，1H)，7.85-7.87(dd，J 1＝8.8Hz，J 2＝2.7Hz，1H)，7.95-7.97(d，J＝8.7Hz，2H)，8.20(d，J＝2.7Hz，1H)，11.29(s，1H)。
Embodiment 64 N-[4-chloro-3-(trifluoromethyl) phenyl]-5-[4-(pyridin-3-yl oxygen base) phenyl]-1,3,4- diazole-2-
Synthesizing of amine trifluoroacetate
Figure A20058003591801391
[0257] with 4-(5-{[4-chloro-3-(trifluoromethyl)-phenyl] amino-1,3,4- diazole-2-yl)-phenol (100mg, 0.281 mmole) is dissolved under argon gas in about 2mL dry DMF.Add two (trimethyl silyl) acid amides potassium (140.2mg, 0.702 mmole) of solid, the yellow solution that produces was heated 15 minutes at 80 ℃.Add solid K then 2CO 3(19.4mg, 0.140 mmole) adds 3-bromopyridine (89.0mg, 0.562 mmole) subsequently.With reaction mixture 250 ℃ of microwave heatings 10 minutes.With its usefulness 1mL MeOH dilution, filtration and the acetonitrile/water system that contains the 0.1%TFA gradient by anti-phase preparative scale chromatography usefulness carry out purifying then.Collection has the main peak of product quality; Solvent removed in vacuo obtains this title product, is brown oil (20.6mg).
【0258】ESI-MS：[M+H] +433.5，434.3. 1H NMR(DMSO-d 6)：δ7.24-7.26(d，J＝8.8Hz，2H)，7.57-7.59(dd，J 1＝8.4Hz，J 2＝4.7Hz，1H)，7.68-7.71(dq，J 1＝8.4Hz，J 2＝1.4Hz，1H)，7.71-7.73(d，J＝8.8Hz，1H)，7.84-7.86(dd，J 1＝8.8Hz，J 2＝2.7Hz，1H)，7.92-7.94(d，J＝8.8Hz，2H)，8.17-8.18(d，J＝2.7Hz，1H)，8.50(br d，J＝4.0Hz，1H)，8.54(br s，1H)，11.24(s，1H)。
Embodiment 65 N-[4-chloro-3-(trifluoromethyl) phenyl]-5-[4-(pyridin-4-yl oxygen base) phenyl]-1,3,4- diazole-2-
Synthesizing of amine trifluoroacetate
[0259] with 4-(5-{[4-chloro-3-(trifluoromethyl)-phenyl] amino-1,3,4- diazole-2-yl)-phenol (100mg, 0.281 mmole) is dissolved under argon gas in about 2mL dry DMF.Add two (trimethyl silyl) acid amides potassium (225mg, 1.12 mmoles) of solid, the yellow solution that produces was heated 15 minutes at 80 ℃.Add solid K then 2CO 3(38.8mg, 0.281 mmole) adds 4-chloropyridine hydrochloric acid (84.3mg, 0.562 mmole) subsequently.With reaction mixture 200 ℃ of microwave heatings 25 minutes (Initiator, Biotage).Then it is diluted with 1mL MeOH, filter, and carry out purifying with the acetonitrile/water gradient that contains 0.1%TFA by anti-phase preparative scale chromatography by 0.22 μ m syringe filter.Collection has the main peak of product quality; Solvent removed in vacuo obtains this title product, is white fine hair shape solid (85.6mg).
【0260】ESI-MS：[M+H] + 435.3. 1H NMR(DMSO-d 6)：δ7.37-7.38(d，J＝4.8Hz，2H)，7.48-7.50(d，J＝8.8Hz，2H)，7.72-7.74(d，J＝8.8Hz，1H)，7.85-7.88(dd，J 1＝8.8Hz，J 2＝2.7Hz，1H)，8.03-8.06(d，J＝8.8Hz，1H)，8.19-8.20(d，J＝2.7Hz，1H)，8.74(br s.，2H)，11.31(s，1H)。
Embodiment 66 N-[4-chloro-3-(trifluoromethyl) phenyl]-5-[4-(pyrimidine-5-base oxygen base) phenyl]-1,3,4- diazole-2-
Synthesizing of amine trifluoroacetate
Figure A20058003591801401
[0261] with 4-(5-{[4-chloro-3-(trifluoromethyl)-phenyl] amino-1,3,4- diazole-2-yl)-phenol (100mg, 0.281 mmole) is dissolved under argon gas in about 2mL dry DMF.Add two (trimethyl silyl) acid amides potassium (140.2mg, 0.702 mmole) of solid, the yellow solution that produces was heated 15 minutes at 80 ℃.Add solid K then 2CO 3(19.4mg, 0.140 mmole) adds 3-bromo pyrimi piperidine (89.4mg, 0.562 mmole) subsequently.With reaction mixture 200 ℃ of microwave heatings 15 minutes.Then it is diluted with 1mL MeOH, filter, and carry out purifying with the acetonitrile/water gradient that contains 0.1%TFA by anti-phase preparative scale chromatography by 0.22 μ m syringe filter.Collection has the main peak of product quality; Solvent removed in vacuo obtains this title product, is white fine hair shape solid (73.0mg white crystalline solid).
【0262】ESI-MS：[M+H] + 434.3，435.3. 1H NMR(DMSO-d 6)：δ7.31-7.33(d，J＝8.8Hz，2H)，7.71-7.73(d，J＝8.8Hz，1H)，7.84-7.86(dd，J 1＝8.8Hz，J 2＝2.7Hz，1H)，7.93-7.95(d，J＝8.8Hz，2H)，8.17-8.18(d，J＝2.7Hz，1H)，8.77(s，2H)，9.09(s，1H)，11.25(s，1H)。
Embodiment 67 4-[4-(5-{[4-chloro-3-(trifluoromethyl) phenyl] amino }-1,3,4- diazole-2-yl) phenoxy group]-N-
Synthesizing of picoline-2-methane amide trifluoroacetate
Figure A20058003591801411
[0263] with 4-(5-{[4-chloro-3-(trifluoromethyl)-phenyl] amino-1,3,4- diazole-2-yl)-phenol (100mg, 0.281 mmole) is dissolved under argon gas in about 2mL dry DMF.Add two (trimethyl silyl) acid amides potassium (140.2mg, 0.702 mmole) of solid, the yellow solution that produces was heated 15 minutes at 80 ℃.Add solid K then 2CO 3(19.4mg, 0.140 mmole) adds 4-chloro-2-pyridine-2-carboxamide (52.7mg, 0.309 mmole) subsequently.With reaction mixture 200 ℃ of microwave heatings 15 minutes.Then it is diluted with 1mL MeOH, filter, and carry out purifying with the acetonitrile/water gradient that contains 0.1%TFA by anti-phase preparative scale chromatography by 0.22 μ m syringe filter.Collection has the main peak of product quality; Solvent removed in vacuo obtains this title product, is white solid (67.5mg).
【0264】ESI-MS：[M+H] +490.4，491.3. 1H NMR(DMSO-d 6)：δ2.79-2.80(d，J＝4.9Hz，3H)，7.26-7.28(dd，J 1＝5.6Hz，J 2＝2.6Hz，1H)，7.43-7.44(d，J＝6.8Hz，2H)，7.49(d，J＝2.6Hz，1H)，7.72-7.74(d，J＝8.8Hz，1H)，7.85-7.86(dd，J 1＝8.8Hz，J 2＝2.6Hz，1H)，8.01-8.03(d，J＝6.8Hz，2H)，8.19(d，J＝2.6Hz，1H)，8.57-8.58(d，J＝5.7Hz，1H)，8.79-8.81(q，J＝4.9Hz，1H)，11.28(s，1H)。
Embodiment 68 4-[5-(4-chloro-3-(trifluoromethyl)-phenyl)-4H-1,2,4-triazole-3-base is amino] phenol synthetic
Figure A20058003591801412
[0265] 4-chloro-3-trifluoromethyl benzoyl hydrazine (2.89g, 12.1 mmoles) and S-methyl N-(4-hydroxy phenyl) isothiourea hydriodide (3.75g, 12.1 mmoles) are suspended in the 40mL anhydrous pyridine.With reaction mixture refluxed 18 hours, its color became scarlet by yellow during this period.Then it is cooled to room temperature and is stirring and pouring in the 250mL frozen water.The aqueous solution is decanted, and oily residue is carried out purifying by silica gel chromatography with 1: 1 ethyl acetate/hexane mixture.Solvent removed in vacuo obtains this title product, is white solid (1.95g).Yield 45.5%.
Embodiment 69 6-[4-({ 5-[4-chloro-3-(trifluoromethyl) phenyl-4H-1,2,4-triazole-3-yl } amino) phenoxy group] pyrimidine
-2,4-diamines trifluoroacetate synthetic
Figure A20058003591801413
[0266] with 4-[5-(4-chloro-3-(trifluoromethyl)-phenyl)-4H-1,2,4-triazole-3-base is amino] phenol (100mg, 0.282 mmole) is dissolved in the 2mL dry DMF.Add two (trimethyl silyl) acid amides potassium (140.6mg, 0.705 mmole) of solid, the solution that produces was heated 15 minutes at 80 ℃.Add solid K then 2CO 3(20mg, 0.141 mmole) adds 4-chloro-2 subsequently, 6-diamino-pyrimidine (61.1mg, 0.422 mmole).With reaction mixture 200 ℃ of microwave heatings 20 minutes.Then it is diluted with 1mL MeOH, filter, and carry out purifying with the acetonitrile/water gradient that contains 0.1%TFA by anti-phase preparative scale chromatography by 0.22 μ m syringe filter.Collection has the main peak of product quality, and solvent removed in vacuo obtains the trifluoroacetate of product, is white solid (28.6mg).
【0267】ESI-MS：[M+H] + 463.4，464.4. 1H NMR(DMSO-d 6)：δ5.24(s，1H)，7.14-7.16(d，J＝8.8Hz，2H)，7.65-7.66(d，J＝8.8Hz，2H)，7.81(br s.，4H)，7.88-7.90(d，J＝8.4Hz，1H)，8.23-8.25(dd，J 1＝8.4Hz，J 2＝1.7Hz，1H)，8.37(s，1H)，9.66(br s.，1H)。
Embodiment 70 5-[4-chloro-3-(trifluoromethyl) phenyl]-N-[4-(pyridin-4-yl oxygen base) phenyl]-4H-1,2,4-triazole-3-
Synthesizing of amine trifluoroacetate
Figure A20058003591801421
[0268] with 4-[5-(4-chloro-3-(trifluoromethyl)-phenyl)-4H-1,2,4-triazole-3-base is amino] phenol (100mg, 0.282 mmole) is dissolved in the 2mL dry DMF.Add two (trimethyl silyl) acid amides potassium (196.2mg, 0.983 mmole) of solid, the solution that produces was heated 15 minutes at 80 ℃.Add solid K then 2CO 3(20mg, 0.141 mmole) adds 4-chloropyridine hydrochloric acid (63.2mg, 0.421 mmole) subsequently.With reaction mixture 220 ℃ of microwave heatings 30 minutes.Then it is diluted with 1mL MeOH, filter, and carry out purifying with the acetonitrile/water gradient that contains 0.1%TFA by anti-phase preparative scale chromatography by 0.22 μ m syringe filter.Collection has the main peak of product quality, and solvent removed in vacuo obtains the trifluoroacetate of product, is light brown solid (23.5mg).
【0269】ESI-MS：[M+H] + 432，433. 1H NMR(DMSO-d 6)：δ7.23-7.25(d，J＝8.8Hz，2H)，7.39-7.40(d，J＝7.2Hz，2H)，7.74-7.77(d，J＝8.8Hz，2H)，7.89-7.90(m，1H)，8.24-8.26(dd，J 1＝8.4Hz，J 2＝2.0Hz，1H)，8.38(s，1H)，8.73-8.74(d，J＝7.2Hz，2H)，9.75(br s.，1H)。
Embodiment 71 5-[4-chloro-3-(trifluoromethyl) phenyl]-N-[4-(pyrimidine-5-base oxygen base) phenyl]-4H-1,2,4-triazole-3-
Synthesizing of amine trifluoroacetate
[0270] with 4-[5-(4-chloro-3-(trifluoromethyl)-phenyl)-4H-1,2,4-triazole-3-base is amino] phenol (100mg, 0.282 mmole) is dissolved in the 2mL dry DMF.Add two (trimethyl silyl) acid amides potassium (84.1mg, 0.421 mmole) of solid, the solution that produces was heated 15 minutes at 80 ℃.Add solid K then 2CO 3(20mg, 0.141 mmole) adds 5-bromo pyrimi piperidine (67.0mg, 0.421 mmole) subsequently.With reaction mixture 220 ℃ of microwave heatings 20 minutes.Then it is diluted with 1mL MeOH, filter, and carry out purifying with the acetonitrile/water gradient that contains 0.1%TFA by anti-phase preparative scale chromatography by 0.22 μ m syringe filter.Collection has the main peak of product quality, and solvent removed in vacuo obtains the trifluoroacetate of product, is light brown solid (25.0mg).
【0271】ESI-MS：[M+H] + 432.9，435. 1H NMR(DMSO-d 6)：δ7.14-7.16(d，J＝8.9Hz，2H)，7.63-7.67(d，J＝8.9Hz，2H)，7.87-7.89(d，J＝8.4Hz，1H)，8.22-8.24(dd，J 1＝8.4Hz，J 2＝2.0Hz，1H)，8.36(s，1H)，8.54(s，2H)，8.93(s，1H)，9.57(br s.，1H)。
Embodiment 72 6-[4-({ 5-[4-chloro-3-(trifluoromethyl) phenyl-4H-1,2,4-triazole-3-yl } amino) phenoxy group] pyridazine
Synthesizing of-3-amine trifluoroacetate
[0272] with 4-[5-(4-chloro-3-(trifluoromethyl)-phenyl)-4H-1,2,4-triazole-3-base is amino] phenol (100mg, 0.282 mmole) is dissolved in the 2mL dry DMF.Add two (trimethyl silyl) acid amides potassium (140.6mg, 0.705 mmole) of solid, the solution that produces was heated 15 minutes at 80 ℃.Add solid K then 2CO 3(20mg, 0.141 mmole) adds 3-amino-6-chlorine pyridazine (54.6mg, 0.421 mmole) subsequently.With reaction mixture 220 ℃ of microwave heatings 40 minutes.Then it is diluted with 1mL MeOH, filter, and carry out purifying with the acetonitrile/water gradient that contains 0.1%TFA by anti-phase preparative scale chromatography by 0.22 μ m syringe filter.Collection has the main peak of product quality, and solvent removed in vacuo obtains the trifluoroacetate of product, is light brown solid (23.1mg).
【0273】ESI-MS：[M+H] + 448，449. 1H NMR(DMSO-d 6)：δ7.16-7.18(d，J＝8.9Hz，2H)，7.51-7.53(d，J＝9.7Hz，1H)，7.62-7.66(d，J＝8.9Hz，2H)，7.73-7.75(d，J＝9.7Hz，1H)，7.88(d，J＝8.4Hz，1H)，8.23-8.25(dd，J 1＝8.4Hz，J 2＝2.0Hz，1H)，8.36(s，1H)，8.48(br s.，2H)，9.62(br s.，1H)。
Embodiment 73 4-[4-(5-[4-chloro-3-(trifluoromethyl) phenyl]-4H-1,2,4-triazole-3-yl } amino) phenoxy group]-N-
Synthesizing of picoline-2-methane amide trifluoroacetate
Figure A20058003591801441
[0274] with 4-[5-(4-chloro-3-(trifluoromethyl)-phenyl)-4H-1,2,4-triazole-3-base is amino] phenol (100mg, 0.282 mmole) is dissolved in the 2mL dry DMF.Add two (trimethyl silyl) acid amides potassium (140.6mg, 0.705 mmole) of solid, the solution that produces was heated 15 minutes at 80 ℃.Add solid K then 2CO 3(20mg, 0.141 mmole) adds 4-chloro-2-pyridine-2-carboxamide (71.9mg, 0.421 mmole) subsequently.With reaction mixture 220 ℃ of microwave heatings 20 minutes.Then it is diluted with 1mL MeOH, filter, and carry out purifying with the acetonitrile/water gradient that contains 0.1%TFA by anti-phase preparative scale chromatography by 0.22 μ m syringe filter.Collection has the main peak of product quality, and solvent removed in vacuo obtains the trifluoroacetate of product, is yellow solid (25.4mg).
【0275】ESI-MS：[M+H] + 489，490. 1H NMR(DMSO-d 6)：δ2.77-2.78(d，J＝4.8Hz，3H)，7.14-7.15(dd，J 1＝5.6Hz，J 2＝2.5Hz，1H)，7.15-7.17(d，J＝9.0Hz，2H)，7.40(d，J＝2.5Hz，1H)，7.68-7.71(d，J＝9.0Hz，2H)，7.87-7.89(d，J＝8.4Hz，1H)，8.23-8.25(dd，J 1＝8.4Hz，J 2＝2.0Hz，1H)，8.37(s，1H)，8.49-8.50(d，J＝5.6Hz，1H)，8.75-8.78(q，J＝4.8Hz，1H)，9.65(br s.，1H)。
Embodiment 74 5-[4-chloro-3-(trifluoromethyl) phenyl]-N-[4-(pyridin-3-yl oxygen base) phenyl]-4H-1,2,4-triazole-3-
Synthesizing of amine trifluoroacetate
[0276] with 4-[5-(4-chloro-3-(trifluoromethyl)-phenyl)-4H-1,2,4-triazole-3-base is amino] phenol (200mg, 0.562 mmole) is dissolved in the 2mL dry DMF.Add two (trimethyl silyl) acid amides potassium (280.3mg, 1.405 mmoles) of solid, the solution that produces was heated 15 minutes at 80 ℃.Add solid K then 2CO 3(40mg, 0.282 mmole) adds 3-bromopyridine (177.6mg, 1.12 mmoles) subsequently.With reaction mixture 250 ℃ of microwave heatings 20 minutes.Then it is diluted with 1mL MeOH, filter, and carry out purifying with the acetonitrile/water gradient that contains 0.1%TFA by anti-phase preparative scale chromatography by 0.22 μ m syringe filter.Collection has the main peak of product quality, and solvent removed in vacuo obtains the trifluoroacetate of product, is yellow solid (17.0mg).
【0277】ESI-MS：[M+H] + 432，433. 1H NMR(DMSO-d 6)：δ7.09-7.11(d，J＝9.0Hz，2H)，7.50-7.52(m，2H)，7.63-7.66(d，J＝9.0Hz，2H)，7.87-7.89(d，J＝8.4Hz，1H)，8.22-8.25(dd，J 1＝8.4Hz，J 2＝2.0Hz，1H)，8.37-8.38(m，2H)，8.43(m，1H)，9.56(brs.，1H)。
Embodiment 75 4-(5-{[3-(trifluoromethyl) phenyl] amino }-1,3,4- diazole-2-yl) phenol synthetic
Figure A20058003591801451
[0278] yellow precipitate (II) (5.33g, 24.60 mmoles) is suspended in about 70mL anhydrous methanol.In this bright orange suspension, add 4-hydroxybenzoyl hydrazine (3.74g, 24.60 mmoles), add 3-trifluoromethyl lsothiocyanates (5.0g, 24.60 mmoles) subsequently.With reaction mixture refluxed 2 hours.The color of reaction mixture becomes pitch-dark and forms black precipitate.Then it is cooled to room temperature and passes through short Celite pad filtration, then by short silicagel pad filtration.With final vacuum remove methyl alcohol and from about 100mL EtOAc with the gray precipitate recrystallization that produces.The white crystalline solid that forms is filtered,, obtain this title product, be white crystals (7.182g) with a small amount of EtOAc washing and vacuum-drying.Yield 71.3%.
【0279】ESI-MS：[M+H] + 322.0. 1H NMR(DMSO-d 6)：δ6.92-6.95(d，J＝8.7Hz，2H)，7.33-7.35(d，J＝8.3Hz，1H)，7.57-7.60(t，J＝8.0Hz，1H)，7.72-7.75(d，J＝8.7Hz，2H)，7.80-7.82(dd，J 1＝8.0Hz，J 2＝1.8Hz，1H)，8.06(s，1H)，10.21(s，1H)，10.99(brs.，1H)。 13C NMR(DMSO-d 6)112.9，114.5，116.1，117.9，120.6，127.6，129.7，130.0，130.3，139.6，158.3，158.9，160.1。
Embodiment 76 6-[4-(5-{[3-(trifluoromethyl) phenyl] amino }-1,3,4- diazole-2-yl) phenoxy group] pyrimidine-2,4-
Synthesizing of diamines
Figure A20058003591801452
[0280] with 4-(5-{[3-(trifluoromethyl)-phenyl] amino-1,3,4- diazole-2-yl)-phenol (160.6mg, 0.5 mmole) is dissolved in the 3mL dry DMF in 2-5mL microwave tube (Personal Chemistry).Add two (trimethyl silyl) acid amides potassium (119.7mg, 0.6 mmole) of solid, and with reaction mixture 80 ℃ of heated and stirred 10 minutes, add 6-chloro-2 then, 4-diamino-pyrimidine (86.7mg, 0.6 mmole) adds anhydrous K subsequently 2CO 3(69.1mg, 0.5 mmole).Cover bottle cap then and 200 ℃ of microwave heatings 20 minutes.Then reaction mixture is diluted with about 1mL MeOH, filter, and carry out purifying with the acetonitrile/water system that contains 0.01%TFA by anti-phase preparation HPLC by 0.22 μ m syringe filter.The part that will contain product is collected, and at approximately 40mL EtOAc and the approximately saturated NaHCO of 40mL 3Between distribute.With the salt water washing of EtOAc layer, in anhydrous Na 2SO 4Last dry and filtration.Solvent removed in vacuo obtains this title product, is light brown solid (87.0mg).Yield 37.7%.
【0281】ESI-MS：[M+H] + 430.29. 1H NMR(DMSO-d 6)：δ5.19(s，1H)，6.04(s，2H)，6.33(s，2H)，7.27-7.30(d，J＝8.7Hz，2H)，7.36-7.37(d，J＝7.9Hz，1H)，7.59-7.63(t，J＝8.0Hz，1H)，7.82-7.83(dd，J 1＝8.0Hz，J 2＝1.8Hz，1H)，7.89-7.92(d，J＝8.7Hz，2H)，8.08(s，1H).11.11(s，1H)。
Embodiment 77 5-[4-(pyrimidine-5-base oxygen base) phenyl]-N-[3-(trifluoromethyl) phenyl]-1,3,4- diazole-2-amine
Synthetic
Figure A20058003591801461
[0282] with 4-(5-{[3-(trifluoromethyl)-phenyl] amino-1,3,4- diazole-2-yl)-phenol (160.6mg, 0.5 mmole) is dissolved in the 3mL dry DMF in 2-5mL microwave tube (Personal Chemistry).Add two (trimethyl silyl) acid amides potassium (149.6mg, 0.75 mmole) of solid, and with reaction mixture 80 ℃ of heated and stirred 10 minutes, add 5-bromo pyrimi piperidine (119.2mg, 0.75 mmole) then, add anhydrous K subsequently 2CO 3(69.1mg, 0.5 mmole).Cover bottle cap then and 200 ℃ of microwave heatings 20 minutes.Then reaction mixture is diluted with about 1mL MeOH, filter, and carry out purifying with the acetonitrile/water system that contains 0.01%TFA by anti-phase preparation HPLC by 0.22 μ m syringe filter.The part that will contain product is collected, and at approximately 40mL EtOAc and the approximately saturated NaHCO of 40mL 3Between distribute.With the salt water washing of EtOAc layer, in anhydrous Na 2SO 4Last dry and filtration.Solvent removed in vacuo obtains this title product, is light brown solid (81.5mg).Yield 43.5%.
【0283】ESI-MS：[M+H] + 400.16. 1H NMR(DMSO-d 6)：δ7.31-7.33(d，J＝8.7Hz，2H)，7.35-7.37(d，J＝7.9Hz，1H)，7.59-7.62(t，J＝8.0Hz，1H)，7.81-7.83(dd，J 1＝8.0Hz，J 2＝1.8Hz，1H)，7.93-7.95(d，J＝8.7Hz，2H)，8.07(s，1H)，8.76(s，2H)，9.08(s，1H)，11.11(s，1H)。
Embodiment 78 4-{5-[(4-chloro-phenyl-s) amino]-1,3,4- diazole-2-yl } phenol synthetic
Figure A20058003591801462
[0284] yellow precipitate (II) (6.38g, 29.47 mmoles) is suspended in about 70mL anhydrous methanol.4-hydroxybenzoyl hydrazine (4.48g, 29.47 mmoles) is added in this bright orange suspension, add 4-chloro-phenyl-lsothiocyanates (5.0g, 29.47 mmoles) subsequently.With reaction mixture refluxed 2 hours.The color of reaction mixture becomes pitch-dark and forms black precipitate.Then it is cooled to room temperature and passes through short Celite pad filtration, then by short silicagel pad filtration.With final vacuum remove methyl alcohol and from about 40mL EtOAc with the gray precipitate recrystallization that produces.The white crystals that forms is filtered,, obtain this title product, be white powder with a small amount of EtOAc washing and vacuum-drying.
【0285】ESI-MS：[M+H] +287.94. 1H NMR(DMSO-d 6)：δ6.91-6.94(d，J＝8.7Hz，2H)，7.39-7.41(d，J＝8.9Hz，2H)，7.61-7.63(d，J＝8.9Hz，2H)，7.71-7.74(d，J＝8.7Hz，2H)，10.19(s，1H)，10.73(s，1H)。 13C NMR(DMSO-d 6)114.6，116.1，118.5，125.3，127.5，128.9，137.8，158.1，159.1，160.0。
Embodiment 79 6-(4-{5-[(4-chloro-phenyl-) amino]-1,3,4- diazole-2-yl } phenoxy group) pyrimidine-2, the closing of 4-diamines
Become
[0286] with the 4-{5-[(4-chloro-phenyl-) amino]-1,3,4- diazole-2-yl } phenol (144.0mg, 0.5 mmole) is dissolved in the 3mL dry DMF in 2-5mL microwave tube (Personal Chemistry).Add two (trimethyl silyl) acid amides potassium (100.0mg, 0.5 mmole) of solid, and with reaction mixture 80 ℃ of heated and stirred 10 minutes, add 6-chloro-2 then, 4-diamino-pyrimidine (72.3mg, 0.5 mmole) adds anhydrous K subsequently 2CO 3(34.5mg, 0.25 mmole).Cover bottle cap then and 200 ℃ of microwave heatings 15 minutes.Then reaction mixture is diluted with about 1mL MeOH, filter, and carry out purifying with the acetonitrile/water system that contains 0.01%TFA by anti-phase preparation HPLC by 0.22 μ m syringe filter.The part that will contain product is collected, and at approximately 40mL EtOAc and the approximately saturated NaHCO of 40mL 3Between distribute.With the salt water washing of EtOAc layer, in anhydrous Na 2SO 4Last dry and filtration.Solvent removed in vacuo obtains this title product, is light brown solid (24.5mg).
【0287】ESI-MS：[M+H] + 396.25. 1H NMR(DMSO-d 6)：δ5.19(s，1H)，6.04(s，2H)，6.33(s，2H)，7.26-7.29(d，J＝8.7Hz，2H)，7.41-7.43(d，J＝8.9Hz，2H)，7.63-7.65(d，J＝8.9Hz，2H)，7.88-7.90(d，J＝8.7Hz，2H)，10.85(s，1H)。
Embodiment 80 5-[4-(pyrimidine-5-base oxygen base) phenyl]-N-[4-chloro-phenyl]-1,3,4- diazole-2-amine synthetic
Figure A20058003591801472
[0288] with the 4-{5-[(4-chloro-phenyl-) amino]-1,3,4- diazole-2-yl } phenol (144.0mg, 0.5 mmole) is dissolved in the 3mL dry DMF in 2-5mL microwave tube (Personal Chemistry).Add two (trimethyl silyl) acid amides potassium (100.0mg, 0.5 mmole) of solid, and with reaction mixture 80 ℃ of heated and stirred 10 minutes, add 5-bromo pyrimi piperidine (79.5mg, 0.5 mmole) then, add anhydrous K subsequently 2CO 3(34.5mg, 0.25 mmole).Cover bottle cap then and 200 ℃ of microwave heatings 15 minutes.Then reaction mixture is diluted with about 1mL MeOH, filter, and carry out purifying with the acetonitrile/water system that contains 0.01%TFA by anti-phase preparation HPLC by 0.22 μ m syringe filter.The part that will contain product is collected, and at approximately 40mL EtOAc and the approximately saturated NaHCO of 40mL 3Between distribute.With the salt water washing of EtOAc layer, in anhydrous Na 2SO 4Last dry and filtration.Solvent removed in vacuo obtains this title product, is light brown solid (61.6mg).
【0289】ESI-MS：[M+H] +366.24. 1H NMR(DMSO-d 6)：δ7.30-7.32(d，J＝8.7Hz，2H)，7.41-7.43(d，J＝8.9Hz，2H)，7.63-7.65(d，J＝8.9Hz，2H)，7.92-7.94(d，J＝8.7Hz，2H)，8.76(s，2H)，9.08(s，1H)，10.85(s，1H)。
Embodiment 81 4-(5-{[2-chloro-5-(trifluoromethyl) phenyl] amino }-1,3,4- diazole-2-yl) phenol synthetic
Figure A20058003591801481
[0290] yellow precipitate (II) (1.82g, 8.41 mmoles) is suspended in about 50mL anhydrous methanol.4-hydroxybenzoyl hydrazine (1.28g, 8.41 mmoles) is added in this bright orange suspension, add 2-chloro-5-trifluoromethyl-phenyl lsothiocyanates (2.0g, 8.41 mmoles) subsequently.With reaction mixture refluxed 2 hours.The color of reaction mixture becomes pitch-dark and forms black precipitate.Then it is cooled to room temperature and passes through short Celite pad filtration, then by short silicagel pad filtration.With final vacuum remove methyl alcohol and from about 20mL EtOAc with the gray solid recrystallization that produces.The white precipitate that forms is filtered, use anhydrous Et 2O washing and vacuum-drying obtain this title product, are white solid (2.638g).Yield 88.1%.
【0291】ESI-MS：[M+H] + 356.22. 1H NMR(DMSO-d 6)：δ6.93-6.96(d，J＝8.7Hz，2H)，7.41-7.43(dd，J 1＝8.3Hz，J 2＝1.7Hz，1H)，7.72-7.75(m，3H)，8.61(s，1H)，10.23(s，1H)，10.30(s，1H)。
Embodiment 82 6-(4-{5-[(2-chloro-5-trifluoromethyl-phenyl) amino]-1,3,4- diazole-2-yl } phenoxy group) pyrimidine
-2,4-diamines synthetic
Figure A20058003591801482
[0292] with 4-(5-{[2-chloro-5-(trifluoromethyl) phenyl] amino-1,3,4- diazole-2-yl) phenol (177.85mg, 0.5 mmole) is dissolved in the 3mL dry DMF in 2-5mL microwave tube (Personal Chemistry).Add two (trimethyl silyl) acid amides potassium (200.0mg, 1.0 mmoles) of solid, and with reaction mixture 80 ℃ of heated and stirred 10 minutes, add 6-chloro-2 then, 4-diamino-pyrimidine (86.7mg, 0.6 mmole) adds anhydrous K subsequently 2CO 3(69.1mg, 0.5 mmole).Cover bottle cap then and 180 ℃ of microwave heatings 30 minutes.Then reaction mixture is diluted with about 1mL MeOH, filter, and carry out purifying with the acetonitrile/water system that contains 0.01%TFA by anti-phase preparation HPLC by 0.22 μ m syringe filter.The part that will contain product is collected, and at approximately 50mL EtOAc and the approximately saturated NaHCO of 50mL 3Distribute between the aqueous solution.With the salt water washing of EtOAc layer, in anhydrous Na 2SO 4Last dry and filtration.Solvent removed in vacuo obtains this title product, is pale solid (131.1mg).Yield 56.5%.
【0293】ESI-MS：[M+H] + 464.21. 1H NMR(DMSO-d 6)：δ5.20(s，1H)，6.05(s，2H)，6.34(s，2H)，7.28-7.31(d，J＝8.7Hz，2H)，7.46-7.48(dd，J 1＝8.3Hz，J 2＝1.8Hz，1H)，7.76-7.78(d，J＝8.3Hz，1H)，7.90-7.92(d，J＝8.7Hz，2H)，8.62(s，1H)，10.47(s，1H)。
Embodiment 83 5-[4-(pyrimidine-5-base oxygen base) phenyl]-N-[2-chloro-5-(trifluoromethyl)-phenyl]-1,3,4- diazole-2-
Synthesizing of amine
Figure A20058003591801491
[0294] with 4-(5-{[2-chloro-5-(trifluoromethyl) phenyl] amino-1,3,4- diazole-2-yl) phenol (177.85mg, 0.5 mmole) is dissolved in the 3mL dry DMF in 2-5mL microwave tube (Personal Chemistry).Add two (trimethyl silyl) acid amides potassium (200.0mg, 1.0 mmoles) of solid, and with reaction mixture 80 ℃ of heated and stirred 10 minutes, add 5-bromo pyrimi piperidine (95.4mg, 0.6 mmole) then, add anhydrous K subsequently 2CO 3(69.1mg, 0.5 mmole).Cover bottle cap then and 180 ℃ of microwave heatings 40 minutes.Then reaction mixture is diluted with about 1mL MeOH, filter, and carry out purifying with the acetonitrile/water system that contains 0.01%TFA by anti-phase preparation HPLC by 0.22 μ m syringe filter.The part that will contain product is collected, and at approximately 50mL EtOAc and the approximately saturated NaHCO of 50mL 3Distribute between the aqueous solution.With the salt water washing of EtOAc layer, in anhydrous Na 2SO 4Last dry and filtration.Solvent removed in vacuo obtains this title product, is light brown solid (129.1mg).Yield 59.5%.
【0295】ESI-MS：[M+H] + 434.20. 1H NMR(DMSO-d 6)：δ7.32-7.35(d，J＝8.7Hz，2H)，7.46-7.48(dd，J 1＝8.3Hz，J 2＝1.8Hz，1H)，7.76-7.78(d，J＝8.3Hz，1H)，7.94-7.96(d，J＝8.7Hz，2H)，8.61(s，1H)，8.77(s，2H)，9.09(s，1H)，10.47(s，1H)。
Embodiment 84 4-{5-[(3-chloro-phenyl-s) amino]-1,3,4- diazole-2-yl } phenol synthetic
Figure A20058003591801492
[0296] yellow precipitate (II) (6.38g, 29.47 mmoles) is suspended in about 100mL anhydrous methanol.4-hydroxybenzoyl hydrazine (4.48g, 29.47 mmoles) is added in this bright orange suspension, add 3-chloro-phenyl-lsothiocyanates (5.0g, 29.47 mmoles) subsequently.With reaction mixture refluxed 2 hours.The color of reaction mixture becomes pitch-dark and forms black precipitate.Then it is cooled to room temperature and passes through short Celite pad filtration.With the EtOAc that contains 0% to 20% methyl alcohol gradient it is carried out purifying by silica gel chromatography then.Solvent removed in vacuo and from about 50mL EtOAc with the gray precipitate recrystallization that produces.The white crystalline solid that forms is filtered, with a small amount of EtOAc and anhydrous Et 2O washing, and vacuum-drying obtain this title product, are white powder (7.606g).Yield 89.7%.
【0297】ESI-MS：[M+H] + 288.26. 1H NMR(DMSO-d 6)：δ6.92-6.94(d，J＝8.7Hz，2H)，7.00-7.02(dd，J 1＝7.9Hz，J 2＝1.8Hz，1H)，7.33-7.36(t，J＝8.1Hz，1H)，7.47-7.49(dd，J 1＝8.1Hz，J 2＝1.8Hz，1H)，7.72-7.74(d，J＝8.7Hz，2H)，7.76-7.78(t，J＝2.1Hz，1H)，10.19(s，1H)，10.81(s，1H)。 13C NMR(DMSO-d 6)114.6，115.5，116.1，116.4，121.3，127.6，130.6，133.5，140.3，158.3，159.0，160.1。
Embodiment 85 6-(4-{5-[(3-chloro-phenyl-) amino]-1,3,4- diazole-2-yl } phenoxy group) pyrimidine-2, the closing of 4-diamines
Become
Figure A20058003591801501
[0298] with the 4-{5-[(3-chloro-phenyl-) amino]-1,3,4- diazole-2-yl } phenol (143.8mg, 0.5 mmole) is dissolved in the 3mL dry DMF in 2-5mL microwave tube (Personal Chemistry).Add two (trimethyl silyl) acid amides potassium (200.0mg, 1.0 mmoles) of solid, and with reaction mixture 80 ℃ of heated and stirred 10 minutes, add 6-chloro-2 then, 4-diamino-pyrimidine (86.7mg, 0.6 mmole) adds anhydrous K subsequently 2CO 3(69.1mg, 0.5 mmole).Cover bottle cap then and 180 ℃ of microwave heatings 40 minutes.Then reaction mixture is diluted with about 1mL MeOH, filter, and carry out purifying with the acetonitrile/water system that contains 0.01%TFA by anti-phase preparation HPLC by 0.22 μ m syringe filter.The part that will contain product is collected, and at approximately 50mL EtOAc and the approximately saturated NaHCO of 50mL 3Distribute between the aqueous solution.With the salt water washing of EtOAc layer, in anhydrous Na 2SO 4Last dry and filtration.Solvent removed in vacuo obtains this title product, is light yellow solid (62.0mg).Yield 31.3%.
【0299】ESI-MS：[M+H] + 396.22. 1H NMR(DMSO-d 6)：δ5.19(s，1H)，6.04(s，2H)，6.33(s，2H)，7.06-7.08(m，1H)，7.27-7.29(d，J＝8.7Hz，2H)，7.37-7.41(t，J＝8.1Hz，1H)，7.50-7.52(dd，J 1＝8.1Hz，J 2＝1.8Hz，1H)，7.78-7.79(t，J＝2.1Hz，1H)，7.89-7.90(d，J＝8.7Hz，2H)，10.95(s，1H)。
Embodiment 86 5-[4-(pyrimidine-5-base oxygen base) phenyl]-N-[3-chloro-phenyl]-1,3,4- diazole-2-amine synthetic
Figure A20058003591801502
[0300] with the 4-{5-[(3-chloro-phenyl-) amino]-1,3,4- diazole-2-yl } phenol (143.8mg, 0.5 mmole) is dissolved in the 3mL dry DMF in 2-5mL microwave tube (Personal Chemistry).Add two (trimethyl silyl) acid amides potassium (200.0mg, 1.0 mmoles) of solid, and with reaction mixture 80 ℃ of heated and stirred 10 minutes, add 5-bromo pyrimi piperidine (95.4mg, 0.6 mmole) then, add anhydrous K subsequently 2CO 3(69.1mg, 0.5 mmole).Cover bottle cap then and 180 ℃ of microwave heatings 30 minutes.Then reaction mixture is diluted with about 1mL MeOH, filter, and carry out purifying with the acetonitrile/water system that contains 0.01%TFA by anti-phase preparation HPLC by 0.22 μ m syringe filter.The part that will contain product is collected, and at approximately 50mL EtOAc and the approximately saturated NaHCO of 50mL 3Distribute between the aqueous solution.With the salt water washing of EtOAc layer, in anhydrous Na 2SO 4Last dry and filtration.Solvent removed in vacuo obtains this title product, is light yellow solid (74.7mg).Yield 40.8%.
【0301】ESI-MS：[M+H] + 366.23. 1H NMR(DMSO-d 6)：δ7.06-7.08(m，1H)，7.31-7.33(d，J＝8.7Hz，2H)，7.37-7.41(t，J＝8.1Hz，1H)，7.50-7.52(dd，J 1＝8.1Hz，J 2＝1.8Hz，1H)，7.77-7.79(t，J＝2.0Hz，1H)，7.93-7.94(d，J＝8.7Hz，2H)，8.77(s，2H)，9.09(s，1H)，10.96(s，1H)。
Embodiment 87 5-[4-(pyridin-3-yl oxygen base) phenyl]-1,3,4- diazole-2-amine hydrobromate synthetic
Figure A20058003591801511
[0302] 4-(pyridin-3-yl oxygen base) benzo hydrazides (3.7g, 16.14 mmoles) is dissolved among the anhydrous THF of 100mL, and adds the cyanogen bromide (5.38mL, 16.14 mmoles) of 3.0M by syringe.Stirred 5-10 minute, the orange precipitation begins to form.With reaction mixture refluxed 1 hour.Then it is cooled to room temperature and filtration.The orange of collecting is precipitated with about 100mL THF, about 100mL EtOAc, anhydrous Et 2O washing and vacuum-drying obtain this title product, are orange solid (4.40g).Yield 81.4%.
【0303】ESI-MS：[M+H] + 255.05. 1H NMR(DMSO-d 6)：δ7.27-7.29(d，J＝8.8Hz，2H)，7.75-7.78(dd，J 1＝8.5Hz，J 2＝5.0Hz，1H)，7.85-7.87(d，J＝8.8Hz，2H)，7.92-7.94(m，1H)，8.59-8.60(dd，J 1＝5.0Hz，J 2＝1.0Hz，1H)，8.69-8.70(d，J＝2.7Hz，1H)。
Embodiment 88 N-{5-[4-(pyridin-3-yl oxygen base) phenyl]-1,3,4- diazole-2-yl }-4-(trifluoromethoxy) benzene first
Synthesizing of acid amides
[0304] with 5-[4-(pyridin-3-yl oxygen base) phenyl]-1,3,4- diazole-2-amine hydrobromate (167.5mg, 0.5 mmole) is suspended in the 2mL anhydrous pyridine.4-trifluoromethoxy Benzoyl chloride (167.2mg, 117 μ L, 0.75 mmole) is directly added in this solution.Reaction mixture forms the orange solution that has small amount of precipitate.It was stirred 6 hours.With about 1mL MeOH it is diluted then, filter, and carry out purifying with the acetonitrile/water mixture that contains 0.01%TFA by anti-phase preparation HPLC by 0.22 μ m syringe filter.The part that will contain product merges, and at approximately 40mL EtOAc and the approximately saturated NaHCO of 40mL 3Distribute between the aqueous solution.With the salt water washing of EtOAc layer, in anhydrous Na 2SO 4Last dry and filtration.Solvent removed in vacuo obtains this title product, is yellow solid (89.0mg).Yield 40.2%.
【0305】ESI-MS：[M+H] +442.82. 1H NMR(DMSO-d 6)：δ7.20-7.22(d，J＝8.8Hz，2H)，7.44-7.46(d，J＝8.6Hz，2H)，7.48-7.51(dd，J 1＝8.4Hz，J 2＝4.6Hz，1H)，7.59-7.62(ddd，J 1＝8.4Hz，J 2＝2.8Hz，J 3＝1.2Hz，1H)，7.94-7.96(d，J＝8.8Hz，2H)，8.17-8.19(d，J＝8.6Hz，2H)，8.45-8.46(dd，J 1＝4.6Hz，J 2＝1.2Hz，1H)，8.48-8.49(d，J＝2.8Hz，1H)。
Embodiment 89 N-{5-[4-(pyridin-3-yl oxygen base) phenyl]-1,3,4- diazole-2-yl }-3-(trifluoromethyl) benzoyl
Synthesizing of amine
Figure A20058003591801521
[0306] with 5-[4-(pyridin-3-yl oxygen base) phenyl]-1,3,4- diazole-2-amine hydrobromate (167.5mg, 0.5 mmole) is suspended in the 2mL anhydrous pyridine.3-trifluoromethyl benzoyl chloride (156.4mg, 0.75 mmole) is added in this solution.Reaction mixture forms the orange solution that has a small amount of white precipitate.It was stirred 3 hours.With about 1mL MeOH dilution, filter by 0.22 μ m syringe filter, and carry out purifying with the acetonitrile/water mixture that contains 0.01%TFA then by anti-phase preparation HPLC.The part that will contain product merges, and at approximately 40mL EtOAc and the approximately saturated NaHCO of 40mL 3Distribute between the aqueous solution.With the salt water washing of EtOAc layer, dry and filtration on anhydrous sodium sulphate.Solvent removed in vacuo obtains this title product, is yellow solid (50.0mg).Yield 23.4%.
【0307】ESI-MS：[M+H] + 426.94. 1H NMR(DMSO-d 6)：δ7.21-7.23(d，J＝8.8Hz，2H)，7.49-7.51(dd，J 1＝8.4Hz，J 2＝4.6Hz，1H)，7.60-7.62(ddd，J 1＝8.4Hz，J 2＝2.8Hz，J 3＝1.2Hz，1H)，7.75-7.76(t，J＝7.7Hz，1H)，7.95-7.98(m，3H)，8.33-8.34(d，J＝7.7Hz，1H)，8.39(s，1H)，8.46-8.47(dd，J 1＝4.6Hz，J 2＝1.2Hz，1H)，8.48-8.49(d，J＝2.8Hz，1H)。
Embodiment 90 4-bromo-N-{5-[4-(pyridin-3-yl oxygen base) phenyl]-1,3,4- diazole-2-yl }-the closing of benzamide
Become
Figure A20058003591801522
[0308] with 5-[4-(pyridin-3-yl oxygen base) phenyl]-1,3,4- diazole-2-amine hydrobromate (167.5mg, 0.5 mmole) is suspended in the 2mL anhydrous pyridine.4-bromo-benzoyl chloride (164.6mg, 0.75 mmole) is added in this solution.Reaction mixture forms the orange solution that has a small amount of white precipitate.It was stirred 3 hours.With about 1mL MeOH dilution, filter by 0.22 μ m syringe filter, and carry out purifying with the acetonitrile/water mixture that contains 0.01%TFA then by anti-phase preparation HPLC.The part that will contain product merges, and at approximately 40mL EtOAc and the approximately saturated NaHCO of 40mL 3Distribute between the aqueous solution.With the salt water washing of EtOAc layer, dry and filtration on anhydrous sodium sulphate.Solvent removed in vacuo obtains this title product, is yellow solid (46.5mg).Yield 21.2%.
【0309】ESI-MS：[M+H] +438.84. 1H NMR(DMSO-d 6)：δ7.20-7.22(d，J＝8.8Hz，2H)，7.49-7.51(dd，J 1＝8.4Hz，J 2＝4.6Hz，1H)，7.60-7.62(ddd，J 1＝8.4Hz，J 2＝2.8Hz，J 3＝1.2Hz，1H)，7.68-7.70(d，J＝8.4Hz，2H)，7.95-7.97(d，J＝8.8Hz，2H)，8.00-8.02(d，J＝8.4Hz，2H)，8.45-8.46(dd，J 1＝4.6Hz，J 2＝1.2Hz，1H)，8.48-8.49(d，J＝2.8Hz，1H)。
Embodiment 91 N-{5-[4-(pyridin-3-yl oxygen base) phenyl]-1,3,4- diazole-2-yl }-3-(trifluoromethoxy)-benzene first
Synthesizing of acid amides
Figure A20058003591801531
[0310] with 5-[4-(pyridin-3-yl oxygen base) phenyl]-1,3,4- diazole-2-amine hydrobromate (167.5mg, 0.5 mmole) is suspended in the 2mL anhydrous pyridine.(117 μ L) directly adds in this solution with pure 3-trifluoromethoxy Benzoyl chloride.Reaction mixture forms the orange solution that has a small amount of white precipitate.It was stirred 3 hours.With about 1mL MeOH it is diluted then, filter, and carry out purifying with the acetonitrile/water mixture that contains 0.01%TFA by anti-phase preparation HPLC by 0.22 μ m syringe filter.The part that will contain product merges, and at approximately 40mL EtOAc and the approximately saturated NaHCO of 40mL 3Distribute between the aqueous solution.With the salt water washing of EtOAc layer, dry and filtration on anhydrous sodium sulphate.Solvent removed in vacuo obtains this title product, is yellow solid (38.8mg).Yield 17.5%.
【0311】ESI-MS：[M+H] +442.85. 1H NMR(DMSO-d 6)：δ7.22-7.24(d，J＝8.8Hz，2H)，7.49-7.51(dd，J 1＝8.4Hz，J 2＝4.6Hz，1H)，7.60-7.62(ddd，J 1＝8.4Hz，J 2＝2.8Hz，J 3＝1.2Hz，1H)，7.61-7.63(m，1H)，7.68.-7.71(t，J＝7.7Hz，1H)，7.97-7.98(m，3H)，8.08-8.10(d，J＝7.7Hz，1H)，8.46-8.47(dd，J 1＝4.6Hz，J 2＝1.2Hz，1H)，8.48-8.49(d，J＝2.8Hz，1H)。
Embodiment 92 4-methoxyl group-N-{5-[4-(pyridin-3-yl oxygen base) phenyl]-1,3,4- diazole-2-yl }-3-(fluoroform
Base)-benzamide synthetic
Figure A20058003591801532
[0312] with 5-[4-(pyridin-3-yl oxygen base) phenyl]-1,3,4- diazole-2-amine hydrobromate (167.5mg, 0.5 mmole) is suspended in the 2mL anhydrous pyridine.Pure 4-methoxyl group-3-trifluoromethyl benzoyl chloride (179.0mg, 0.75 mmole) is directly added in this solution.Reaction mixture forms the orange solution that has a small amount of white precipitate.It was stirred 3 hours.With about 1mL MeOH it is diluted then, filter, and carry out purifying with the acetonitrile/water mixture that contains 0.01%TFA by anti-phase preparation HPLC by 0.22 μ m syringe filter.The part that will contain product merges, and at approximately 40mL EtOAc and the approximately saturated NaHCO of 40mL 3Distribute between the aqueous solution.With the salt water washing of EtOAc layer, dry and filtration on anhydrous sodium sulphate.Solvent removed in vacuo obtains this title product, is yellow solid (37.0mg).Yield 16.2%.
【0313】ESI-MS：[M+H] + 456.85. 1H NMR(DMSO-d 6)：δ3.97(s，3H)，7.21-7.23(d，J＝8.8Hz，2H)，7.38-7.40(d，J＝9.1Hz，1H)，7.49-7.51(dd，J 1＝8.4Hz，J 2＝4.6Hz，1H)，7.60-7.62(ddd，J 1＝8.4Hz，J 2＝2.8Hz，J 3＝1.2Hz，1H)，7.95-7.97(d，J＝8.8Hz，2H)，8.34-8.35(m，2H)，8.46-8.47(dd，J 1＝4.6Hz，J 2＝1.2Hz，1H)，8.48-8.49(d，J＝2.8Hz，1H)。
Embodiment 93 2,2-two fluoro-N-{5-[4-(pyridin-3-yl oxygen base) phenyl]-1,3,4- diazole-2-yl }-1, between the 3-benzo
Synthesizing of dioxolane-5-carboxylic acid amides
Figure A20058003591801541
[0314] with 5-[4-(pyridin-3-yl oxygen base) phenyl]-1,3,4- diazole-2-amine hydrobromate (167.5mg, 0.5 mmole) is suspended in the 2mL anhydrous pyridine.With pure 2,2-two fluoro-1, dioxolane between the 3-benzo-5-formyl chloride (165.4mg, 0.75 mmole) directly adds in this solution.Reaction mixture forms the orange solution that has a small amount of white precipitate.It was stirred 3 hours.With about 1mL MeOH it is diluted then, filter, and carry out purifying with the acetonitrile/water mixture that contains 0.01%TFA by anti-phase preparation HPLC by 0.22 μ m syringe filter.The part that will contain product merges, and at approximately 40mL EtOAc and the approximately saturated NaHCO of 40mL 3Distribute between the aqueous solution.With the salt water washing of EtOAc layer, dry and filtration on anhydrous sodium sulphate.Solvent removed in vacuo obtains this title product, is yellow solid (27.0mg).Yield 12.3%.
【0315】ESI-MS：[M+H] +456.85. 1H NMR(DMSO-d 6)：δ7.19-7.21(d，J＝8.8Hz，2H)，7.47-7.51(m，2H)，7.58-7.60(ddd，J 1＝8.4Hz，J 2＝2.8Hz，J 3＝1.2Hz，1H)，7.93-7.95(d，J＝8.8Hz，2H)，7.99-8.01(m，2H)，8.45-8.46(dd，J 1＝4.6Hz，J 2＝1.2Hz，1H)，8.48-8.49(d，J＝2.8Hz，1H)。
Embodiment 94 3-chloro-2-fluoro-N-{5-[4-(pyridin-3-yl oxygen base) phenyl]-1,3,4- diazole-2-yl }-5-(fluoroform
Base)-benzamide synthetic
Figure A20058003591801542
[0316] with 5-[4-(pyridin-3-yl oxygen base) phenyl]-1,3,4- diazole-2-amine hydrobromate (167.5mg, 0.5 mmole) is suspended in the 2mL anhydrous pyridine.Pure 3-chloro-2-fluoro-5-trifluoromethyl benzoyl chloride (250 μ L) is directly added in this solution.Reaction mixture forms the red solution that has a small amount of white precipitate.It was stirred 18 hours.With about 1mL MeOH it is diluted then, filter, and carry out purifying with the acetonitrile/water mixture that contains 0.01%TFA by anti-phase preparation HPLC by 0.22 μ m syringe filter.The part that will contain product merges, and at approximately 40mL EtOAc and the approximately saturated NaHCO of 40mL 3Distribute between the aqueous solution.With the salt water washing of EtOAc layer, dry and filtration on anhydrous sodium sulphate.Solvent removed in vacuo obtains this title product, is yellow solid (83.4mg).Yield 34.8%.
【0317】ESI-MS：[M+H] +480.71. 1H NMR(DMSO-d 6)：δ7.18-7.20(d，J＝8.8Hz，2H)，7.47-7.50(dd，J 1＝8.4Hz，J 2＝4.6Hz，1H)，7.58-7.60(ddd，J 1＝8.4Hz，J 2＝2.8Hz，J 3＝1.2Hz，1H)，7.92-7.94(d，J＝8.8Hz，2H)，8.13-8.16(m，2H)，8.44-8.45(dd，J 1＝4.6Hz，J 2＝1.2Hz，1H)，8.47-8.48(d，J＝2.8Hz，1H)。
Embodiment 95 4-fluoro-N-{5-[4-(pyridin-3-yl oxygen base) phenyl]-1,3,4- diazole-2-yl }-3-(trifluoromethyl)-
Synthesizing of benzamide
Figure A20058003591801551
[0318] with 5-[4-(pyridin-3-yl oxygen base) phenyl]-1,3,4- diazole-2-amine hydrobromate (167.5mg, 0.5 mmole) is suspended in the 2mL anhydrous pyridine.Pure 4-fluoro-3-trifluoromethyl benzoyl chloride (200 μ L) is directly added in this solution.It was stirred 18 hours.Reaction mixture forms the red solution that has yellow mercury oxide.With about 1mL MeOH it is diluted then, filter, and carry out purifying with the acetonitrile/water mixture that contains 0.01%TFA by anti-phase preparation HPLC by 0.22 μ m syringe filter.The part that will contain product merges, and at approximately 40mL EtOAc and the approximately saturated NaHCO of 40mL 3Distribute between the aqueous solution.With the salt water washing of EtOAc layer, dry and filtration on anhydrous sodium sulphate.Solvent removed in vacuo obtains this title product, is yellow solid (105.1mg).Yield 47.3%.
【0319】ESI-MS：[M+H] +444.79. 1H NMR(DMSO-d 6)：δ7.18-7.20(d，J＝8.8Hz，2H)，7.47-7.50(dd，J 1＝8.4Hz，J 2＝4.6Hz，1H)，7.53-7.60(m，2H)，7.93-7.94(d，J＝8.8Hz，2H)，8.40-8.43(m，1H)，8.43-8.45(dd，J 1＝4.6Hz，J 2＝1.2Hz，1H)，8.47-8.48(d，J＝2.8Hz，1H)。
Embodiment 96 N-{5-[4-(pyridin-3-yl oxygen base) phenyl]-1,3,4- diazole-2-yl }-2-(trifluoromethoxy)-benzene first
Synthesizing of acid amides
Figure A20058003591801552
[0320] with 5-[4-(pyridin-3-yl oxygen base) phenyl]-1,3,4- diazole-2-amine hydrobromate (167.5mg, 0.5 mmole) is suspended in the 2mL anhydrous pyridine.(100 μ L) directly adds in this solution with pure 2-trifluoromethoxy Benzoyl chloride.It was stirred 18 hours.Reaction mixture forms the orange solution that has yellow mercury oxide.With about 1mL MeOH it is diluted then, filter, and carry out purifying with the acetonitrile/water mixture that contains 0.01%TFA by anti-phase preparation HPLC by 0.22 μ m syringe filter.The part that will contain product merges, and at approximately 40mL EtOAc and the approximately saturated NaHCO of 40mL 3Distribute between the aqueous solution.With the salt water washing of EtOAc layer, dry and filtration on anhydrous sodium sulphate.Solvent removed in vacuo obtains this title product, is glassy yellow solid (20.2mg).Yield 9.1%.
【0321】ESI-MS：[M+H] +443.04. 1H NMR(DMSO-d 6)：δ7.22-7.24(d，J＝8.8Hz，2H)，7.48-7.54(m，4H)，7.60-7.63(ddd，J 1＝8.4Hz，J 2＝2.8Hz，J 3＝1.2Hz，1H)，7.69-7.71(t，J＝7.8Hz，1H)，7.80-7.81(d，J＝7.5Hz，1H)，7.94-7.96(d，J＝8.8Hz，2H)，8.47-8.49(m，2H)。
Synthesizing of embodiment 97 N-amino-N '-(4-chloro-3-trifluoromethyl-phenyl-guanidine) hydriodide
Figure A20058003591801561
[0322] mixture with 2.54g4-chloro-3-trifluoromethyl-phenylthiourea, 0.62mL methyl iodide refluxes 1 hour so that 1-[4-chloro-3-(trifluoromethyl) phenyl to be provided in the anhydrous EtOH of 50mL]-S-methyl-isothiourea hydriodide.Then it is cooled to room temperature and uses the hydrazine of 0.35g 98% to handle, mild heat calms down until the violent release of original M eSH under stirring, and then refluxes 1 hour.
Embodiment 98 4-(3-{[4-chloro-3-(trifluoromethyl) phenyl] amino }-1,2,4-triazine-5-yl) phenol synthetic
Figure A20058003591801562
[0323] N-amino-N '-[4-chloro-3-(trifluoromethyl) phenyl]-guanidine hydriodide and the normal 4-hydroxyl of the about 1.0-1.5-phenyl oxalic dialdehyde in 1: 1 methanol/water mixture can be carried out reacting to produce this title product.This product can perhaps be separated by silica gel column chromatography by precipitation or by with a large amount of solvents such as ethyl acetate, methylene dichloride or extracted with diethyl ether.
Embodiment 99 4-[4-(3-{[4-chloro-3-(trifluoromethyl) phenyl] amino }-[1,2,4] triazine-5-yl) phenoxy group]-the N-first
Synthesizing of yl pyridines-2-carboxylic acid amides
Figure A20058003591801563
[0324] 4-of 7.23g (19.73 mmole) (3-{[4-chloro-3-(trifluoromethyl)-phenyl] amino-1,2,4-triazine-5-yl) phenol can be dissolved in the 80mL dry DMF under argon gas.2.44g the solid potassium tert-butoxide of (21.71 mmoles, 1.1 equivalents) can be added in this solution.The mixture that is produced can be heated to about 100 ℃ and stirred 15 minutes in this temperature.Can add 10mL then and contain the anhydrous DMF solution of the 4-chloro-pyridine-2-carboxylic acids methyl nitrosourea of 3.7g (21.71 mmoles, 1.1 equivalents), add the anhydrous K of 3.28g (23.68 mmoles, 1.2 equivalents) subsequently 2CO 3Can be with reaction mixture 140 ℃ of heating 30 hours.This reaction process can be monitored by LC/MS.It can be cooled to room temperature then.The mixture that is produced can be introduced in 500mL water and the 100mL ethyl acetate.The waterbearing stratum can be extracted with a large amount of solvents such as ethyl acetate, methylene dichloride or ether.Extraction liquid after the merging can be used the salt water washing and drying on anhydrous sodium sulphate then with 100mL water washing 3 times.Can solvent removed in vacuo, produce rough 4-[4-(3-phenyl amino-[1,2,4] triazine-6-yl)-phenoxy group]-the pyridine-2-carboxylic acids methyl nitrosourea.Then can be with product with silica gel column chromatography purifying in addition.Those of ordinary skill in the art can determine which kind of solvent systems can be used as the eluent in the chromatographic purification process.
Synthesizing of embodiment 100 4-(3-ethylmercapto group-[1,2,4] triazine-5-yl)-phenol
Figure A20058003591801571
[0325] can be with the normal 4-hydroxy phenyl of 1.0-1.5 oxalic dialdehyde with containing 1.0-2.0 equivalent K 2CO 31: 1 methanol/water mixture in 1-amino-S-ethyl isothiourea hydrobromide react to produce 4-(3-ethylmercapto group-[1,2,4] triazine-5-yl)-phenol.This product can perhaps be separated by silica gel column chromatography by big metering method well known by persons skilled in the art such as precipitation or with a large amount of solvents such as ethyl acetate, methylene dichloride or extracted with diethyl ether.
Synthesizing of embodiment 101 4-(3-amino-[1,2,4] triazine-5-yl)-phenol
Figure A20058003591801572
[0326] the normal ammonia of 1-5 in 1.0 normal 4-(3-ethylmercapto group-[1,2,4] triazine-6-yl)-phenol and the two  alkane can be reacted so that 4-(3-amino-[1,2,4] triazine-5-yl)-phenol to be provided.This product can perhaps be separated by silica gel column chromatography by big metering method well known by persons skilled in the art such as precipitation or with a large amount of solvents such as ethyl acetate, methylene dichloride or extracted with diethyl ether.
Embodiment 102 4-[4-(3-amino-[1,2,4] triazine-5-yl)-phenoxy group]-N-picoline-2-carboxylic acid amides synthetic
Figure A20058003591801573
[0327] 4-of 3.71g (19.73 mmole) (3-amino-[1,2,4] triazine-5-yl)-phenol can be dissolved in the 80mL dry DMF under argon gas.2.44g the solid potassium tert-butoxide of (21.71 mmoles, 1.1 equivalents) can be added in this solution.The mixture that is produced can be heated to about 100 ℃ and stirred 15 minutes in this temperature.Can add 10mL then and contain the anhydrous DMF solution of the 4-chloro-pyridine-2-carboxylic acids methyl nitrosourea of 3.7g (21.71 mmoles, 1.1 equivalents), add the anhydrous K of 3.28g (23.68 mmoles, 1.2 equivalents) subsequently 2CO 3Reaction mixture was heated 30 hours at 140 ℃.The process of this reaction can be monitored by LC/MS.It can be cooled to room temperature then.The mixture that is produced can be introduced in 500mL water and the 100mL ethyl acetate.The waterbearing stratum can be extracted with a large amount of solvents such as ethyl acetate, methylene dichloride or ether.Extraction liquid after the merging can be used the salt water washing and drying on anhydrous sodium sulphate then with 100mL water washing 3 times.Can solvent removed in vacuo to produce rough 4-[4-(3-amino-[1,2,4] triazine-5-yl)-phenoxy group]-N-picoline-2-carboxylic acid amides.Then can be with product with silica gel column chromatography purifying in addition.Those of ordinary skill in the art can determine which kind of solvent systems can be used as the eluent in the chromatographic purification process.
Embodiment 103 4-[4-(3-{[4-chloro-3-(trifluoromethyl) benzoyl] amino }-[1,2,4] triazine-5-yl)-benzene oxygen
Base]-N-picoline-2-carboxylic acid amides synthetic
Figure A20058003591801581
[0328] 4-[4-of 108.6mg (0.337 mmole, 1.0 equivalents) (3-amino-[1,2,4] triazine-5-yl)-phenoxy group]-N-picoline-2-carboxylic acid amides can be dissolved in the 2mL dry DMF and be heated to about 100 ℃.45.4mg the solid potassium tert-butoxide of (0.405 mmole, 1.2 equivalents) can be added in this solution, adds the 4-chloro-3-trifluoromethyl benzoyl chloride of 0.405 mmole (1.2 equivalent) subsequently.It was at room temperature stirred 1-2 hour.This product can perhaps by silica gel column chromatography, perhaps be separated by anti-phase preparation HPLC chromatogram by big metering method well known by persons skilled in the art such as precipitation or by with a large amount of solvents such as ethyl acetate, methylene dichloride or extracted with diethyl ether.
Embodiment 104 4-{4-[3-({ [4-chloro-3-(trifluoromethyl) phenyl] alkylsulfonyl } amino)-[1,2,4] triazine-5-yl]-benzene
The oxygen base }-N-picoline-2-carboxylic acid amides synthetic
Figure A20058003591801582
[0329] 4-[4-of 108.6mg (0.337 mmole, 1.0 equivalents) (3-amino-[1,2,4] triazine-5-yl)-phenoxy group]-N-picoline-2-carboxylic acid amides can be dissolved in the 2mL anhydrous pyridine and be heated to about 100 ℃.The 4-chloro-3-trifluoromethyl benzene sulfonyl chloride that can add 0.405 mmole (1.2 equivalent).Reaction mixture was at room temperature stirred 1-2 hour.This product can perhaps by silica gel column chromatography, perhaps be separated by anti-phase preparation HPLC chromatogram by big metering method well known by persons skilled in the art such as precipitation or by with a large amount of solvents such as ethyl acetate, methylene dichloride or extracted with diethyl ether.
In embodiment 105 test cell lines to the inhibiting test of MAPK path
[0330] tested some compounds of describing with formula (B) restraining effect in cell experiment to the MAPK path.Western blot analysis: the former generation Human umbilical vein endothelial cells (HUVECs) that will go down to posterity in early days be kept at contain SingleQuots (Cambrex, East Rutherford, NJ), among the EGM-2 of 10%FBS, 10mM HEPES and 50 μ g/ml gentamicins.Before handling this cell, made HUVECs hungry 18 hours by replacing the complete culture solution that contains serum with the nutrient solution of serum-free and no SingleQuot with inhibitor.With the cell after this hunger with inhibitor (0-20 μ M) pre-treatment 60 minutes under multiple concentration.Then (Peprotech, Rocky Hill NJ) handled 6 minutes, and immediately with ice-cold PBS cleaning cell with 50ng/mlVEGF or FGF with this HUVECs.With cell with ice-cold RIPA damping fluid cracking, this damping fluid contains 100mM Tris pH 7.5,150mMNaCl, 1mM EDTA, 1% Septochol, 1%Triton X-100,0.1%SDS, 2mM PMSF, a Complete-Mini proteinase inhibitor (Complete-Mini protease inhibitor) tablet (Roche, Indianapolis, IN; Every 7ml lysis buffer a slice) and inhibitors of phosphatases NaF (500mM) and ortho-vanadate (1mM).Cell is scraped, shift lysate and, centrifugal 10 minutes of 000g 15.Supernatant is changed in the new pipe also with BCA protein reagent (Pierce, Rockford, IL) mensuration protein concentration.The cell lysate that will contain 20 μ g total proteins separates with 10%SDS-PAGE, it is transferred on the nitrocellulose, and seals in containing the TBST liquid of 5% milk.As an anti-anti-phosphorylation ERK Thr202/Tyr204 (Cell Signaling, Beverly, MA), anti-phosphorylation MEK Ser217/221 (Cell Signaling) and c-Raf (BD BioscencesPharmingen, San Diego, CA) with the goat anti-mouse of horseradish peroxidase or goat antirabbit two anti-detections, and (as seen Rochester NY) makes band to use SuperSignal West Pico chemical illuminating reagent system (Pierce) and Kodak's X-ray film.
[0331] when testing in this experiment, Bay 43-9006 (Raf/FGF inhibitor) shows the reduction of p-MEK and p-ERK expression, has 200 to 300nM IC 50The reduction that U0126 (mek inhibitor) shows the p-Erk level has 200 to 300nM IC 50, and the p-MEK level is unaffected.The result is illustrated in the table 1.As can be seen, compound of the present invention shows the reduction of p-MEK and p-ERK level, has the IC of 400nM to 20 μ M 50
Embodiment 106 cell viability analyses
[0332] tested the effect of some compound pair cell vigor of describing with formula (B).XTT analyzes: HUVECs is inoculated in tissue culture treated 96 orifice plates of handling through type i collagen albumen with 10,000 cells/well, and in aforesaid complete EGM-2 nutrient solution grow overnight.Morning next day is with the described inhibitor of DMSO serial dilution and with in 1% the DMSO final concentration adding cell.(Sigma, St.Louis MO) measure cell viability with the XTT assay method after 72 hours.Also be the take a picture morphology difference of the XTT trend that arrives with comparative observation of cell.(Prism Software package, GraphPad Software, San Diego CA) determines IC with quantitation software 50Value.Some kinds of inhibitor have stoped cell proliferation, and apoptosis-induced when being lower than the concentration of 1 μ M, and repeated experiments three times is to determine observations.Compound of the present invention shows the IC of 100nM to 40 μ M in this experiment 50(table 2).
Table 2. embodiment 105 and 106 test result
Embodiment Western blotting Restraining effect to HUVEC cell proliferation
(IC50)
4-{4-[5-(4-chloro-3-trifluoromethyl-phenyl amino)-4H-[1,2,4] triazole-3-yl]-phenoxy group }-pyridine-2-carboxylic acid methyl acid amides Activity is arranged during 10 μ M 2.85μM
4-{4-[5-(4-trifluoromethoxy-phenyl)-4H-[1,2,4] triazole-3-base is amino]-phenoxy group }-the pyridine-2-carboxylic acids methyl nitrosourea Non-activity 2.2μM
(4-chloro-3-trifluoromethyl-phenyl)-5-[4-(pyridin-3-yl oxygen base)-phenyl]-4H-[1,2,4] triazole-3-yl }-amine Activity is arranged during 5 μ M 1.81μM
4-{4-[5-(4-trifluoromethoxy-phenyl amino)-4H-[1,2,4] triazole-3-yl]-phenoxy group }-pyridine-2-carboxylic acid methyl acid amides Non-activity ＞40μM
5-[4-(pyridin-4-yl oxygen base)-phenyl]-4H-[1,2,4] triazole-3-yl }-(4-trifluoromethoxy-phenyl)-amine Non-activity ＞40μM
6-{4-[5-(4-trifluoromethoxy-phenyl amino)-4H-[1,2,4] triazole-3-yl]-phenoxy group }-pyridazine-3-base amine Non-activity ＞20μM
6-{4-[5-(4-trifluoromethoxy-phenyl amino)-4H-[1,2,4] triazole-3-yl]-phenoxy group }-pyrimidine-2, the 4-diamines Non-activity 6.0μM
6-[4-({ 5-[4-(trifluoromethoxy)-phenyl-4H-1,2,4-triazole-3-yl } amino) phenoxy group]-pyrimidine-2, the 4-diamines Non-activity 6.58μM
6-{4-[5-(4-chloro-3-trifluoromethyl-phenyl amino)-4H-[1,2,4] triazole-3-yl]-phenoxy group }-pyrimidine-2, the 4-diamines Activity is arranged during 5 μ M 0.089μM
6-{4-[5-(4-chloro-3-trifluoromethyl-phenyl amino)-4H-[1,2,4] triazole-3-yl]-phenoxy group }-the basic amine of pyridazine-3 Non-activity 1.79μM
4-{3-[5-(4-chloro-3-trifluoromethyl-phenyl amino)-4H-[1,2,4] triazole-3-yl]-phenoxy group }-pyridine-2-carboxylic acid methyl acid amides Non-activity ＞20μM
6-{3-[5-(4-chloro-3-trifluoromethyl-phenyl amino)-4H-[1,2,4] triazole-3-yl]-phenoxy group }-pyrimidine-2, the 4-diamines Activity is arranged during 5 μ M 0.404μM
(4-chloro-3-trifluoromethyl-phenyl)-5-[3-(pyridin-4-yl oxygen base)-phenyl]-4H-[1,2,4] triazole-3-yl }-amine Activity is arranged during 5 μ M 1.79μM
6-{3-[5-(4-chloro-3-trifluoromethyl-phenyl amino)-4H-[1,2,4] triazole-3-yl]-phenoxy group }-pyridazine-3-base amine Non-activity ＞10μM
6-[4-(5-[4-chloro-3-trifluoromethyl-phenyl] and amino }-1,3,4- diazole-2-yl)-phenoxy group]-pyrimidine-2, the 4-diamines Activity is arranged during 5 μ M 1.57μM
N-[4-chloro-3-(trifluoromethyl) phenyl]-5-[4-(pyridine-3-base oxygen base)-phenyl]-1,3,4- diazole-2-amine Activity is arranged during 5 μ M 1.72μM
N-[4-chloro-3-(trifluoromethyl) phenyl]-5-[4-(pyridine-4-base oxygen base)-phenyl]-1,3,4- diazole-2-amine Activity is arranged during 5 μ M 8.6μM
N-[4-chloro-3-(trifluoromethyl) phenyl]-5-[4-(pyridine-5-base oxygen base)-phenyl]-1,3,4- diazole-2-amine Activity is arranged during 5 μ M 9.65μM
4-[4-(5-[4-chloro-3-(trifluoromethoxy)-phenyl] and amino }-1,3,4- diazole-2-yl)-phenoxy group]-N-picoline-2-carboxylic acid amides Activity is arranged during 5 μ M 5.6μM
6-[4-(5-[4-chloro-3-(trifluoromethyl) phenyl-4H-1,2,4-triazole-3-yl] amino]-phenoxy group]-pyrimidine-2, the 4-diamines Activity is arranged during 5 μ M 9.57μM
5-[4-chloro-3-(trifluoromethyl) phenyl]-N-[4-(pyridine-4-base oxygen base) phenyl]-4H-1,2,4-triazole-3-amine Non-activity ＞40μM
5-[4-chloro-3-(trifluoromethyl) phenyl]-N-[4-(pyrimidine-5-base oxygen base) phenyl]-4H-1,2,4-triazole-3-amine Activity is arranged during 5 μ M ＞10μM
6-[4-(5-[4-chloro-3-(trifluoromethyl) phenyl]-4H-1,2,4-triazole-3-yl } amino) phenoxy group]-pyridazine-3-amine Activity is arranged during 5 μ M ＞40μM
4-[4-({ 5-[4-chloro-3-(trifluoromethyl) phenyl-4H-1,2,4-triazole-3-yl] amino } phenoxy group)-N-picoline-2-carboxylic acid amides Non-activity ＞40μM
5-[4-chloro-3-(trifluoromethyl) phenyl]-N-[4-(pyridine-3-base oxygen base) phenyl]-4H-1,2,4-triazole-3-amine Activity is arranged during 5 μ M ＞40μM
6-[4-(5-{[3-(trifluoromethyl) phenyl] amino }-1,3,4- diazole-2-yl) phenoxy group] pyrimidine-2, the 4-diamines Activity is arranged during 5 μ M ＞10μM
5-[4-(pyrimidine-5-base oxygen base) phenyl]-N-[3-(trifluoromethyl) phenyl]-1,3,4- diazole-2-amine Activity is arranged during 5 μ M ＞10μM
6-(4-{5-[(4-chloro-phenyl-) amino]-1,3,4- diazole-2- Activity is arranged during 5 μ M 2.6μM
Base } phenoxy group) pyrimidine-2, the 4-diamines
5-[4-(pyrimidine-5-base oxygen base) phenyl]-N-[4-chloro-phenyl]-1,3,4- diazole-2-amine Activity is arranged during 5 μ M ＞20μM
6-(4-{5-[(2-chloro-5-trifluoromethyl-phenyl) amino]-1,3,4- diazole-2-yl } phenoxy group) pyrimidine-2, the 4-diamines Non-activity ～20μM
5-[4-(pyrimidine-5-base oxygen base) phenyl]-N-[2-chloro-5-(trifluoromethyl)-phenyl]-1,3,4- diazole-2-amine Non-activity ～20μM
6-(4-{5-[(3-chloro-phenyl-) amino]-1,3,4- diazole-2-yl } phenoxy group) pyrimidine-2, the 4-diamines Activity is arranged during 5 μ M ～20μM
5-[4-(pyrimidine-5-base oxygen base) phenyl]-N-[2-chloro-phenyl]-1,3,4- diazole-2-amine Activity is arranged during 5 μ M ～20μM
5-[4-(pyridin-3-yl oxygen base) phenyl]-N-[4-chloro-phenyl]-1,3,4- diazole-2-amine Activity is arranged during 10 μ M 9.6μM
5-[4-(pyridin-3-yl oxygen base) phenyl]-N-[3-trifluoromethyl-phenyl]-1,3,4- diazole-2-amine Activity is arranged during 10 μ M ＞20μM
5-[4-(pyridin-3-yl oxygen base) phenyl]-1,3,4- diazole-2-amine Non-activity during 10 μ M ＞40μM
N-{5-[4-(pyridin-3-yl oxygen base) phenyl]-1,3,4- diazole-2-yl }-4-(trifluoromethoxy)-benzamide Non-activity during 10 μ M ＞40μM
N-{5-[4-(pyridin-3-yl oxygen base) phenyl]-1,3,4- diazole-2-yl }-3-(trifluoromethyl)-benzamide Activity is arranged during 10 μ M ＞40μM
4-bromo-N-{5-[4-(pyridin-3-yl oxygen base) phenyl]-1,3,4- diazole-2-yl }-benzamide Non-activity during 10 μ M ＞40μM
N-{5-[4-(pyridin-3-yl oxygen base) phenyl]-1,3,4- diazole-2-yl }-3-(trifluoromethoxy)-benzamide Non-activity during 10 μ M ＞40μM
4-methoxyl group-N-{5-[4-(pyridin-3-yl oxygen base) phenyl]-1,3,4- diazole-2-yl }-3-(trifluoromethyl)-benzamide Activity is arranged during 10 μ M ＞40μM
2,2-two fluoro-N-{5-[4-(pyridin-3-yl oxygen base) phenyl]-1,3,4- diazole-2-yl }-1, dioxolane between the 3-benzo-5-carboxylic acid amides Non-activity during 10 μ M ＞40μM
3-chloro-2-fluoro-N-{5-[4-(pyridin-3-yl oxygen base) phenyl]-1,3,4- diazole-2-yl }-5-(trifluoromethyl)-benzamide Non-activity during 10 μ M ＞40μM
4-fluoro-N-{5-[4-(pyridin-3-yl oxygen base) phenyl]-1,3,4- diazole-2-yl }-3-(trifluoromethyl)-benzamide Activity is arranged during 10 μ M ～20μM
N-{5-[4-(pyridin-3-yl oxygen base) phenyl]-1,3,4- diazole-2-yl }-2-(trifluoromethoxy)-benzamide Non-activity during 10 μ M ～20μM
[0333] although the above embodiment of oneself reference of the present invention is carried out description, should be appreciated that to comprise numerous modifications and variations within the spirit and scope of the present invention.Therefore the present invention is limited by claims only.

Claims (90)

1. have the compound of structure (A) or its N-oxide compound, N, N '-dioxide, N, N ', N "-trioxide or pharmacology on acceptable salt:
Figure A2005800359180002C1
Wherein:
Y does not exist or is selected from:
Figure A2005800359180002C2
R 1Be substituting group, be selected from aryl, heterocycle, heteroaryl, the heterocycle of replacement and the heteroaryl of replacement of aryl, replacement;
R 2Be substituting group, be selected from hydrogen, hydroxyl, C 1-C 6Alkyl, C 1-C 6Alkylamino, halogen, C 1-C 6Alkoxyl group ,-NO 2,-NH 2With-C ≡ N; And
R 3Be substituting group, be selected from aryl, heterocycle, heteroaryl, the heterocycle of replacement and the heteroaryl of replacement of aryl, replacement.
2. the described compound of claim 1, wherein:
R 1Be selected from C 6-C 12Aryl, has the heteroatomic C that 1-3 is selected from N, S and O 3-C 12Heteroaryl, has the C that 0-3 is selected from the heteroatomic replacement of N, S and O 3-C 10The C of cycloalkyl, replacement 6-C 12Aryl, has the C that 1-3 is selected from the heteroatomic replacement of N, S and O 3-C 12Heteroaryl, C 7-C 24Aralkyl, C 7-C 24The C of alkylaryl, replacement 7-C 24The C of aralkyl and replacement 7-C 24Alkaryl;
R 3Be selected from C 6-C 12Aryl, has the heteroatomic C that 1-3 is selected from N, S and O 3-C 12Heteroaryl, has the C that 0-3 is selected from the heteroatomic replacement of N, S and O 3-C 10The C of cycloalkyl, replacement 6-C 12Aryl, has the C that 1-3 is selected from the heteroatomic replacement of N, S and O 3-C 12Heteroaryl, C 7-C 24Aralkyl, C 7-C 24The C of alkylaryl, replacement 7-C 24The C of aralkyl and replacement 7-C 24Alkaryl.
3. the described compound of claim 1, the compound that wherein has described structure (A) are selected from have structure (A1), (A2), (A3) and compound (A4):
Figure A2005800359180003C1
4. the described compound of claim 3, wherein said compound have structure (A1) and wherein:
R 1Be selected from
Figure A2005800359180004C1
Figure A2005800359180005C1
Figure A2005800359180006C1
R 3Be selected from:
Figure A2005800359180006C2
Figure A2005800359180008C1
Figure A2005800359180010C1
And n is selected from 0,1,2 and 3 integer.
5. the described compound of claim 3, wherein said compound with structure (A1) are selected from the have structure compound of (1) and (2):
Figure A2005800359180010C2
6. the described compound of claim 3, wherein said compound with structure (A1) are selected from the compound of have structure (3), (4), (5) and (6):
Figure A2005800359180010C3
7. the described compound of claim 3, wherein said compound with structure (A1) are selected from the compound of (7)-(16) that have structure:
Figure A2005800359180011C1
8. the described compound of claim 7, wherein said compound has following formula:
Figure A2005800359180011C2
9. the described compound of claim 7, wherein said compound has following formula:
10. the described compound of claim 7, wherein said compound has following formula:
Figure A2005800359180012C2
11. the described compound of claim 7, wherein said compound has following formula:
Figure A2005800359180012C3
12. the described compound of claim 7, wherein said compound has following formula:
Figure A2005800359180012C4
13. the described compound of claim 7, wherein said compound has following formula:
Figure A2005800359180012C5
14. the described compound of claim 7, wherein said compound has following formula:
Figure A2005800359180012C6
15. the described compound of claim 7, wherein said compound has following formula:
Figure A2005800359180013C1
16. the described compound of claim 7, wherein said compound has following formula:
Figure A2005800359180013C2
17. the described compound of claim 7, wherein said compound has following formula:
Figure A2005800359180013C3
18. have the compound of structure (B) or its N-oxide compound, N, N '-dioxide, N, N ', N "-trioxide or pharmacology on acceptable salt:
Figure A2005800359180013C4
Wherein:
Z 1, Z 2And Z 3In each be independently selected from N, CH, N=CH, O, S and N-R 4, R wherein 4Be hydrogen or low-carbon alkyl, condition is Z 1, Z 2And Z 3In at least one is not CH;
X does not exist or NH; And
Y does not exist or is selected from:
Figure A2005800359180013C5
R 1Be to have 1-3 the heteroatomic C that does not replace or replace 3-C 12Heteroaryl;
R 2Be selected from hydrogen, halogen, C 1-C 18Alkyl ,-OH ,-NO 2,-CN, C 1-C 18Alkoxyl group ,-NHSO 2R 5,-SO 2NHR 5,-NHCOR 5,-NH 2,-NR 5R 6,-S (O) R 5,-S (O) 2R 5,-CO 2R 5,-CONR 5R 6, R wherein 5And R 6Be independently selected from hydrogen, C 1-C 18The C of alkyl and replacement 1-C 12Alkyl; And
R 3Be selected from hydrogen, C 1-C 18The C of alkyl, replacement 1-C 12Alkyl, C 1-C 12The C of cycloalkyl, replacement 1-C 12Cycloalkyl, has the C of 0-3 heteroatomic replacement 3-C 10Cycloalkyl, C 6-C 12The C of aryl, replacement 6-C 12The heterocycle of aryl, heterocycle, replacement, has 1-3 heteroatomic C 3-C 12Heteroaryl, has the C of 1-3 heteroatomic replacement 3-C 12Heteroaryl, C 7-C 24The C of aralkyl, replacement 7-C 24Aralkyl, C 7-C 24The C of alkylaryl and replacement 7-C 24Alkaryl.
19. the described compound of claim 18, wherein R 1Be selected from:
Figure A2005800359180014C1
Figure A2005800359180015C1
R 3Be selected from:
Figure A2005800359180016C1
Figure A2005800359180017C1
Figure A2005800359180018C1
N is selected from 0,1,2 and 3 integer, and
R ' is selected from hydrogen, C 1-C 18The C of alkyl and replacement 1-C 18Alkyl.
20. the described compound of claim 18, wherein said compound with structure (B) are selected from the compound of (17)-(35) that have formula:
Figure A2005800359180018C2
Figure A2005800359180019C1
Figure A2005800359180020C1
Figure A2005800359180021C1
21. the described compound of claim 20, wherein said compound has following formula:
Figure A2005800359180021C2
22. the described compound of claim 20, wherein said compound has following formula:
23. the described compound of claim 20, wherein said compound has following formula:
Figure A2005800359180022C1
24. the described compound of claim 20, wherein said compound has following formula:
Figure A2005800359180022C2
25. the described compound of claim 20, wherein said compound has following formula:
Figure A2005800359180022C3
26. the described compound of claim 20, wherein said compound has following formula:
Figure A2005800359180022C4
27. the described compound of claim 20, wherein said compound has following formula:
Figure A2005800359180022C5
28. the described compound of claim 20, wherein said compound has following formula:
Figure A2005800359180022C6
29. the described compound of claim 20, wherein said compound has following formula:
Figure A2005800359180022C7
30. the described compound of claim 20, wherein said compound has following formula:
31. the described compound of claim 20, wherein said compound has following formula:
Figure A2005800359180023C2
32. the described compound of claim 20, wherein said compound has following formula:
Figure A2005800359180023C3
33. the described compound of claim 20, wherein said compound has following formula:
Figure A2005800359180023C4
34. the described compound of claim 20, wherein said compound has following formula:
Figure A2005800359180023C5
35. the described compound of claim 20, wherein said compound has following formula:
Figure A2005800359180023C6
36. the described compound of claim 20, wherein said compound has following formula:
Figure A2005800359180023C7
37. the described compound of claim 20, wherein said compound has following formula:
Figure A2005800359180024C1
38. the described compound of claim 20, wherein said compound has following formula:
Figure A2005800359180024C2
39. the described compound of claim 20, wherein said compound has following formula:
Figure A2005800359180024C3
40. comprise the compound of the derivative of phentriazine, described compound comprises the phentriazine part, this part has first substituting group on the phenyl ring that is connected in phentriazine at least and is connected in second substituting group on the triazine ring of phentriazine, wherein:
(a) described first substituting group comprises the phenyl of replacement, the pyridyl of replacement or the pyrimidyl group of replacement; And
(b) described second substituting group is selected from the amide group of secondary amino group, replacement and replaces the sulfonamido group.
41. the described compound of claim 40, the substituting group in the pyridyl of wherein said replacement comprise amido part, aminoalkyl group, carboxylic group or carboxylate salt or carboxylate group.
42. the described compound of claim 41, the nitrogen in the wherein said amido part has carried the 3rd substituting group again, and described the 3rd substituting group is selected from alkyl, alkyl aminoalkyl, pyridyl, alkyl pyrrolidine, alkyl morpholine and alkylpiperazine group.
43. the described compound of claim 40, wherein said second substituting group comprises the group derived from the compound that is selected from benzene, pyridine, thiophene and different  azoles.
44. the described compound of claim 43, wherein said group derived from benzene is selected from tert-butyl-phenyl, Trifluoromethoxyphen-l, p-methoxy-phenyl, dimethylamino, dimethylaminophenyl, aminophenyl, trifluoro ethoxy phenyl, trifluoromethoxy chloro-phenyl-, trifluoro-methoxyl bromobenzene base, trifluoro ethoxy chloro-phenyl-, chloro-phenyl-, dichlorophenyl, trifluoromethyl, trifluoromethyl chloro-phenyl-, chloromethane phenyl, phenyl acetanilide,Phenacetylaniline, N, N-alkyl-benzamide, isopropyl phenyl, alkoxyl phenyl, dialkoxy phenyl, acetyl phenyl.
45. compound, it comprises the benzenesulfonamide derivative part of bridging in heterocyclic moiety, wherein:
(a) described benzenesulfonamide derivative partly comprises having substituent benzene molecular, and described substituting group is selected from:
Logical peroxide bridge is connected in the pyridine group of described benzene molecular, and sulfonyl group; And
(b) described heterocyclic moiety is selected from triazine, triazole,  diazole, pyridazine, pyrimidine, pyridine,  azoles, pyrazoles, pyrroles, imidazoles, thiadiazoles.
46. the described compound of claim 45, wherein said pyridine group comprises first substituting group, and this substituting group comprises amido part, alkylamino group or carboxylic group.
47. the described compound of claim 46, the nitrogen in the wherein said amido part has carried second substituting group again, and described second substituting group is selected from alkyl, alkyl aminoalkyl, pyridyl, alkyl pyrrolidine, alkyl morpholine and alkylpiperazine group.
48. the described compound of claim 45, wherein said heterocyclic moiety randomly comprise the 3rd substituting group that is connected in this heterocyclic moiety, wherein said the 3rd substituting group is selected from the amide group of secondary amino group, replacement and the sulfonamido group of replacement.
49. the described compound of claim 48, wherein said the 3rd substituting group comprises the group derived from the compound that is selected from benzene, thiophene and different  azoles.
50. the described compound of claim 49, wherein said group derived from benzene is selected from tert-butyl-phenyl, Trifluoromethoxyphen-l, p-methoxy-phenyl, dimethylamino, dimethylaminophenyl, aminophenyl, trifluoro ethoxy phenyl, trifluoromethoxy chloro-phenyl-, trifluoro-methoxyl bromobenzene base, trifluoro ethoxy chloro-phenyl-, chloro-phenyl-, dichlorophenyl, trifluoromethyl, trifluoromethyl chloro-phenyl-, chloromethane phenyl, phenyl acetanilide,Phenacetylaniline, N, N-alkyl-benzamide, isopropyl phenyl, alkoxyl phenyl, dialkoxy phenyl, acetyl phenyl.
51. the described compound of claim 45, the bridge between wherein said benzenesulfonamide derivative part and the described heterocyclic moiety comprises single key or nitrogen-atoms.
52. sanatory method comprises compound from significant quantity to the object of needs treatment that use, wherein said compound is illustrated in structure (A), (B) or their combination.
53. the described method of claim 52, wherein said illness is selected from cancer, illness in eye, inflammation, psoriatic and virus infection.
54. the described method of claim 53, wherein said cancer are esophagus/gastrointestinal cancer, colorectal carcinoma, liver cancer, skin carcinoma, mammary cancer, ovarian cancer, prostate cancer, lymphoma, leukemia, kidney, lung cancer, flesh cancer, osteocarcinoma, bladder cancer or the cancer of the brain.
55. the described method of claim 52, wherein said illness is relevant with kinases.
56. the described method of claim 55, wherein said illness is relevant with the mapk kinase path.
57. sanatory method comprises the compound with structure (A) from significant quantity to the object of needs treatment that use:
Figure A2005800359180026C1
Wherein:
Y does not exist or is selected from:
R 1Be substituting group, be selected from aryl, heterocycle, heteroaryl, the heterocycle of replacement and the heteroaryl of replacement of aryl, replacement;
R 2Be substituting group, be selected from hydrogen, hydroxyl, C 1-C 6Alkyl, C 1-C 6Alkylamino, halogen, C 1-C 6Alkoxyl group ,-NO 2,-NH 2With-C ≡ N; And
R 3Be substituting group, be selected from aryl, heterocycle, heteroaryl, the heterocycle of replacement and the heteroaryl of replacement of aryl, replacement.
58. the described method of claim 57, wherein:
R 1Be selected from C 6-C 12Aryl, has the heteroatomic C that 1-3 is selected from N, S and O 3-C 12Heteroaryl, has the C that 0-3 is selected from the heteroatomic replacement of N, S and O 3-C 10The C of cycloalkyl, replacement 6-C 12Aryl, has the C that 1-3 is selected from the heteroatomic replacement of N, S and O 3-C 12Heteroaryl, C 7-C 24Aralkyl, C 7-C 24The C of alkylaryl, replacement 7-C 24The C of aralkyl and replacement 7-C 24Alkaryl;
R 3Be selected from C 6-C 12Aryl, has the heteroatomic C that 1-3 is selected from N, S and O 3-C 12Heteroaryl, has the C that 0-3 is selected from the heteroatomic replacement of N, S and O 3-C 10The C of cycloalkyl, replacement 6-C 12Aryl, has the C that 1-3 is selected from the heteroatomic replacement of N, S and O 3-C 12Heteroaryl, C 7-C 24Aralkyl, C 7-C 24The C of alkylaryl, replacement 7-C 24The C of aralkyl and replacement 7-C 24Alkaryl.
59. the described method of claim 57, wherein said compound with structure (A) are selected from have structure (A1), (A2), (A3) and compound (A4):
60. the described method of claim 57, wherein: R 1Be selected from
Figure A2005800359180028C1
Figure A2005800359180029C1
Figure A2005800359180030C1
R 3Be selected from:
Figure A2005800359180030C2
Figure A2005800359180031C1
Figure A2005800359180032C1
Figure A2005800359180033C1
And n is selected from 0,1,2 and 3 integer.
61. the described method of claim 59, wherein said compound with structure (A1) are selected from the have structure compound of (1) and (2):
Figure A2005800359180034C2
62. the described method of claim 59, wherein said compound with structure (A1) are selected from the compound of have structure (3), (4), (5) and (6):
Figure A2005800359180034C3
63. the described method of claim 62, wherein said compound with structure (A1) are selected from the compound of (7)-(16) that have structure:
Figure A2005800359180035C1
64. sanatory method comprises the compound with structure (B) from significant quantity to the object of needs treatment that use:
Figure A2005800359180036C1
Wherein:
Z 1, Z 2And Z 3In each be independently selected from N, CH, N=CH, O, S and N-R 4, R wherein 4Be hydrogen or low-carbon alkyl, condition is Z 1, Z 2And Z 3In at least one is not CH;
X does not exist or NH; And
Y does not exist or is selected from:
Figure A2005800359180036C2
R 1Be to have 1-3 the heteroatomic C that does not replace or replace 3-C 12Heteroaryl;
R 2Be selected from hydrogen, halogen, C 1-C 18Alkyl ,-OH ,-NO 2,-CN, C 1-C 18Alkoxyl group ,-NHSO 2R 5,-SO 2NHR 5,-NHCOR 5,-NH 2,-NR 5R 6,-S (O) R 5,-S (O) 2R 5,-CO 2R 5,-CONR 5R 6, R wherein 5And R 6Be independently selected from hydrogen, C 1-C 18The C of alkyl and replacement 1-C 12Alkyl; And
R 3Be selected from hydrogen, C 1-C 18The C of alkyl, replacement 1-C 12Alkyl, C 1-C 12The C of cycloalkyl, replacement 1-C 12Cycloalkyl, has the C of 0-3 heteroatomic replacement 3-C 10Cycloalkyl, C 6-C 12The C of aryl, replacement 6-C 12The heterocycle of aryl, heterocycle, replacement, has 1-3 heteroatomic C 3-C 12Heteroaryl, has the C of 1-3 heteroatomic replacement 3-C 12Heteroaryl, C 7-C 24The C of aralkyl, replacement 7-C 24Aralkyl, C 7-C 24The C of alkylaryl and replacement 7-C 24Alkaryl.
65. the described method of claim 64, wherein R 1Be selected from:
Figure A2005800359180037C1
Figure A2005800359180038C1
R 3Be selected from:
Figure A2005800359180038C2
Figure A2005800359180039C1
Figure A2005800359180041C1
N is selected from 0,1,2 and 3 integer, and
R ' is selected from hydrogen, C 1-C 18The C of alkyl and replacement 1-C 18Alkyl.
66. the described method of claim 64, wherein said compound with structure (B) are selected from the compound of (17)-(35) that have formula:
Figure A2005800359180042C1
Figure A2005800359180043C1
Figure A2005800359180044C1
67. claim 57 or 64 described methods, wherein said illness is selected from cancer, illness in eye, inflammation, psoriatic and virus infection.
68. the described method of claim 67, wherein said cancer are esophagus/gastrointestinal cancer, colorectal carcinoma, liver cancer, skin carcinoma, mammary cancer, ovarian cancer, prostate cancer, lymphoma, leukemia, kidney, lung cancer, flesh cancer, osteocarcinoma, bladder cancer or the cancer of the brain.
69. pharmaceutical composition, it comprises and is in the compound that the usefulness structure (A) in the acceptable carrier, (B) or their any combination are illustrated on the pharmacology.
70. goods, comprise wrapping material and the pharmaceutical composition that is included in the described wrapping material, wherein said wrapping material comprise label, described label indicates described pharmaceutical composition can be used to treat illness, and wherein said pharmaceutical composition comprises the compound of illustrating with structure (A), (B) or their any combination.
71. goods, comprise wrapping material and the pharmaceutical composition that is included in the described wrapping material, wherein said wrapping material comprise label, described label indicates described pharmaceutical composition can be used to treat cancer, and wherein said pharmaceutical composition comprises the compound of illustrating with structure (A), (B) or their any combination.
72. sanatory method, comprise acceptable salt, hydrate, solvate, crystal formation and each diastereomer at least a compound of significant quantity on the object administering therapeutic of needs treatments or its pharmacology, described compound is as illustrated in structure (A), (B) or their any combination.
73. the described method of claim 72, wherein said illness is selected from cancer, illness in eye, inflammation, psoriatic and virus infection.
74. the described method of claim 73, wherein said cancer are esophagus/gastrointestinal cancer, colorectal carcinoma, liver cancer, skin carcinoma, mammary cancer, ovarian cancer, prostate cancer, lymphoma, leukemia, kidney, lung cancer, flesh cancer, osteocarcinoma, bladder cancer or the cancer of the brain.
75. sanatory method, comprise acceptable salt, hydrate, solvate, crystal formation and each diastereomer at least a compound of significant quantity on the object administering therapeutic of needs treatments or its pharmacology, described compound is as illustrated in structure (A), (B) or their any combination, and combination is with chemotherapeutics, immunomodulator, therapeutic antibodies or kinases inhibitor.
76. treatment suffers from the method for the object of cancer, comprises the compound of significant quantity on described object administering therapeutic, described compound such as structure (A), (B) or their any combination are set forth, thereby treat described object.
77. the method for pharmaceutical compositions comprises and will be made up by acceptable carrier on acceptable salt, hydrate, solvate, crystal formation and each diastereomer and the pharmacology on the illustrated compound of structure (A), (B) or their any combination or its pharmacology.
78. pharmaceutical composition, it comprises the compound of illustrating as structure (A1) in acceptable carrier on pharmacology.
79. pharmaceutical composition, it comprises the compound of illustrating as structure (A2) in acceptable carrier on pharmacology.
80. pharmaceutical composition, it comprises the compound of illustrating as structure (A3) in acceptable carrier on pharmacology.
81. pharmaceutical composition, it comprises the compound of illustrating as structure (A4) in acceptable carrier on pharmacology.
82. pharmaceutical composition, it comprises the compound of illustrating as structure (B) in acceptable carrier on pharmacology.
83. the cancer of treatment target or the method for tumour, comprise therapeutic antibodies from significant quantity to the object of needs treatment, chemotherapeutics or the immune toxic agent of using, and combination is with by structure (A), (B) or their the illustrated compound of any combination, thereby treats the cancer or the tumour of described object.
84. pharmaceutical composition comprises therapeutical agent and at least a compound, described compound is illustrated by structure (A1), (A2), (A3), (A4) or their any combination, and its concentration is effective for the cancer of treatment target.
85. the described composition of claim 84, wherein said cancer are esophagus/gastrointestinal cancer, colorectal carcinoma, liver cancer, skin carcinoma, mammary cancer, ovarian cancer, prostate cancer, lymphoma, leukemia, kidney, lung cancer, flesh cancer, osteocarcinoma, bladder cancer or the cancer of the brain.
86. the described composition of claim 85, wherein said cancer are colorectal carcinoma or lung cancer.
87. the described method of claim 84, wherein said therapeutical agent is a metabolic antagonist; The DNA linking agent; Alkylating agent; The topoisomerase I inhibitor; The microtubule inhibitor; Vinca alkaloids; Mitomycin type microbiotic and bleomycin type microbiotic.
88. the described method of claim 84, wherein said therapeutical agent is a methotrexate, cis-platinum/carboplatin, canbusil, gengshengmeisu, taxol (handkerchief nit west), antifol, colchicine, Omaine, etoposide, Taxan/taxol, Docetaxel, Zorubicin, anthracycline antibiotics, Zorubicin, daunorubicin, carminomycin, pidorubicin, idarubicin, mitoxantrone, 4-dimethoxy-daunorubicin, 11-deoxidation daunorubicin, 13-deoxidation daunorubicin, doxorubicin hydrochloride-14-benzoic ether, doxorubicin hydrochloride-14-octanoate or doxorubicin hydrochloride-14-naphthylacetic acid ester, irinotecan, topotecan, gemcitabine, 5 FU 5 fluorouracil, the formyl tetrahydrofolic acid carboplatin, cis-platinum, Taxan, for pricking his shore, endoxan, vinca alkaloids, imatinib, anthracycline drug, Rituximab or Herceptin.
89. the described method of claim 88, wherein said therapeutical agent are Zorubicin, Docetaxel or taxol.
90. the described method of claim 84, wherein said therapeutical agent are Herceptin, rhuMAb-VEGF, OSI-774 or Vitaxin.
CN 200580035918 2004-08-25 2005-08-24 Heterocyclic compounds and methods of use Pending CN101044125A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60429804P 2004-08-25 2004-08-25
US60/604,298 2004-08-25
US60/696,168 2005-07-01

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN200910170703A Division CN101654452A (en) 2004-08-25 2005-08-24 Heterocyclic compounds and methods of use.

Publications (1)

Publication Number Publication Date
CN101044125A true CN101044125A (en) 2007-09-26

Family

ID=38808948

Family Applications (2)

Application Number Title Priority Date Filing Date
CN 200580035918 Pending CN101044125A (en) 2004-08-25 2005-08-24 Heterocyclic compounds and methods of use
CN200910170703A Pending CN101654452A (en) 2004-08-25 2005-08-24 Heterocyclic compounds and methods of use.

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN200910170703A Pending CN101654452A (en) 2004-08-25 2005-08-24 Heterocyclic compounds and methods of use.

Country Status (1)

Country Link
CN (2) CN101044125A (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010068738A1 (en) 2008-12-10 2010-06-17 Dana-Farber Cancer Institute, Inc. Mek mutations conferring resistance to mek inhibitors
CN101302193B (en) * 2008-05-27 2010-06-23 上海瑞恒生物技术有限公司 Entironment-friendly preparation of sorafenib intermediate
WO2011106298A1 (en) 2010-02-25 2011-09-01 Dana-Farber Cancer Institute, Inc. Braf mutations conferring resistance to braf inhibitors
CN102884060A (en) * 2010-03-24 2013-01-16 阿米泰克治疗方案公司 Heterocyclic compounds useful for kinase inhibition
WO2013169858A1 (en) 2012-05-08 2013-11-14 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
CN104143443A (en) * 2013-10-12 2014-11-12 成都精容电子有限公司 Capacitor
CN108191781A (en) * 2018-01-08 2018-06-22 浙江大学 Substituted 1,2,4-triazole analog derivative and its application in medicine for anti transfer of tumor is prepared
US11078540B2 (en) 2010-03-09 2021-08-03 Dana-Farber Cancer Institute, Inc. Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101302193B (en) * 2008-05-27 2010-06-23 上海瑞恒生物技术有限公司 Entironment-friendly preparation of sorafenib intermediate
WO2010068738A1 (en) 2008-12-10 2010-06-17 Dana-Farber Cancer Institute, Inc. Mek mutations conferring resistance to mek inhibitors
US9084781B2 (en) 2008-12-10 2015-07-21 Novartis Ag MEK mutations conferring resistance to MEK inhibitors
US9279144B2 (en) 2010-02-25 2016-03-08 Dana-Farber Cancer Institute, Inc. Screening method for BRAF inhibitors
WO2011106298A1 (en) 2010-02-25 2011-09-01 Dana-Farber Cancer Institute, Inc. Braf mutations conferring resistance to braf inhibitors
US8637246B2 (en) 2010-02-25 2014-01-28 Dana-Farber Cancer Institute, Inc. BRAF mutations conferring resistance to BRAF inhibitors
EP3028699A1 (en) 2010-02-25 2016-06-08 Dana-Farber Cancer Institute, Inc. Braf mutations conferring resistance to braf inhibitors
US11078540B2 (en) 2010-03-09 2021-08-03 Dana-Farber Cancer Institute, Inc. Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy
CN102884060A (en) * 2010-03-24 2013-01-16 阿米泰克治疗方案公司 Heterocyclic compounds useful for kinase inhibition
US10214513B2 (en) 2010-03-24 2019-02-26 Amitech Therapeutic Solutions, Inc. Heterocyclic compounds useful for kinase inhibition
CN102884060B (en) * 2010-03-24 2019-07-19 阿米泰克治疗方案公司 For inhibiting the heterocyclic compound of kinases
WO2013169858A1 (en) 2012-05-08 2013-11-14 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
CN104143443A (en) * 2013-10-12 2014-11-12 成都精容电子有限公司 Capacitor
CN108191781A (en) * 2018-01-08 2018-06-22 浙江大学 Substituted 1,2,4-triazole analog derivative and its application in medicine for anti transfer of tumor is prepared
CN108191781B (en) * 2018-01-08 2020-01-21 浙江大学 Substituted triazole derivative and application thereof in preparation of anti-tumor metastasis drugs

Also Published As

Publication number Publication date
CN101654452A (en) 2010-02-24

Similar Documents

Publication Publication Date Title
US7652051B2 (en) Heterocyclic compounds and methods of use
CN1142912C (en) Amide derivs. useful as inhibitors of production of cytokines
CN1934100A (en) Substituted quinazoline or pyridopyrimidine derivative
CN1237061C (en) Chemokine receptor binding heterocyclic compounds
CN1178932C (en) Amide derivatives
CN1252054C (en) Qinoline derivatives inhibiting effect of growth factors such as VEGF
CN1269813C (en) Imidazolo-5-yl-2-anilino-pyrimidines as agents for inhibition of cell proliferation
CN1147294C (en) Pentafluorobenzenesulfonamides and analogs
CN101044125A (en) Heterocyclic compounds and methods of use
CN1678586A (en) Substituted quinoline CCR5 receptor antagonists
US20070161645A1 (en) Thiazole inhibitors targeting resistant kinase mutations
CN1494541A (en) Heterocyclic inhibitors of ERK 2 and uses thereof
CN1328550A (en) Oxazole compounds as prostaglandin E2 agonists or antagonists
CN1378537A (en) Pyrimidine derivatives
CN1688573A (en) Pyrrole based inhibitors of glycogen synthase kinase 3
CN1520296A (en) Amino nicotinate derivatives as glucokinase (GLK) modulators
CN1553899A (en) Quinoline derivative and quinazoline derivative inhibiting self-phosphorylation of hepatocytus proliferator receptor and medicinal composition containing the same
CN1457339A (en) Chemokine receptor binding heterocyclic compounds
CN1097753A (en) 5-membered heterocycles, preparation method and the pharmaceutical composition that contains these compounds
CN1732146A (en) Cycloalkyl inhibitors of potassium channel function
CN1902171A (en) Benzylether amine compounds useful as CCR-5 antagonists
CN1119856A (en) Inhibitors of HIV reverse transcriptase
CN1294126C (en) N-phenyl-arylsulfonamide compound, drug comprising the compound as active ingredient, intermediate for the compound
CN1674892A (en) Hetero biaryl derivatives as matrix metalloproteinase inhibitors
CN1826111A (en) Imidazole derivatives for treatment of allergic and hyperproliferative disorders

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20070926